3-Substituted piperidine compounds for inhibiting cbl-b and use of cbl-b inhibitors in combination with cancer vaccines and / or oncolytic viruses - Patent Application 20070123333
Cbl-b inhibitors are used to enhance the efficacy of cancer vaccines and oncolytic viruses by modulating the immune system, addressing the limitations of current cancer treatments and improving T-cell activation and immune response.
Patent Information
- Application Number
- JP2021559950
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-19
- Filing Date
- 2020-04-09
- Publication Date
- 2024-11-11
- Estimated Expiration
- 2040-04-09
AI Technical Summary
Current cancer vaccines and oncolytic viruses have limited effectiveness in treating cancer, with low response rates and insufficient improvement in overall survival, highlighting the need for enhanced therapeutic methods to modulate the ubiquitin proteasome pathway and enhance immune response against tumors.
Development of Cbl-b inhibitors, which can be administered alone or in combination with cancer vaccines and oncolytic viruses, to modulate immune cell activity and enhance T-cell activation, thereby improving the efficacy of cancer treatments.
Cbl-b inhibitors enhance T-cell activation and immune response, potentially leading to improved treatment outcomes for cancer by increasing T-cell proliferation and reducing immune tolerance, thereby enhancing the effectiveness of cancer vaccines and oncolytic viruses.
Smart Images

Figure 0007580393000242 
Figure 0007580393000243 
Figure 0007580393000001
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application Nos. 62 / 831,392, filed April 9, 2019; 62 / 866,909, filed June 26, 2019; 62 / 880,267, filed July 30, 2019; 62 / 888,845, filed August 19, 2019; and 62 / 888,870, filed August 19, 2019, the contents of each of which are incorporated herein by reference in their entirety.
[0002] Technical field of the invention
[0002] Provided herein are compounds and compositions for the inhibition of the Cbl-b enzyme and methods for their use in modulating the immune system, treating disease, and treating cells in vivo, in vitro, or ex vivo. Also provided herein are pharmaceutical compositions, kits, and methods for treating cancer that include a combination of an inhibitor of the Cbl-b enzyme and a cancer vaccine; and pharmaceutical compositions, kits, and methods for treating cancer that include a combination of an inhibitor of the Cbl-b enzyme and an oncolytic virus. [Background technology]
[0003] background The ubiquitin-proteasome pathway is a complex system involved in regulating protein function and catabolism. Proteins in eukaryotic cells are conjugated to ubiquitin, a 76-amino acid, 8.5-kilodalton protein. This conjugation, known as ubiquitination, results in altered function or degradation of the target protein. Ubiquitination of a target protein occurs through a series of conjugation reactions involving ubiquitin and a series of enzymes known as E1, E2, and E3 enzymes. Ubiquitin is activated by a ubiquitin-activating enzyme, or E1 enzyme. Next, ubiquitin is transferred to a ubiquitin-conjugating enzyme, or E2 enzyme. Finally, a ubiquitin ligase, or E3 enzyme, facilitates the transfer of ubiquitin from the E2 enzyme to the target protein. Polyubiquitination of a target protein primarily serves as a signal leading to degradation of the ubiquitinated protein by the proteasome, which carries out the protein degradation. Ubiquitination by E3 ligases can also result in altered protein activity, interaction, or localization. Ubiquitination regulates diverse biological functions, including cell division, DNA repair, and intracellular signaling.
[0004]
[0004] The synthesis and degradation of proteins in cells is important for cell cycle regulation, cell proliferation, apoptosis, and many other cellular processes. Therefore, the ability to modulate the ubiquitin-proteasome pathway offers many opportunities to intervene in disease processes. Mechanisms of intervention may include promoting the degradation of oncogene products, reducing the degradation of tumor suppressor proteins, modulating immune cell responses, and modulating anti-tumor immune responses.
[0005]
[0005] Therapeutic cancer vaccines have been evaluated in numerous clinical trials. However, only two therapeutic cancer vaccines have been approved for use in the United States. In particular, the Bacillus of Calmette and Guerin strain of Mycobacterium bovis has been approved for the treatment of bladder cancer, and an ex vivo activated autologous cell vaccine has been approved for the treatment of prostate cancer. Nevertheless, the response rates and overall survival rates of patients treated with cancer vaccines are significantly lower than desired. Therefore, there is a need in the art for methods to improve the effectiveness of cancer vaccines.
[0006]
[0006] Although numerous clinical trials using oncolytic viruses to treat cancer have been conducted, only one oncolytic virus has been approved for use in the United States and Europe. In particular, talimogene laherparepvec is a recombinant herpes simplex virus approved for the treatment of melanoma. However, even talimogene laherparepvec has not been shown to improve overall survival or be effective in patients with visceral metastases. Therefore, there is a need in the art for methods to improve the effectiveness of oncolytic virus therapy.
[0007] Approximately 35 E2 enzymes and over 500 E3 enzymes are encoded in the human genome. Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is an E3 ubiquitin ligase that negatively regulates T cell activation (Wallner et al., Clin Dev Immunol, 2012:692-639). Thus, the discovery of agents that modulate E2 or E3 enzymes offers the potential for therapeutic treatment of disease processes involving specific E2 or E3 enzymes. This patent application relates to agents that inhibit one such E3 enzyme, Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b); agents that inhibit Cbl-b for use in combination with cancer vaccines, and pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine; and agents that inhibit Cbl-b for use in combination with oncolytic viruses, and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus. Summary of the Invention
[0008] Summary of the Invention Disclosed herein are compounds and compositions for inhibiting the Cbl-b enzyme and methods for their use in modulating the immune system, treating disease, and treating cells in vivo, in vitro, or ex vivo. Also disclosed herein are methods for using Cbl-b inhibitors in the treatment of cancer. Briefly, Cbl-b inhibitors can be administered to individuals with cancer, alone or as part of a combination therapy, along with one or more of immune checkpoint inhibitors, anti-tumor agents, and radiation therapy. Furthermore, cells treated in vivo and / or in vitro with the compounds or compositions disclosed herein can be used in adoptive cell therapy to treat cancer.
[0009] Compounds of formula (I): [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof, is disclosed herein, wherein: [ka] but, [ka] and; X is CH or N; Z 1 is CH or N; Z 2 is CH or N; R 1a and R 1b are independently H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 2a is -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or -(C1-C6 alkylene)-O-(C1-C6 alkyl); R 2b is H, halo, or C1-C6 alkyl; or R 2a and R 2b together with the carbon atom to which they are attached form a spiro 3- to 6-membered heterocyclyl or a spiro C3-C6 cycloalkyl; wherein at least one atom of the spiroheterocyclyl adjacent to the connecting piperidinyl ring is carbon; R 3a and R 3b is independently H, halo, or C1-C6 alkyl; or R 3a and R 3b together with the carbon atom to which they are attached form a C3-C4 cycloalkyl; R 4 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; [ka] but, [ka] and Y is CR 5a R 5b or S; or [ka] but, [ka] and Y is a bond; W is O or a bond; R 5a and R 5b is independently H, halo, or C1-C6 alkyl; or R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl; R 6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 7 is H, halo, C3-C6 cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C1-C6 alkyl), -NH-(C3-C6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C1-C6 alkyl), or -O-(C3-C6 cycloalkyl); R 8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 9 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 10 is -CF3 or cyclopropyl.
[0010]
[0010] In one embodiment, [ka] but, [ka] In one embodiment, Z 1 is CH. In one embodiment, Z 1 is N.
[0011]
[0011] In one embodiment, [ka] but, [ka] is.
[0012]
[0012] In one embodiment, [ka] but, [ka] In one embodiment, Z 2 is CH. In one embodiment, Z 2 is N.
[0013] In one embodiment, [ka] but, [ka] is.
[0014] In one embodiment, [ka] but, [ka] and Y is CR 5a R 5b or S. In certain embodiments, W is a bond or O.
[0015]
[0015] In one embodiment, [ka] but, [ka] and Y is a bond.
[0016] In one embodiment, R 8 is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl. 8 is -CH3, -CF3, or cyclopropyl.
[0017] In some embodiments, X is CH. In some embodiments, X is N.
[0018] In some embodiments, Y is a bond. In some embodiments, Y is CR 5a R 5b In some embodiments, Y is S.
[0019] In one embodiment, R 5a and R 5b are independently H, halo, or C1-C3 alkyl, or R 5a and R 5btogether with the carbon atom to which they are attached form a C3-C4 cycloalkyl.
[0020] In one embodiment, R 5a and R 5b is independently H, F, or —CH; or R 5a and R 5b together with the carbon atom to which they are attached form a cyclopropyl.
[0021] In one embodiment, R 5a and R 5b are independently H or F.
[0022] In one embodiment, R 1a and R 1b is independently H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 1a and R 1b is independently H, —CH, —CF, or —CHOH. 1b is H.
[0023] In one embodiment, R 2a is -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkyl-OH, C1-C3 alkyl-CN, or -(C1-C3 alkylene)-O-(C1-C3 alkyl). 2a is -CN, -CH3, -CF3, -CH2OH, -CH2CN, or -CH2-O-CH3.
[0024] In one embodiment, R 2b is H, halo, or C1-C3 alkyl. 2b is H, F, or -CH3.
[0025] In one embodiment, R 2a and R2b together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl or a spiro C3-C4 cycloalkyl. 2a and R 2b together with the carbon atom to which they are attached form spirocyclopropyl, [ka] Form.
[0026] In one embodiment, R 3a and R 3b are independently H, halo, or C1-C3 alkyl, or R 3a and R 3b together with the carbon atom to which they are attached form a C-C cycloalkyl. 3a and R 3b are independently H, F, or —CH; or R 3a and R 3b together with the carbon atom to which they are attached form a cyclopropyl.
[0027] In one embodiment, R 4 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 4 is H, -CH3, -CF3, or -CH2OH.
[0028] In one embodiment, R 6 is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl. 6 is -CH3, -CHF2, or cyclopropyl.
[0029] In one embodiment, R 7is H, halo, C3-C4 cycloalkyl, -NH(4- to 5-membered heterocyclyl), -NH(C1-C3 alkyl), -NH(C3-C5 cycloalkyl), -O(C1-C3 alkyl), -O(4- to 5-membered heterocyclyl), or -O(C3-C5 cycloalkyl). 7 is H, Cl, cyclopropyl, -NH(CH2CH3), -NH(cyclopropyl), -OCH2CH3, -O(cyclopropyl), [ka] is.
[0030] In some embodiments, R 9 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 9 is H, -CH3, -CF3, or -CH2OH.
[0031] Also disclosed herein is a compound selected from the compounds in Table 1, or a tautomer thereof, or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound selected from any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0032]
[0032] Also disclosed herein is a method for regulating the activity of immune cells, comprising contacting immune cells with an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0033]
[0033] Also disclosed herein is a method for treating cancer that responds to inhibition of Cbl-b activity in an individual in need thereof, comprising administering to the individual an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0034]
[0034] Also disclosed herein is a method for inhibiting Cbl-b activity in an individual in need thereof, comprising administering to the individual an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0035]
[0035] Also disclosed herein is a method for treating or preventing a disease or condition associated with Cbl-b activity in an individual in need thereof, comprising administering to the individual any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0036]
[0036] Also disclosed herein is a method for producing modified immune cells, comprising culturing a cell population containing immune cells in the presence of an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0037]
[0037] Also disclosed herein are modified immune cells comprising a Cbl-b inhibitor, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0038]
[0038] Also disclosed herein is an isolated modified immune cell, wherein the immune cell has been or is in contact with any of the compounds described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0039]
[0039] Also disclosed herein is a composition comprising a cell population containing isolated modified immune cells, wherein the immune cells have been or are in contact with any of the compounds described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0040]
[0040] Also disclosed herein is a method for inhibiting abnormal cell proliferation, comprising administering to an individual in need thereof an effective amount of isolated modified immune cells, wherein the immune cells have been or have been contacted with any of the compounds described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0041]
[0041] Also disclosed herein is a method for inhibiting abnormal cell proliferation, comprising administering to an individual in need thereof a composition comprising a cell population containing isolated modified immune cells, wherein the immune cells have been or are in contact with any of the compounds described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0042]
[0042] Also disclosed herein is a method for inhibiting abnormal cell proliferation, comprising administering an effective amount of any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0043]
[0043] Also disclosed herein is a cell culture composition comprising a cell population containing immune cells and a Cbl-b inhibitor, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0044]
[0044] Also disclosed herein is a pharmaceutical composition comprising a Cbl-b inhibitor and one or both of an adjuvant and an antigen, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0045]
[0045] Also disclosed herein are products comprising any modified immune cells disclosed herein, any composition comprising a cell population disclosed herein, any cell culture composition disclosed herein, or any pharmaceutical composition disclosed herein.
[0046]
[0046] Also disclosed herein are kits comprising any of the modified immune cells disclosed herein or any composition comprising the cell populations disclosed herein.
[0047]
[0047] Also disclosed herein is the use of a Cbl-b inhibitor in the manufacture of a medicament for treating or preventing a disease or condition associated with Cbl-b activity, wherein the Cbl-b inhibitor is any compound described above or disclosed herein, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0048] In any of the embodiments disclosed herein, the Cbl-b protein can be mammalian Cbl-b or human Cbl-b.
[0049] Also disclosed herein are Cbl-b inhibitor compounds, vaccines, and compositions comprising the Cbl-b inhibitors and vaccines, and methods of their use in treating cancer. The Cbl-b inhibitors and cancer vaccines can be administered to individuals with cancer.
[0050] Also disclosed herein are Cbl-b inhibitor compounds, oncolytic viruses, and compositions comprising a Cbl-b inhibitor and an oncolytic virus, and methods of using them in the treatment of cancer. The Cbl-b inhibitor and the oncolytic virus can be administered to an individual with cancer.
[0051]
[0051] Provided herein is a method of immunization comprising administering an effective amount of a small molecule Cbl-b inhibitor to an individual in need thereof and administering an effective amount of a vaccine to the individual.
[0052]
[0052] Provided herein is a method for treating cancer, comprising administering to an individual having cancer an effective amount of a small molecule Cbl-b inhibitor and administering to the individual an effective amount of an oncolytic virus.
[0053]
[0053] Provided herein is a method for treating cancer, comprising administering to an individual having cancer an effective amount of an agent capable of lowering the activation threshold of immune cells, and administering to the individual an effective amount of a therapeutic cancer vaccine; or administering to the individual an effective amount of an oncolytic virus.
[0054] Provided herein is a pharmaceutical composition comprising a cancer vaccine and a small molecule Cbl-b inhibitor, optionally further comprising a pharmaceutically acceptable excipient.
[0055]
[0055] Provided herein is a kit for treating cancer, comprising: (a) a small molecule Cbl-b inhibitor; (b) a therapeutic cancer vaccine; and (c) instructions for administering effective amounts of the Cbl-b inhibitor and the therapeutic cancer vaccine to treat cancer in an individual.
[0056]
[0056] Provided herein is a kit for treating cancer comprising: (a) a pharmaceutical composition comprising a small molecule Cbl-b inhibitor and a therapeutic cancer vaccine; and (b) instructions for administering an effective amount of the pharmaceutical composition comprising the Cbl-b inhibitor and the therapeutic cancer vaccine to treat cancer in an individual.
[0057] Provided herein is a pharmaceutical composition comprising an oncolytic virus and a small molecule Cbl-b inhibitor, optionally further comprising a pharmaceutically acceptable excipient.
[0058]
[0058] Provided herein is a kit for treating cancer, comprising: (a) a small molecule Cbl-b inhibitor; (b) an oncolytic virus; and (c) instructions for administering effective amounts of the Cbl-b inhibitor and the oncolytic virus to treat cancer in an individual.
[0059]
[0059] Also provided herein is a kit for treating cancer, comprising: (a) a pharmaceutical composition comprising a small molecule Cbl-b inhibitor and an oncolytic virus; and (b) instructions for administering an effective amount of the pharmaceutical composition comprising the small molecule Cbl-b inhibitor and an oncolytic virus to treat cancer in an individual. [Brief explanation of the drawings]
[0060] [Figure 1A]
[0060] Tumor volumes of individual mice are shown. [Figure 1B]
[0061] Percent conditional survival of mice shown by Kaplan-Meier plot. DETAILED DESCRIPTION OF THE INVENTION
[0061] Detailed Description
[0062] Provided herein are compounds and pharmaceutical compositions that inhibit the Cbl-b enzyme, as well as methods of treatment using such compounds and pharmaceutical compositions. The compounds and compositions can be used in methods of modulating the immune system, for the treatment of diseases, and for treating cells in vivo, in vitro, or ex vivo. Also provided herein are cancer vaccines and pharmaceutical compositions comprising compounds that inhibit the Cbl-b enzyme, as well as methods of treatment using such compounds, cancer vaccines, and pharmaceutical compositions. Also provided herein are oncolytic viruses and pharmaceutical compositions comprising compounds that inhibit the Cbl-b enzyme, as well as methods of treatment using such compounds, oncolytic viruses, and pharmaceutical compositions.
[0062]
[0063] T cell activation and T cell tolerance are tightly controlled processes that regulate immune responses to tumors while preventing autoimmunity. Tolerance prevents the immune system from attacking cells expressing "self" antigens. During peripheral tolerance, T cells that recognize "self" antigens (i.e., autoreactive T cells) become functionally unresponsive or are eliminated after encountering "self" antigens outside the thymus. Therefore, the peripheral tolerance process is important for preventing autoimmune diseases. Normally, cancer cells are eliminated by activated T cells that recognize tumor antigens expressed on their surface. However, in cancer, the tumor microenvironment can support T cell tolerance to cancer cells, allowing them to evade recognition and elimination by the immune system. The ability of cancer cells to evade tumor immune surveillance can contribute to uncontrolled tumor growth. Therefore, T cell tolerance can be a type of T cell dysfunction. The general principles of T cell dysfunction are well known in the art (see Schietinger et al., Trends Immunol., 35:51-60, 2014). Additional types of T cell dysfunction that can contribute to uncontrolled tumor growth include T cell exhaustion, T cell senescence, and / or T cell anergy. Therefore, treating T cell dysfunction, for example, by increasing T cell activation, increasing T cell proliferation, decreasing T cell tolerance, and / or decreasing T cell exhaustion, is beneficial for the prevention or treatment of cancer. Additional cells of the immune system are important for the recognition and elimination of cancer cells during immunosurveillance. For example, natural killer (NK) cells are lymphocytes of the innate immune system that can identify and kill cancer cells (see Martinez-Losato et al., Clin Cancer Res., 21:5048-5056, 2015). Recent studies have also demonstrated that B cell subsets with distinct phenotypes and functions play diverse roles in antitumor responses (see Saravaria et al., Cell Mol Immunol., 14:662-674, 2017). Due to their role in tumor surveillance, NK cells and B cells may also be suitable therapeutic targets for the prevention or treatment of cancer.
[0063]
[0064] Cbl-b is a RING-type E3 ligase that plays an important role in the immune system due to its function as a negative regulator of immune activation. Cbl-b reduces T cell activation, thereby playing an important role in promoting T cell tolerance. Studies have found that cbl-b-deficient T cells exhibit a lower threshold for activation by antigen-recognition receptors and costimulatory molecules (e.g., CD28). For example, loss of Cbl-b in T cells abrogates the need for CD28 costimulation during T cell activation and proliferation (see Bachmaier et al., Nature, 403:211-216, 2000). Such cbl-b − / − T cells are highly resistant to T cell anergy, an immune tolerance mechanism in which T cells are functionally inactivated and T cell proliferation is severely reduced (see Jeon et al., Immunity, 21:167-177, 2004; and Schwartz et al., Annu Rev Immunol., 21:305-34, 2003). In support of this, loss of Cbl-b in cbl-b knockout mice reduced the induction of T cell tolerance and exacerbated autoimmunity (see Jeon et al., Immunity, 21:167-177, 2004). Importantly, loss of Cbl-b in mice also resulted in robust antitumor responses that were primarily dependent on cytotoxic T cells. One study showed that cbl-b − / − CD8+ T cells were resistant to T regulatory cell-mediated suppression and exhibited enhanced activation and tumor infiltration. Therapeutic transfer of naive cbl-b- / - CD8+ T cells was sufficient to mediate the rejection of established tumors (see Loeser et al., J Exp Med., 204:879-891, 2007). Recent studies have shown that Cbl-b also plays a role in NK cell activation. Genetic deletion of Cbl-b or targeted inactivation of its E3 ligase activity enabled NK cells to spontaneously reject metastatic tumors in a mouse model (see Paolino et al., Nature, 507:508-512, 2014).
[0064]
[0065] Provided herein are compounds and compositions that are potent inhibitors of Cbl-b and can be used in novel approaches to treat diseases such as cancer. In some embodiments, the compounds and compositions provided herein can be used in methods of modulating the immune system, for example, activating T cells, NK cells, and B cells, and treating such cells in vivo, in vitro, or ex vivo.
[0065] I. Definition
[0066] An "effective amount" of an agent disclosed herein is an amount sufficient to accomplish a specifically described purpose. An "effective amount" can be determined empirically and routinely for the described purpose. An "effective amount" or a "sufficient amount" of an agent is an amount sufficient to produce a desired biological effect, such as a beneficial result, including a beneficial clinical result. In certain embodiments, the term "effective amount" refers to an amount of an agent effective to "treat" a disease or disorder in an individual (e.g., a mammal such as a human).
[0066]
[0067] As used herein, the term "Cbl-b" refers to a Cbl-b protein. This term also includes naturally occurring variants of Cbl-b, including splice variants or allelic variants. This term also includes non-naturally occurring variants of Cbl-b, such as recombinant Cbl-b proteins or truncated variants thereof, which generally retain the binding ability (e.g., the ability to bind to E2 enzymes) of native Cbl-b or naturally occurring variants of Cbl-b.
[0067]
[0068] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to a preparation that is in a form that allows the biological activity of the active ingredient to be effective and that does not contain additional ingredients that are unacceptably toxic to the individual to whom the formulation or composition may be administered. Such a formulation or composition may be sterile. Such a formulation or composition may be sterile except for containing an oncolytic virus.
[0068]
[0069] As used herein, an "excipient" includes a pharmaceutically acceptable excipient, carrier, vehicle, or stabilizer that is nontoxic to cells or mammals exposed thereto at the dosages and concentrations employed. Often, the physiologically acceptable excipient is an aqueous pH buffered solution.
[0069]
[0070] References to compounds described in pharmaceutical compositions, or in claims of pharmaceutical compositions, refer to the compound represented by the formula described in the pharmaceutical composition, without other elements of the pharmaceutical composition, i.e., without carriers, excipients, etc.
[0070]
[0071] "Treating" or "treatment" of a disease refers to carrying out a protocol that may include administering one or more therapeutic agents to an individual (human or otherwise) to obtain a beneficial or desired result in the individual, including a clinical result. Beneficial or desired clinical results include, but are not limited to, relief or amelioration of one or more symptoms, reduction in the extent of the disease, stable (i.e., not worsening) disease state, prevention of disease spread, delay or slowing of disease progression, improvement or palliation of disease state, and remission (whether partial or total). "Treatment" can also mean prolonging survival as compared to the expected survival of an individual not receiving treatment. Furthermore, "treating" and "treatment" can occur with a single administration of one or more therapeutic agents, or with a series of multiple administrations of one or more therapeutic agents. "Treating" or "treatment" does not require complete alleviation of signs or symptoms, and does not require a cure. "Treatment" can also refer to clinical intervention, such as administering to an individual one or more therapeutic agents designed to alter the natural course of the individual or cells being treated (i.e., to alter the course of the individual or cells that would occur without clinical intervention). The term "therapeutic agent" can refer to a Cbl-b inhibitor, modified immune cells, or compositions thereof.
[0071]
[0072] As used herein, an "individual" or "subject" is a mammal. "Mammals" for treatment include humans; non-human primates; domestic and farm animals; and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual or subject is a human.
[0072]
[0073] As used herein, the term "T cell dysfunction" refers to a state of reduced immune responsiveness to antigenic stimulation. The term "T cell dysfunction" includes the common elements of both T cell exhaustion and / or T cell anergy, in which antigen recognition can occur but the subsequent immune response is ineffective to control tumor growth. The term "T cell dysfunction" can include refractoriness or unresponsiveness to antigen recognition, e.g., a reduced ability to translate antigen recognition into downstream T cell effector functions, such as proliferation, cytokine production, and / or target cell killing.
[0073]
[0074] The term "T cell anergy" refers to a state of unresponsiveness to antigenic stimulation resulting from defective or insufficient signals delivered via the T cell receptor. "T cell anergy" can also result from stimulation by antigen without costimulation, rendering the cells refractory to subsequent activation by antigen, even in the context of costimulation.
[0074]
[0075] The term "T cell exhaustion" refers to a state of T cell dysfunction resulting from persistent TCR signaling, which can occur in cancer. It is distinguished from anergy in that it results from persistent signaling rather than through defective or insufficient signaling. It is defined by insufficient effector function, persistent expression of inhibitory receptors, and a transcriptional state that differs from that of functional effector or memory T cells.
[0075]
[0076] A "T cell dysfunction disorder" is a disorder or condition characterized by reduced responsiveness of T cells to antigenic stimulation. Reduced responsiveness can result in ineffective tumor control. In one embodiment, the term "T cell dysfunction disorder" encompasses cancer, such as hematological or non-hematological cancer. In one embodiment, a "T cell dysfunction disorder" is one in which T cells are anergic or have a reduced ability to secrete cytokines, proliferate, or achieve cytolytic activity.
[0076]
[0077] "Promoting T cell function" means inducing, inducing, or stimulating T cells to have sustained or enhanced biological function, or to restore or reactivate exhausted or inactive T cells. Examples of promoted T cell function include increased T cell activation (e.g., increased cytokine production, increased expression of T cell activation markers, etc.), increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell immune tolerance, compared to the state of the T cells before treatment with a Cbl-b inhibitor. Methods for measuring promotion of T cell function are known in the art.
[0077]
[0078] "Proliferation" is used herein to refer to the proliferation of cells. Increased proliferation includes the production of a greater number of cells compared to a baseline value. Decreased proliferation includes the production of a decreased number of cells compared to a baseline value. In certain embodiments, the cells are immune cells, such as T cells, and increased proliferation is desired. In certain embodiments, the cells are cancer cells and decreased proliferation is desired.
[0078]
[0079] As used herein, "alkyl" refers to a saturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain or combinations thereof. Particular alkyl groups have a specified number of carbon atoms, for example, alkyl groups having 1 to 20 carbon atoms ("C1-C 20 alkyl), alkyl groups having 1 to 10 carbon atoms ("C1-C 10" alkyl), alkyl groups having 1 to 8 carbon atoms ("C1-C8 alkyl"), alkyl groups having 1 to 6 carbon atoms ("C1-C6 alkyl"), alkyl groups having 2 to 6 carbon atoms ("C2-C6 alkyl"), or alkyl groups having 1 to 4 carbon atoms ("C1-C4 alkyl"). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, homologs and isomers of, e.g., n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0079]
[0080] As used herein, "alkenyl" refers to an unsaturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain, or combinations thereof, having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C). Particular alkenyl groups are those having a specified number of carbon atoms, for example, alkenyl groups having 2 to 20 carbon atoms ("C-C"). 20 alkenyl groups having 2 to 10 carbon atoms ("C2-C 10 " alkenyl"), alkenyl groups having 2 to 8 carbon atoms ("C2-C8 alkenyl"), alkenyl groups having 2 to 6 carbon atoms ("C2-C6 alkenyl"), or alkenyl groups having 2 to 4 carbon atoms ("C2-C4 alkenyl"). Alkenyl groups can be in the "cis" or "trans" configuration, or alternatively, the "E" or "Z" configuration. Examples of alkenyl groups include, but are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, homologs, and isomers thereof.
[0080]
[0081] As used herein, "alkynyl" refers to an unsaturated linear (i.e., unbranched) or branched monovalent hydrocarbon chain, or combinations thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula C≡C). Particular alkynyl groups are those having a specified number of carbon atoms, for example, alkynyl groups having 2 to 20 carbon atoms ("C-C"). 20 alkynyl groups having 2 to 10 carbon atoms ("C2-C 10 The alkynyl group may be an alkynyl group having 2 to 8 carbon atoms ("C-C alkynyl"), an alkynyl group having 2 to 6 carbon atoms ("C-C alkynyl"), or an alkynyl group having 2 to 4 carbon atoms ("C-C alkynyl"). Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, homologs, and isomers thereof.
[0081]
[0082] As used herein, "alkylene" refers to the same residue as alkyl, but with divalency. Particular alkylene groups are those having 1 to 6 carbon atoms ("C-C alkylene"), 1 to 5 carbon atoms ("C-C alkylene"), 1 to 4 carbon atoms ("C-C alkylene"), or 1 to 3 carbon atoms ("C-C alkylene"). Examples of alkylene groups include, but are not limited to, groups such as methylene (-CH-), ethylene (-CHCH-), propylene (-CHCHCH-), and butylene (-CHCHCHCHCH-).
[0082]
[0083] As used herein, "cycloalkyl" refers to a non-aromatic, saturated or unsaturated, cyclic monovalent hydrocarbon structure. Particular cycloalkyl groups are those having a specified number of cyclic (i.e., ring) carbon atoms, such as cycloalkyl groups having 3 to 12 cyclic carbon atoms ("C3-C6"). 12Particular cycloalkyls are cyclic hydrocarbons having 3 to 8 annular carbon atoms ("C3-C8 cycloalkyl"), or cyclic hydrocarbons having 3 to 6 annular carbon atoms ("C3-C6 cycloalkyl"). Cycloalkyls can consist of one ring (such as cyclohexyl) or multiple rings (such as adamantyl), but exclude aromatic (e.g., aryl) groups. Cycloalkyls containing two or more rings can be fused, spiro, or bridged, or combinations thereof. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopropyl, cyclopropyl methyl ... [ka] , cyclobutyl, [ka] Cyclopentyl [ka] , cyclohexyl [ka] , 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl [ka] , norbornyl, and the like.
[0083]
[0084] As used herein, "cycloalkylene" refers to the same residue as cycloalkyl, but with divalent character (i.e., as opposed to monovalent). Particular cycloalkylene groups are those having 3 to 12 ring carbon atoms ("C3-C 12cycloalkylene"), those having 3 to 8 ring carbon atoms ("C3-C8 cycloalkylene"), or those having 3 to 6 ring carbon atoms ("C3-C6 cycloalkylene"). Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclopropylene glycol ... [ka] , cyclobutylene [ka] , cyclopentylene [ka] , cyclohexylene [ka] , 1,2-cyclohexenylene, 1,3-cyclohexenylene, 1,4-cyclohexenylene, cycloheptylene [ka] , norbornylene, and the like.
[0084]
[0085] As used herein, "aryl" refers to an aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl), where one or more of the condensed rings cannot be aromatic. Particular aryl groups are those having 6 to 14 cyclic (i.e., ring) carbon atoms ("C6-C6"). 14Aryl groups are groups having two or more rings in which at least one ring is non-aromatic and can be linked to the parent structure at either an aromatic ring position or a non-aromatic ring position. In one form, an aryl group having two or more rings in which at least one ring is non-aromatic is linked to the parent structure at an aromatic ring position. Examples of aryl include, but are not limited to, phenyl, naphthyl, 1-naphthyl, 2-naphthyl, 1,2,3,4-tetrahydronaphthalen-6-yl, [ka] Examples of such groups include:
[0085]
[0086] "Carbocyclyl" or "carbocyclic" refers to an aromatic or non-aromatic monovalent cyclic radical, all of whose ring members are carbon atoms, e.g., cyclohexyl, phenyl, 1,2-dihydronaphthyl, and the like.
[0086]
[0087] As used herein, "arylene" refers to the same residue as aryl, but with a divalent character. Particular arylene groups are those having 6 to 14 ring carbon atoms ("C6-C 14 Examples of arylene include, but are not limited to, groups such as phenylene, o-phenylene (i.e., 1,2-phenylene), m-phenylene (i.e., 1,3-phenylene), p-phenylene (i.e., 1,4-phenylene), naphthylene, 1,2-naphthylene, 1,3-naphthylene, 1,4-naphthylene, 2,7-naphthylene, and 2,6-naphthylene.
[0087]
[0088] As used herein, "heteroaryl" refers to an unsaturated aromatic cyclic group having 1 to 14 ring carbon atoms and at least one ring heteroatom, including, but not limited to, nitrogen, oxygen, and sulfur. Heteroaryl groups can have a single ring (e.g., pyridyl or imidazolyl) or multiple condensed rings (e.g., indolizinyl, indolyl, or quinolinyl), where at least one of the condensed rings is aromatic. Particular heteroaryl groups are 5- to 14-membered rings having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from the group consisting of nitrogen (N), oxygen (O), and sulfur (S) ("5- to 14-membered heteroaryl"); 5- to 10-membered rings having 1 to 8 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5- to 10-membered heteroaryl"); or 5-, 6-, or 7-membered rings having 1 to 5 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5- to 7-membered heteroaryl"). In one form, heteroaryl includes monocyclic aromatic 5-, 6-, or 7-membered rings having 1 to 6 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. In another aspect, heteroaryl includes polycyclic aromatic rings having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. Heteroaryl groups having two or more rings, where at least one ring is non-aromatic, can be linked to the parent structure at either an aromatic ring position or a non-aromatic ring position. Examples of heteroaryl include, but are not limited to, groups such as pyridyl, benzimidazolyl, benzotriazolyl, benzo[b]thienyl, quinolinyl, indolyl, and benzothiazolyl. "Heteroaryl" refers to [ka] (2,4-dihydro-3H-1,2,4-triazol-3-one-2-yl), which also includes moieties such as the aromatic tautomeric structure [ka] (1H-1,2,4-triazol-5-ol-1-yl).
[0088]
[0089] As used herein, "heterocyclyl" and "heterocyclic group" refer to a non-aromatic saturated or partially unsaturated cyclic group having the specified number of atoms and heteroatoms, or if the number of atoms or heteroatoms is not specified, having at least three ring atoms, 1 to 14 ring carbon atoms, and at least one ring heteroatom, including, but not limited to, nitrogen, oxygen, and sulfur. Heterocyclic groups can have a single ring (e.g., tetrahydrothiophenyl, oxazolidinyl) or multiple condensed rings (e.g., decahydroquinolinyl, octahydrobenzo[d]oxazolyl). Multiple condensed rings include, but are not limited to, bicyclic, tricyclic, and tetracyclic rings, as well as bridged or spirocyclic ring systems. Examples of heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, oxazolidinyl, piperazinyl, morpholinyl, dioxanyl, 3,6-dihydro-2H-pyranyl, 2,3-dihydro-1H-imidazolyl, and the like.
[0089]
[0090] As used herein, "heteroarylene" refers to the same residue as heteroaryl, but with a divalent character. Particular heteroarylene groups are 5- to 14-membered rings having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5- to 14-membered heteroarylene"); 5- to 10-membered rings having 1 to 8 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5- to 10-membered heteroarylene"); or 5-, 6-, or 7-membered rings having 1 to 5 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur ("5- to 7-membered heteroarylene"). Examples of heteroarylene include, but are not limited to, pyridylene, benzimidazolylene, benzotriazolylene, benzo[b]thienylene, quinolinylene, indolylene, benzothiazolylene, and other groups.
[0090]
[0091] "Halo" or "halogen" refers to elements of the Group 17 series having atomic numbers 9 to 85. Halo groups include fluoro (F), chloro (Cl), bromo (Br), and iodo (I).
[0091]
[0092] "Haloalkyl," "haloalkylene," "haloaryl," "haloarylene," "haloheteroaryl," and similar terms refer to a moiety substituted with at least one halo group. When a haloalkyl moiety or other halo-substituted moiety is substituted with more than one halogen, it can be indicated by using a prefix corresponding to the number of halogen moieties attached. For example, dihaloaryl, dihaloalkyl, trihaloaryl, trihaloalkyl, etc. refer to aryl and alkyl substituted with two ("di") or three ("tri") halo groups, which may, but are not necessarily, the same halo; thus, for example, the haloaryl group 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. The subset of haloalkyl groups in which every hydrogen (H) in the alkyl group is replaced with a halo group is called "perhaloalkyl." A particular perhaloalkyl group is trifluoroalkyl (-CF). Similarly, "perhaloalkoxy" refers to an alkoxy group in which a halogen replaces every hydrogen (H) in the hydrocarbon comprising the alkyl portion of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (-OCF3). "Haloalkyl" includes monohaloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl, and any other number of halo substituents possible on an alkyl group; and similarly for other groups, such as, for example, haloalkylene, haloaryl, haloarylene, haloheteroaryl, etc.
[0092]
[0093] "Amino" refers to the group -NH2.
[0093]
[0094] "Oxo" refers to the group =O, ie, an oxygen atom double-bonded to carbon or another chemical element.
[0094]
[0095] "Optionally substituted," unless otherwise specified, means that a group is unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4, or 5) of the substituents listed for that group, where the substituents can be the same or different. In one embodiment, an optionally substituted group is unsubstituted. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, or 1 to 5 substituents. When multiple substituents are present, each substituent is independently selected unless otherwise specified. For example, each (C1-C4 alkyl) substituent in the group -N(C1-C4 alkyl)(C1-C4 alkyl) may be selected independently of each other to produce a group such as -N(CH3)(CH2CH3).
[0095]
[0096] Further to the disclosure herein, the term "substituted," when used to modify a specified group or radical, can also mean that one or more hydrogen atoms (H) of the specified group or radical are each, independently of one another, replaced with the same or different substituents, as defined herein. In some embodiments, a substituted group has 1, 2, 3, or 4 substituents, 1, 2, or 3 substituents, 1 or 2 substituents, or 1 substituent.
[0096]
[0097] Unless otherwise specified, a substituent may be bonded to any chemically possible position on a specified group or radical. Thus, for example, in one embodiment, -C1-C8 alkyl-OH includes, for example, -CH2CH2OH, -CH(OH)-CH3, and -CH2C(OH)(CH3)2. As a further example, in one embodiment, -C1-C6 alkyl-OH includes, for example, -CH2CH2OH, -CH(OH)-CH3, and -CH2C(OH)(CH3)2. As a further example, in one embodiment, -C1-C6 alkyl-CN includes, for example, -CH2CH2CN, -CH(CN)-CH3, and -CH2C(CN)(CH3)2.
[0097]
[0098] Unless a specific isotope of an element is indicated in a formula, the present disclosure includes all isotopic species of the compounds disclosed herein, such as, for example, deuterated derivatives of the compounds (where H can be 2H, i.e., deuterium (D)). Deuterated compounds may provide favorable changes in pharmacokinetic (ADME) properties. Isotopic species may have isotopic substitutions at any or all positions in the structure, or may have atoms present at natural abundance at any or all positions in the structure.
[0098]
[0099] As used herein, "small molecule" refers to a compound with a molecular weight of 1,000 daltons or less.
[0099]
[0100] Hydrogen atoms can also be replaced with close bioisosteres, such as fluorine, provided that such replacement results in a stable compound.
[0100]
[0101] The present disclosure also includes any enantiomeric or diastereomeric forms of the compounds described herein, and all stereochemical forms, including cis / trans or E / Z isomers. Unless stereochemistry is explicitly indicated in a chemical structure or chemical name, the structure or name is intended to encompass all possible stereoisomers of the depicted compound. Furthermore, when a specific stereochemical form is depicted, it is understood that all other stereochemical forms, as well as general non-stereospecific forms and mixtures of the disclosed compounds in any ratio, including mixtures of two or more stereochemical forms of the disclosed compounds in any ratio, are also described and encompassed by the present disclosure, and thus encompass racemic, non-racemic, enantiomerically enriched, and scalemic mixtures of the compounds. Compositions comprising the disclosed compounds, including compositions of substantially pure compounds, containing their specific stereochemical forms, are also contemplated. Compositions comprising mixtures of the disclosed compounds in any ratio, including compositions comprising mixtures of two or more stereochemical forms of the disclosed compounds in any ratio, are also encompassed by the present disclosure; thus, racemic, non-racemic, enantiomerically enriched, and scalenic mixtures of the compounds are encompassed by the present disclosure. When stereochemistry is explicitly shown for one or more positions in a molecule but not for another one or more portions of the molecule, the structure is intended to encompass all possible stereoisomers of the one or more portions where stereochemistry is not explicitly shown. The present disclosure also encompasses all tautomers of the compounds described herein.
[0101]
[0102] The present disclosure is intended to encompass all salts of the compounds described herein, as well as methods of using such salts of the compounds. In one embodiment, the salts of the compounds include pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts that can be administered to humans and / or animals as drugs or pharmaceuticals and that retain at least some of the biological activity of the free compound (neutral or non-salt compound) after administration. The desired salt of a basic compound can be prepared by methods known to those skilled in the art by treating the compound with an acid. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, sulfonic acid, and salicylic acid. Salts of basic compounds with amino acids, such as aspartate and glutamate, can also be prepared. The desired salt of an acidic compound can be prepared by treating the compound with a base using methods known to those skilled in the art. Examples of inorganic salts of acidic compounds include, but are not limited to, alkali metal and alkaline earth metal salts, such as sodium, potassium, magnesium, and calcium salts; ammonium salts; and aluminum salts. Examples of organic salts of acidic compounds include, but are not limited to, procaine, dibenzylamine, N-ethylpiperidine, N,N'-dibenzylethylenediamine, and triethylamine salts. Salts of acidic compounds with amino acids, such as lysine salts, can also be prepared. For a list of pharmaceutically acceptable salts, see, for example, PH Stahl and CG Wermuth (eds.) "Handbook of Pharmaceutical Salts, Properties, Selection and Use" Wiley-VCH, 2011 (ISBN: 978-3-90639-051-2). Some pharmaceutically acceptable salts are also disclosed in Berge, J. Pharm. Sci. 66:1 (1977).
[0102]
[0103] IC for Cbl-b inhibition as described in Biological Examples 1, 8, and / or 12 50 The Cbl-b activity assay (Cbl-b inhibition assay) used to measure IC values uses a mixture containing N-terminally biotinylated Avi-tagged Cbl-b, a fluorescently labeled inhibitor probe tagged with BODIPY FL (Example 46), and assay buffer. In one embodiment, the IC value for inhibition of Cbl-b is 50 The Cbl-b activity assay (Cbl-b inhibition assay) used to measure IC for inhibition of Cbl-b uses the conditions described in Biological Examples 1, 8, and / or 12 with 0.5 nM Cbl-b ("high" final concentration). 50 The Cbl-b activity assay (Cbl-b inhibition assay) used to measure Cbl-b activity uses the conditions described in Biological Examples 1, 8, and / or 12 with 0.125 nM Cbl-b ("low" final concentration).
[0103]
[0104] It is understood that certain features disclosed herein that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features disclosed herein that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of embodiments with respect to chemical groups represented by variables are specifically embraced by the present disclosure and, to the extent such combinations include compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity), are disclosed herein as if every combination were individually and explicitly disclosed. Furthermore, all subcombinations of chemical groups listed in the embodiments describing such variables are also specifically embraced by the present disclosure and are disclosed herein as if every such subcombination of chemical groups were individually and explicitly disclosed herein.
[0104]
[0105] It is understood that aspects and embodiments described herein as "comprising" include the embodiments "consisting of" and "consisting essentially of."
[0105]
[0106] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless specifically stated otherwise or unless clear from the context. For example, the singular form "an" excipient includes one or more excipients.
[0106]
[0107] Reference to "about" a value includes 90% to 110% of that value. For example, about 50 billion cells refers to 45 billion to 55 billion cells, including 50 billion cells. For example, a temperature "about 100 degrees" refers to a temperature of about 90 degrees to about 110 degrees.
[0107]
[0108] When a numerical range of compounds is given, all compounds within that numerical limit, including any specified "a" and "b," are included unless expressly excluded. For example, a reference to compounds 41-43 refers to compounds 41, 42, and 43.
[0108] II. Compounds
[0109] In one embodiment, a compound of formula (I): [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof, is provided, During the ceremony: [ka] but, [ka] and; X is CH or N; Z 1 is CH or N; Z 2is CH or N; R 1a and R 1b are independently H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 2a is -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or -(C1-C6 alkylene)-O-(C1-C6 alkyl); R 2b is H, halo, or C1-C6 alkyl; or R 2a and R 2b together with the carbon atom to which they are attached form a spiro 3- to 6-membered heterocyclyl or a spiro C3-C6 cycloalkyl; wherein at least one atom of the spiroheterocyclyl adjacent to the connecting piperidinyl ring is carbon; R 3a and R 3b is independently H, halo, or C1-C6 alkyl; or R 3a and R 3b together with the carbon atom to which they are attached form a C3-C4 cycloalkyl; R 4 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; [ka] but, [ka] and Y is CR 5a R 5b or S; or [ka] but, [ka] and Y is a bond; W is O or a bond; R 5a and R 5b is independently H, halo, or C1-C6 alkyl; or R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl; R 6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 7 is H, halo, C3-C6 cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C1-C6 alkyl), -NH-(C3-C6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C1-C6 alkyl), or -O-(C3-C6 cycloalkyl); R 8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 9 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 10 is -CF3 or cyclopropyl.
[0109]
[0110] In another embodiment, the compound of formula (Ia): [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof, is provided, During the ceremony: [ka] but, [ka] and; X is CH or N; Z 1 is CH or N; Z 2 is CH or N; R 1a and R 1b are independently H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 2a is -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or -(C1-C6 alkylene)-O-(C1-C6 alkyl); R 2b is H, halo, or C1-C6 alkyl; or R 2a and R 2b together with the carbon atom to which they are attached form a spiro 3- to 6-membered heterocyclyl or a spiro C3-C6 cycloalkyl; wherein at least one atom of the spiroheterocyclyl adjacent to the connecting piperidinyl ring is carbon; R 3a and R 3b is independently H, halo, or C1-C6 alkyl; or R 3a and R 3b together with the carbon atom to which they are attached form a C3-C4 cycloalkyl; R 4 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; [ka] but, [ka] and Y is CR 5a R 5b or S; or [ka] but, [ka] and Y is a bond; W is O or a bond; R 5a and R 5b is independently H, halo, or C1-C6 alkyl; or R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl; R 6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 7 is H, C3-C6 cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C1-C6 alkyl), -NH-(C3-C6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C1-C6 alkyl), or -O-(C3-C6 cycloalkyl); R 8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 9 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 10 is -CF3 or cyclopropyl.
[0110]
[0111] In one embodiment, [ka] (i.e., the ring A moiety) is [ka] In one embodiment, Z1 is CH. In another embodiment, Z 1 is N. In one embodiment, the Ring A moiety is [ka] In one embodiment, Z 2 is CH. In another embodiment, Z 2 is N. In one embodiment, R 10 is —CF3. In other embodiments, R 10 is cyclopropyl. In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is selected from the group consisting of: [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] In one embodiment, the Ring A moiety is [ka] is.
[0111]
[0112] In one embodiment, R 1a and R 1b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH. 1a and R 1b is independently H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 1a and R 1b is independently H, —CH, —CF, or —CHOH. 1a is H. In one embodiment, R 1b is H. In one embodiment, R 1a and R 1b are both H. In one embodiment, R 1a and R 1b one of which is H, and the other is C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH.
[0112]
[0113] In one embodiment, R 1a and R 1b is independently C1-C6 alkyl. 1a and R 1b is independently C1-C3 alkyl. 1a and R 1b is independently methyl, ethyl, n-propyl, or isopropyl. 1a and R1b are both methyl. In some embodiments, R 1a and R 1b One of them is H and the other is methyl.
[0113]
[0114] In one embodiment, R 1a and R 1b is independently C1-C6 haloalkyl. 1a and R 1b is independently a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 1a and R 1b is independently a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 1a and R 1b is independently C1-C3 haloalkyl. 1a and R 1b is independently a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 1a and R 1b are independently C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 1a and R 1b is independently —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 1a and R 1b are both -CF3. In some embodiments, R 1a and R 1b One of them is H and the other is -CF3.
[0114]
[0115] In one embodiment, R 1a and R 1b is independently C1-C6 alkyl-OH. 1a and R 1b is independently C1-C3 alkyl-OH. 1a and R 1b is independently —CHOH, —CHCH—OH, —CHCHCH—OH, or —C(CH)—OH. 1a and R 1b are both —CHOH. In some embodiments, R 1a and R 1b One of them is H and the other is -CH2OH.
[0115]
[0116] The compounds of formula (I) contain a substituent R 2a and R 2b In one embodiment, the compound of formula (I) contains a carbon atom directly attached to the piperidinyl ring, which is linked in at least one position corresponding to the substituent R 2a and R 2b The piperidinyl ring contains carbon atoms directly attached to it that are linked at both positions corresponding to:
[0116]
[0117] In one embodiment, R 2a is -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or -(C1-C6 alkylene)-O-(C1-C6 alkyl). 2a is -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkyl-OH, C1-C3 alkyl-CN, or -(C1-C3 alkylene)-O-(C1-C3 alkyl). 2a is -CN, -CH3, -CF3, -CH2OH, -CH2CN, or -CH2-O-CH3.
[0117]
[0118] In one embodiment, R 2ais -CN.
[0118]
[0119] In one embodiment, R 2a is C1-C6 alkyl. 2a is C1-C3 alkyl. 2a is methyl, ethyl, n-propyl, or isopropyl. 2a is -CH3.
[0119]
[0120] In one embodiment, R 2a is C1-C6 haloalkyl. In one embodiment, R 2a is a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 2a is a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 2a is C1-C3 haloalkyl. 2a is a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 2a is a C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 2a is —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 2a is -CF3.
[0120]
[0121] In one embodiment, R 2a is C1-C6 alkyl-OH. 2ais C1-C3 alkyl-OH. 2a is —CHOH, —CHCH—OH, —CHCHCH—OH, or —C(CH)—OH. 2a is -CH2OH.
[0121]
[0122] In one embodiment, R 2a is C1-C6 alkyl-CN. 2a is C1-C3 alkyl-CN. 2a is —CHCN, —CHCH—CN, —CHCHCH—CN, or —C(CH)—CN. 2a is -CH2CN.
[0122]
[0123] In one embodiment, R 2a is -(C1-C6 alkylene)-O-(C1-C6 alkyl). 2a is -(C1-C3 alkylene)-O-(C1-C3 alkyl). 2a is -(C1-C2 alkylene)-O-(C1-C2 alkyl). 2a is -CH2-O-CH3, -CH2-O-CH2CH3, -CH2CH2-O-CH2CH3, and -CH2CH2-O-CH3. In one embodiment, R 2a is -CH2-O-CH3.
[0123]
[0124] In one embodiment, R 2b is H, halo, or C1-C6 alkyl. 2b is H, halo, or C1-C3 alkyl. 2b is H, F, or -CH3.
[0124]
[0125] In one embodiment, R 2b is H.
[0125]
[0126] In one embodiment, R 2b is halo. In some embodiments, R 2b is chloro, fluoro, or bromo. 2b is chloro or fluoro. 2b is fluoro.
[0126]
[0127] In one embodiment, R 2b is C1-C6 alkyl. 2b is C1-C3 alkyl. 2b is methyl, ethyl, n-propyl, or isopropyl. 2b is -CH3.
[0127]
[0128] In one embodiment, R 2a and R 2b together with the carbon atom to which they are attached form a spiro 3- to 6-membered heterocyclyl or spiro C3-C6 cycloalkyl, where at least one of the atoms of the spiroheterocyclyl adjacent to the connecting piperidinyl ring is carbon. 2a and R 2b together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl or a spiro C3-C4 cycloalkyl. 2a and R 2b together with the carbon atom to which they are attached form a spiro C-C cycloalkyl. 2a and R 2b together with the carbon atom to which they are attached form spirocyclopropyl or cyclobutyl. 2a and R 2b together with the carbon atom to which they are attached form a spirocyclopropyl. 2a and R 2btogether with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl. 2a and R 2b together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl containing 1 to 3 heteroatoms selected from the group consisting of O, N, and S. In certain embodiments, R 2a and R 2b together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl containing 1 to 3 nitrogen and / or oxygen atoms. 2a and R 2b together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl containing 1 to 2 oxygen atoms. 2a and R 2b together with the carbon atoms to which they are attached, [ka] In one embodiment, R 2a and R 2b together with the carbon atoms to which they are attached, [ka] In one embodiment, R 2a and R 2b together with the carbon atoms to which they are attached, [ka] In one embodiment, R 2a and R 2b together with the carbon atoms to which they are attached, [ka] Form.
[0128]
[0129] In one embodiment, R 3a and R 3b is independently H, halo, or C1-C6 alkyl. 3a and R 3b is independently H, halo, or C1-C3 alkyl. 3a and R 3b are independently H, F, or —CH3.
[0129]
[0130] In one embodiment, R 3a is H. In one embodiment, R 3b is H. In one embodiment, R 3a and R 3b are both H. In one embodiment, R 3a and R 3b One of them is H, and the other is halo or C1-C6 alkyl.
[0130]
[0131] In one embodiment, R 3a and R 3b is independently halo. 3a and R 3b is independently chloro, fluoro, or bromo. 3a and R 3b is independently chloro or fluoro. 3a is fluoro. In some embodiments, R 3b is fluoro. In some embodiments, R 3a and R 3b are both halo. In some embodiments, R 3a and R 3b Both are fluoro.
[0131]
[0132] In one embodiment, R 3a and R 3b is independently C1-C6 alkyl. 3a and R 3bis independently C1-C3 alkyl. 3a and R 3b is independently methyl, ethyl, n-propyl, or isopropyl. 3a and R 3b are both -CH3. In one embodiment, R 3a and R 3b One of them is -CH3.
[0132]
[0133] In one embodiment, R 3a and R 3b together with the carbon atom to which they are attached form a C-C cycloalkyl. 3a and R 3b together with the carbon atom to which they are attached form a cyclopropyl. 3a and R 3b together with the carbon atom to which they are attached to form cyclobutyl.
[0133]
[0134] In one embodiment, R 4 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH. 4 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 4 is H, -CH3, -CF3, or -CH2OH.
[0134]
[0135] In one embodiment, R 4 is H.
[0135]
[0136] In one embodiment, R 4 is C1-C6 alkyl. 4 is C1-C3 alkyl. 4 is methyl, ethyl, n-propyl, or isopropyl. 4is -CH3.
[0136]
[0137] In one embodiment, R 4 is C1-C6 haloalkyl. 4 is a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 4 is a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 4 is C1-C3 haloalkyl. 4 is a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 4 is a C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 4 is —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 4 is -CF3.
[0137]
[0138] In one embodiment, R 4 is C1-C6 alkyl-OH. 4 is C1-C3 alkyl-OH. 4 is —CHOH, —CHCH—OH, —CHCHCH—OH, or —C(CH)—OH. 4 is -CH2OH.
[0138]
[0139] In some embodiments, X is CH. In other embodiments, X is N.
[0139]
[0140] In one embodiment, [ka] (i.e., the ring D portion) is [ka] In one embodiment, W is O and the ring D moiety is [ka] In other embodiments, W is a bond and the ring D moiety is [ka] In one embodiment, the Ring D moiety is [ka] In one embodiment, the Ring D moiety is [ka] is.
[0140]
[0141] In one embodiment, the Ring D moiety is [ka] and R 8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl. 8 is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl. 8 is -CH3, -CF3, or cyclopropyl. In certain embodiments, the Ring D moiety is [ka] is.
[0141]
[0142] In one embodiment, R 8 is C1-C6 alkyl. 8 is C1-C3 alkyl. 8 is methyl, ethyl, n-propyl, or isopropyl. 8 is -CH3.
[0142]
[0143] In one embodiment, R 8 is C1-C6 haloalkyl. 8 is a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 8 is a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 8 is C1-C3 haloalkyl. 8 is a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 8 is a C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 8 is —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 8 is -CF3.
[0143]
[0144] In one embodiment, R 8 is C3-C4 cycloalkyl. 8 is cyclopropyl. In one embodiment, R 8 is cyclobutyl.
[0144]
[0145] In some embodiments, Y is S. In other embodiments, Y is a bond. In further embodiments, Y is CR 5a R 5b where R 5a and R 5b are independently H, halo, or C1-C6 alkyl, or R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl.
[0145]
[0146] In one embodiment, R 5a and R 5b is independently H, halo, or C1-C6 alkyl. 5a and R 5b is independently H, halo, or C1-C3 alkyl. 5a and R 5b are independently H, F, or —CH3.
[0146]
[0147] In one embodiment, R 5a is H. In one embodiment, R 5b is H. In one embodiment, R 5a and R 5b are both H. In one embodiment, R 5a and R 5b One of R is H and the other is halo or C1-C6 alkyl. 5a and R 5b One of R is H and the other is F or -CH3. 5a and R 5b One of them is H and the other is F.
[0147]
[0148] In one embodiment, R 5a and R 5b is independently halo. 5a and R 5b is independently chloro, fluoro, or bromo. 5a and R 5b is independently chloro or fluoro. 5a and R 5b are both halo. In some embodiments, R 5a and R 5b are both fluoro. 5a and R 5b One of them is fluoro.
[0148]
[0149] In one embodiment, R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl. 5a and R 5b together with the carbon atom to which they are attached form a C-C cycloalkyl. 5a and R 5b together with the carbon atom to which they are attached form a cyclopropyl. 5a and R 5b together with the carbon atom to which they are attached to form cyclobutyl.
[0149]
[0150] In one embodiment, R 6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl. 6 is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl. 6 is -CH3, -CHF2, or cyclopropyl.
[0150]
[0151] In one embodiment, the Ring D moiety is [ka] and Y is CR 5a R 5b In one embodiment, the Ring D moiety is [ka] W is O and Y is CR 5a R 5b In one embodiment, the Ring D moiety is [ka] where W is a bond and Y is CR 5a R 5b In one embodiment, the Ring D moiety is [ka] and Y is S. In one embodiment, the ring D moiety is [ka] and W is O and Y is S. In one embodiment, the ring D moiety is [ka] and W is a bond and Y is S. In one embodiment, the ring D moiety is [ka] and Y is a bond.
[0151]
[0152] In one embodiment, R 6 is C1-C6 alkyl.6 is C1-C3 alkyl. 6 is methyl, ethyl, n-propyl, or isopropyl. 6 is -CH3.
[0152]
[0153] In one embodiment, R 6 is C1-C6 haloalkyl. 6 is a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 6 is a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 6 is C1-C3 haloalkyl. 6 is a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 6 is a C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 6 is —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 6 is -CHF2.
[0153]
[0154] In one embodiment, R 6 is C3-C6 cycloalkyl. 6 is C3-C5 cycloalkyl. 6 is C3-C4 cycloalkyl. 6is cyclopropyl, cyclobutyl, or cyclopentyl. 6 is cyclopropyl. In one embodiment, R 6 is cyclobutyl.
[0154]
[0155] In one embodiment, R 7 is H, halo, C3-C6 cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C1-C6 alkyl), -NH-(C3-C6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C1-C6 alkyl), or -O-(C3-C6 cycloalkyl). 7 is H, halo, C3-C4 cycloalkyl, -NH(4- to 5-membered heterocyclyl), -NH(C1-C3 alkyl), -NH(C3-C5 cycloalkyl), -O(C1-C3 alkyl), -O(4- to 5-membered heterocyclyl), or -O(C3-C5 cycloalkyl). 7 is H, Cl, cyclopropyl, -NH(CH2CH3), -NH(cyclopropyl), -OCH2CH3, -O(cyclopropyl), [ka] is.
[0155]
[0156] In one embodiment, R 7 is H.
[0156]
[0157] In one embodiment, R 7 is halo. In some embodiments, R 7 is chloro, fluoro, or bromo. 7 is chloro or fluoro. 7 is chloro.
[0157]
[0158] In one embodiment, R 7 is C3-C6 cycloalkyl.7 is C3-C4 cycloalkyl. 7 is cyclopropyl or cyclobutyl. 7 is cyclopropyl.
[0158]
[0159] In one embodiment, R 7 is -NH-(3- to 6-membered heterocyclyl). 7 is -NH(4- to 5-membered heterocyclyl). 7 The heterocyclyl portion of R contains 1 to 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen. 7 The heterocyclyl portion of R contains one oxygen atom. 7 The heterocyclyl portion of R contains one nitrogen atom. 7 The heterocyclyl portion of [ka] In one embodiment, R 7 but, [ka] is.
[0159]
[0160] In one embodiment, R 7 is -NH-(C1-C6 alkyl). 7 is -NH-(C1-C3 alkyl). 7 is —N(H)CH, —NH(CHCH), —NH(CHCHCH), or —N(H)CH(CH). In certain embodiments, R 7 is -NH(CH2CH3).
[0160]
[0161] In one embodiment, R7 is —NH—(C3-C6 cycloalkyl). In one embodiment, R 7 is —NH—(C3-C5 cycloalkyl). In one embodiment, R 7 is —NH—(C-C cycloalkyl). In one embodiment, R 7 is -NH-(cyclopropyl), -NH-(cyclobutyl), -NH-(cyclopentyl), or -NH-(cyclohexyl). 7 is -NH-(cyclopropyl).
[0161]
[0162] In one embodiment, R 7 is —O-(3- to 6-membered heterocyclyl). 7 is —O-(4- to 5-membered heterocyclyl). 7 The heterocyclyl portion of R contains 1 to 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen. 7 The heterocyclyl portion of R contains one oxygen atom. 7 The heterocyclyl portion of R contains one nitrogen atom. 7 The heterocyclyl portion of [ka] In one embodiment, R 7 but, [ka] is.
[0162]
[0163] In one embodiment, R 7 is —O—(C1-C6 alkyl). In one embodiment, R 7 is —O—(C1-C3 alkyl). In one embodiment, R 7is —OCH3, —OCH2CH3, —OCH2CH2CH3, or —OCH(CH3)2. In some embodiments, R 7 is -OCH2CH3.
[0163]
[0164] In one embodiment, R 7 is —O—(C3-C6 cycloalkyl). In one embodiment, R 7 is —O—(C3-C5 cycloalkyl). In one embodiment, R 7 is —O—(C-C cycloalkyl). In one embodiment, R 7 is —O-(cyclopropyl), —O-(cyclobutyl), —O-(cyclopentyl), or —O-(cyclohexyl). 7 is -O-(cyclopropyl).
[0164]
[0165] In one embodiment, R 9 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH. 9 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH. 9 is H, -CH3, -CF3, or -CH2OH.
[0165]
[0166] In one embodiment, R 9 is H.
[0166]
[0167] In one embodiment, R 9 is C1-C6 alkyl. 9 is C1-C3 alkyl. 9 is methyl, ethyl, n-propyl, or isopropyl. 9 is -CH3.
[0167]
[0168] In one embodiment, R 9is C1-C6 haloalkyl. 9 is a C1-C6 haloalkyl containing 1 to 13 halogen atoms. 9 is a C1-C6 haloalkyl containing 1 to 7 halogen atoms. 9 is C1-C3 haloalkyl. 9 is a C1-C3 haloalkyl containing 1 to 7 halogen atoms. 9 is a C1-C2 haloalkyl containing 1 to 5 halogen atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro, bromo, and fluoro atoms. In some embodiments, the halogen atoms are independently selected from the group consisting of chloro and fluoro atoms. In some embodiments, all of the halogen atoms are fluoro atoms. In some embodiments, the halogen atoms are a combination of chloro and fluoro atoms. In some embodiments, R 9 is —CF, —CCl, —CFCl, —CFCl, —CHF, —CHF, —CHCl, —CHF, or —CHFCl. 9 is -CF3.
[0168]
[0169] In one embodiment, R 9 is C1-C6 alkyl-OH. 9 is C1-C3 alkyl-OH. 9 is —CHOH, —CHCH—OH, —CHCHCH—OH, or —C(CH)—OH. 9 is -CH2OH.
[0169]
[0170] In some embodiments, the compound has formula (IA) or (IB): [ka] wherein R1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 6 , R 7 , R 9 , R 10 , X, Y, Z 1 , Z 2 and the Ring D moiety are as described for compounds of formula (I).
[0170]
[0171] In some embodiments, the compound has formula (IC), (ID), (IE), or (IF): [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 6 , R 7 , R 9 , R 10 , W, X, Y, Z 1 , and Z 2 is as defined for compounds of formula (I).
[0171]
[0172] In some embodiments, the compound has formula (IG), (IH), (II), (IJ), (IK), (IL), (IM), or (IN): [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 6 , R 7 , R 9 , R10 , W, X, and Y are as defined for compounds of formula (I).
[0172]
[0173] In some embodiments, the compound has formula (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (II-G), (II-H), (II-I), (II-J), (II-K), or (II-L): [ka] [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , and R 9 is as defined for compounds of formula (I), and p in formula (II-G) is 1 or 2.
[0173]
[0174] In some embodiments, the compound has formula (III-A), (III-B), (III-C), or (III-D): [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 5a , R 5b , R 7 , and R 9 is as defined for compounds of formula (I).
[0174]
[0175] In certain embodiments, the compound has formula (IV-A), (IV-B), or (IV-C): [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R 7 , and R 9 is as defined for compounds of formula (I).
[0175]
[0176] In certain embodiments, the compound has the formula (VA), (VB), (VC), (VD), (VE), (VF), or (VG): [ka] wherein R 1a , R 1b , R 2a , R 2b , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R 7 , and R 9 is as defined for compounds of formula (I).
[0176]
[0177] In certain embodiments, the compound has formula (VI-A), (VI-B), (VI-C), or (VI-D): [ka] wherein R 1a , R 1b , R 2a , R2b , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R 7 , and R 9 is as defined for compounds of formula (I).
[0177] [Table 1]
[0178] [Table 2]
[0179] [Table 3]
[0180] [Table 4]
[0181]
[0178] In one embodiment, there is provided a compound selected from compound numbers 1 to 45 in Table 1, or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof. In one embodiment, there is provided a compound selected from compound numbers 47 to 52 in Table 1, or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof.
[0182] In one aspect, provided herein is a method for preparing a compound of formula (I) described herein. In another aspect, provided herein is an intermediate compound for preparing a compound of formula (I). Also provided herein is a compound that is an assay probe, e.g., optionally tagged with a fluorescent label. In a further aspect, provided herein is a method for assaying the inhibition of Cbl-b. In one form, provided herein is a method for assaying the inhibition of Cbl-b, comprising pre-incubating Cbl-b with an assay probe, such as an assay probe tagged with a fluorescent label, followed by exposing the Cbl-b / assay probe mixture to a candidate compound, and then determining whether and to what extent the assay probe is displaced by the candidate compound, e.g., using FRET signal detection.
[0183] In any of the pharmaceutical compositions, methods, or kits described herein, the Cbl-b inhibitor may be selected from one or more Cbl-b inhibitors disclosed in the following patent applications: compounds 1-719 (including the "a" and "b" variants thereof) of International Patent Application WO 2019 / 148005 or any compound of formula (IA), formula (I), formula (II-A), formula (II), formula (III-A), formula (III), or formula (IV) therein. The contents of International Patent Application WO 2019 / 148005 are incorporated herein by reference in their entirety.
[0184]
[0181] Representative compounds for use in the pharmaceutical compositions and methods described herein are listed in Table 1A.
[0185] [Table 5]
[0186]
[0182] In certain embodiments, provided for use in the compositions and methods described herein is a compound selected from compound numbers 53-61 in Table 1A, or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof.
[0187] In one embodiment, the small molecule Cbl-b inhibitor for the methods, pharmaceutical compositions, and kits disclosed herein has a molecular weight of 1,000 daltons or less, or about 1,000 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 900 daltons or less, or about 900 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 800 daltons or less, or about 800 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 750 daltons or less, or about 750 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 700 daltons or less, or about 700 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 650 daltons or less, or about 650 daltons or less. In another embodiment, the small molecule Cbl-b inhibitor has a molecular weight of 600 daltons or less, or about 600 daltons or less. For any of the above embodiments, the lower molecular weight limit of the small molecule Cbl-b inhibitor may be 100 daltons, 200 daltons, or 300 daltons, or about 100 daltons, about 200 daltons, or about 300 daltons.
[0188] The following schemes illustrate methods for synthesizing the compounds disclosed herein. Mixtures of stereoisomers produced during synthesis, such as racemic mixtures of the final compounds, can be separated into their individual enantiomers using common chromatographic methods, such as supercritical fluid chromatography in combination with chiral stationary phases, chiral column chromatography, or other methods known in the art. [ka] In the formula, Z 1 , R6 , and R 10 is as defined for compounds of formula (I); X' is Br or NH; R a and R b is a suitable protecting group; (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0189] Compounds of general formula I-9 can be synthesized as outlined in Scheme I. Coupling of boronic ester I-1 with alkene I-2 under rhodium catalysis gives ester I-3. Triazoles are assembled via hydrazide formation (I-4), cyclization, and desulfurization to give compound I-6. Compound I-6 (where X' is NH) is reacted with bromoester I-8 to give compound I-9, which is subsequently converted to compound I-10 by reductive amination with a substituted piperidine. Compound I-6 (where X' is Br) is reacted with piperidine derivative I-7 under palladium catalysis to give compound I-10 directly. [ka] In the formula, Z 1 , R 6 , R 9 , and R 10 is as defined for compounds of formula (I); X' is Br or NH; R a and R b is a suitable protecting group; (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0190] Compounds of general formula I-9a can be synthesized as outlined in Scheme Ia. Coupling of boronic ester I-1 with alkene I-2 under rhodium catalysis gives ester I-3. Triazoles are assembled via hydrazide formation (I-4), cyclization, and desulfurization to give compound I-6. Compound I-6 (where X' is NH) is reacted with bromoester I-8a to give compound I-9a, which is subsequently converted to compound I-10a by reductive amination with a substituted piperidine. Compound I-6 (where X' is Br) is reacted with piperidine derivative I-7a under palladium catalysis to give compound I-10a directly. [ka] In the formula, R 6 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0191] Scheme II outlines the synthesis of compounds of general formula II-4. Aldehyde II-1 is converted to piperidine derivative II-2 by reductive amination with a substituted piperidine, followed by ester hydrolysis under basic conditions. Piperidine II-2 is then coupled to amine I-6 with a coupling reagent such as HATU or T3P to give compound II-4. [ka] In the formula, Z 2 , R 6 , and R 10 is as defined for compounds of formula (I); (R) nis R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 corresponds to ;R b is a suitable protecting group; Y b is an alkyl group (such as methyl), a cycloalkyl group (such as cyclopropyl), a haloalkyl group (such as bromomethyl), or CHO; Y c is hydroxyl or NH2.
[0192] Scheme II-a outlines the synthesis of compounds of general formula II-5a. Compounds of formula II-1a can be converted to compounds II-2a by oxidation to the aldehyde with a reagent such as SeO2 or brominated with Br2, followed by reductive amination or direct substitution with a substituted piperidine to form compounds of formula II-3a. Compound II-3a can then be subjected to ester hydrolysis under basic conditions to give compounds II-4a (Y c =OH) to give the amide II-5a. Acid II-4a is then coupled to amine I-6 with a coupling reagent such as HATU or T3P to give amide II-5a. [ka] In the formula, Z 1 , R 6 , and R 10 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0193] Compounds of general formula III-4 can be prepared according to Scheme III. Alcohol III-1 is converted to ester III-2 by conversion to the halide, displacement with cyanide, and then hydrolysis. The triazole is formed as in Scheme I. The bromide is converted to aniline III-3 by palladium-catalyzed coupling with t-butyl carbamate, followed by deprotection. Compound III-3 is then elaborated as in Scheme I to give compound III-4. [ka] In the formula, Z 1 , R 6 , R 9 , and R 10 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0194] Compounds of general formula III-4a can be prepared according to Scheme III-a. Alcohol III-1 is converted to ester III-2 by conversion to the halide, displacement with cyanide, and then hydrolysis. The triazole is formed as in Scheme Ia. The bromide is converted to aniline III-3 by palladium-catalyzed coupling with t-butyl carbamate, followed by deprotection. Compound III-3 is then elaborated as in Scheme Ia to give compound III-4a. [ka] In the formula, Z 1 , R 6 , and R 10 is as defined for compounds of formula (I), and (R) nis R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0195] Scheme IV shows a method for preparing compounds of general formula IV-5. Ester IV-1 is converted to α-hydroxyester IV-2 by deprotonation and treatment with an oxidizing agent such as oxaziridine. The ester is elaborated to triazole IV-3 as in Scheme I. The hydroxy is converted to fluoride IV-4 with DAST. Compound IV-4 is then worked up as in Scheme I to give compound IV-5. [ka] In the formula, Z 1 , R 6 , R 9 , and R 10 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0196] Scheme IV-a shows a method for preparing compounds of general formula IV-5a. Ester IV-1 is converted to α-hydroxyester IV-2 by deprotonation and treatment with an oxidizing agent such as oxaziridine. The ester is elaborated to triazole IV-3 as in Scheme Ia. The hydroxy is converted to fluoride IV-4 with DAST. Compound IV-4 is then worked up as in Scheme Ia to give compound IV-5a. [ka] In the formula, R 6 , R 7 , R 10 , and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0197] The synthesis of compounds of general formula V-7 is shown in Scheme V. Trichloropyridine V-1 is coupled with dimethyl malonate to give diester V-2. Reaction of diester V-2 with allyl bromide, followed by reduction, gives dihydroxide V-3. Compound V-3 is then reacted under Mitsunobu conditions to give oxetane V-4. The allyl group is oxidized to an acid, which is then converted to triazole V-5 as in Scheme I. Subsequent reaction of V-5 with a nucleophile, such as an amine or alcohol, or an organometallic reagent under palladium catalysis gives V-6, which is then coupled with indolone I-7 to give compound V-7. [ka] In the formula, R 6 , R 7 , R 9 , R 10 , and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0198] The synthesis of compounds of general formula V-7a is shown in Scheme Va. Trichloropyridine V-1 is coupled with dimethyl malonate to give diester V-2. Reaction of diester V-2 with allyl bromide, followed by reduction, gives dihydroxide V-3. Compound V-3 is then reacted under Mitsunobu conditions to give oxetane V-4. The allyl group is oxidized to an acid, which is then converted to triazole V-5 as in Scheme Ia. Subsequent reaction of V-5 with a nucleophile, such as an amine or alcohol, or an organometallic reagent under palladium catalysis gives V-6, which is then coupled with indolone I-7a to give compound V-7a. [ka] In the formula, R 10 and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0199] Intermediate compounds of general formula I-7 used in the general synthesis outlined in Scheme I can be synthesized according to Scheme VI: Aldehyde VI-1 is coupled with a substituted piperidine under reductive amination conditions to give piperidine intermediate VI-2, which is treated with ammonia to give compounds of formula I-7. [ka] In the formula, R 9 , R 10 , and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0200] Intermediate compounds of general formula I-7a used in the general synthesis outlined in Scheme Ia can be synthesized according to Scheme VI-a: Aldehyde VI-1a is coupled with a substituted piperidine under reductive amination conditions to give piperidine intermediate VI-2a, which is treated with ammonia to give compounds of formula I-7a. [ka] In the formula, R 10 and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0201] Scheme VII outlines the synthesis of compounds of general formula VII-5. Bromide VII-1 is coupled with 3-nitrophenylboronic acid to give nitro VII-2. The ester of compound VII-2 is converted to the triazole as in Scheme I, and reduction of the nitro affords amine VII-3, which is then elaborated as in Scheme I to give VII-5. [ka] In the formula, R 9 , R 10 , and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I)1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 Corresponds to.
[0202] Scheme VII-a outlines the synthesis of compounds of general formula VII-5a. Bromide VII-1 is coupled with 3-nitrophenylboronic acid to give nitro VII-2. The ester of compound VII-2 is converted to the triazole as in Scheme Ia, and reduction of the nitro affords amine VII-3, which is then elaborated as in Scheme Ia to give VII-5a. [ka] In the formula, R 9 , R 10 , and Z 1 is as defined for compounds of formula (I), and (R) n is R as described for compounds of formula (I) 1a , R 1b , R 2a , R 2b , R 3a , R 3b , and R 4 where P is a protecting group such as pivaloyl.
[0203] Scheme VIII outlines the synthesis of compounds of general formula VIII-6. Hydroxybromide VIII-1 is converted to sulfide VIII-2 by displacement with a thiol source such as trityl SH (Croft, Rosemary A. et al. Chemistry-A European Journal, 24(4), 818-821; 2018). Triazoles are converted to sulfides VIII-2 by S with triazolyl chloride. NAr substitution provides VIII-4, which is coupled with an isoindolone such as I-5 to give VIII-5. The protecting group is then removed under Ni catalysis (Correa, Arkaitz et al., Journal of the American Chemical Society, 136(3), 1062-1069; 2014) to give analogs VIII-6.
[0204] Compounds 1, 2, 10, 22, 23, 24, 32, 36, 39, 40, 44, and 49-51 had IC values of less than 1 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 3, 4, 11, 13-20, 25, 26, 28, 31, 33-35, 37, 38, 41-43, 45, 48, and 52 exhibit IC values of 1 nM to 5 nM in the Cbl-b inhibition assay of Biological Example 1. 50 Compounds 5-9, 12, 21, 27, 29, 30, and 47 exhibit IC values of 5.1-100 nM in the Cbl-b inhibition assay of Biological Example 1. 50 values and, in one embodiment, are used in the pharmaceutical compositions and methods disclosed herein.
[0205] In various embodiments, and as further described herein, the compounds provided herein (as well as compositions comprising the compounds described herein, and methods of using the compounds or compositions) have an IC50 of less than 1 nM, 1 nM to 5 nM, 5.1 to 100 nM, or greater than 100 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50 In further embodiments, and as further described herein, the compounds provided herein (as well as compositions comprising the compounds described herein, and methods of using the compounds or compositions) have an IC value of less than 1 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50In further embodiments, and as further described herein, the compounds provided herein (as well as compositions comprising the compounds described herein, and methods of using the compounds or compositions) have an IC value of 1 nM to 5 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50 In further embodiments, and as further described herein, the compounds provided herein (as well as compositions comprising the compounds described herein, and methods of using the compounds or compositions) have an IC value of 5.1 to 100 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50 In further embodiments, and as further described herein, the compounds provided herein (as well as compositions comprising the compounds described herein, and methods of using the compounds or compositions) have an IC value of greater than 100 nM, as determined by the Cbl-b inhibition assay of Biological Example 1. 50 It has a value.
[0206]
[0202] With respect to IL-2 secretion from immune cells (e.g., T cells) costimulated with anti-CD3 and anti-CD28 antibodies, the compounds provided herein (and compositions comprising the compounds described herein) induce a change of ≦10-fold, 11-15-fold, or more than 15-fold over baseline at inhibitor concentrations of 1 micromolar or 0.3 micromolar.
[0207]
[0203] With respect to IL-2 secretion from immune cells (e.g., T cells) stimulated with anti-CD3 antibodies, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of ≦0.33-fold, 0.34-0.66-fold, or greater than 0.66-fold relative to baseline at inhibitor concentrations of 3 micromolar or 1 micromolar.
[0208]
[0204] For CD25 staining on the cell surface of immune cells (e.g., T cells) costimulated with anti-CD3 antibody and anti-CD28 antibody, the compounds provided herein (and compositions comprising the compounds described herein) induce a change of ≦1.24-fold, 1.25-1.39-fold, or greater than 1.39-fold over baseline at inhibitor concentrations of 1 micromolar or 0.3 micromolar.
[0209]
[0205] In CD25 staining on the cell surface of immune cells (e.g., T cells) stimulated with anti-CD3 antibodies, the compounds provided herein (as well as compositions comprising the compounds described herein) induce a change of ≦1.04-fold, 1.05-1.14-fold, or greater than 1.14-fold over baseline at inhibitor concentrations of 3 micromolar or 1 micromolar.
[0210] III. METHODS, AGENTS, AND USES Provided herein are methods for modulating the activity of immune cells (e.g., T cells, B cells, or NK cells), such as by contacting the immune cells with an effective amount of a Cbl-b inhibitor or composition thereof described herein. Also provided herein are in vitro methods for generating immune cells with modulated activity, referred to herein as "modified immune cells," wherein the modified immune cells can be administered to an individual in need thereof (e.g., an individual with cancer) by ex vivo methods. Further provided are in vivo methods for modulating a response in an individual in need thereof (e.g., an individual with cancer), comprising administering an effective amount of a Cbl-b inhibitor or composition thereof described herein. Furthermore, the present disclosure provides in vitro methods for generating an expanded population of lymphocytes following in vivo lymphoconditioning in an individual, wherein lymphoconditioning occurs as a result of administering to the individual an effective amount of a Cbl-b inhibitor or composition thereof described herein. Furthermore, the expanded population of lymphocytes can then be administered to an individual with cancer. In certain embodiments, expanded populations of engineered immune cells or lymphocytes are generated from a biological sample containing immune cells obtained from an individual, such as a blood sample containing peripheral blood mononuclear cells or a tumor biopsy containing tumor infiltrating lymphocytes (TILs).
[0211]
[0207] Further provided is a Cbl-b inhibitor for use as an effective therapeutic agent. Provided is a Cbl-b inhibitor for use in treating or preventing a disease or condition associated with Cbl-b activity. Also provided is a Cbl-b inhibitor for use in treating cancer. Further provided is the use of a Cbl-b inhibitor in the manufacture of a medicament for treating or preventing a disease or condition associated with Cbl-b activity. Also provided is the use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer. Furthermore, the present disclosure provides therapeutic methods, medicaments, and uses comprising a Cbl-b inhibitor as part of a combination therapy for treating cancer requiring one or more of an immune checkpoint inhibitor, an anti-tumor agent, and radiation therapy.
[0212] In some embodiments of the disclosed methods of treatment, medicaments, and uses, the cancer is a blood cancer such as lymphoma, leukemia, or myeloma. In other embodiments of the disclosed methods of treatment, medicaments, and uses, the cancer is a non-blood cancer such as sarcoma, carcinoma, or melanoma.
[0213] Hematological cancers include, but are not limited to, one or more leukemias, such as B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), and acute lymphoblastic leukemia (ALL); one or more chronic leukemias, including, but not limited to, chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL); and one or more chronic leukemias, including, but not limited to, B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and hairy cell leukemia. Additional blood cancers or hematological conditions include small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and "preleukemia," which are a diverse group of hematological conditions united by ineffective production (or dysplasia) of bone marrow blood cells.
[0214]
[0210] Non-hematological cancers include, but are not limited to, neuroblastoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer (e.g., NSCLC), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, uterine cancer, adrenal cancer, and head and neck cancer.
[0215] In some aspects, the efficacy of administering a Cbl-b inhibitor in treating a disease or disorder, such as cancer, is measured by assessing clinical outcomes, such as a reduction in tumor size or number of tumors and / or survival. In some embodiments, "treating cancer" includes assessing a patient's response to a treatment regimen according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), as described (see, e.g., Eisenhauer et al., Eur J Cancer, 45:228-247, 2009; and Nishino et al., Am J Roentgenol, 195:281-289, 2010). Response criteria for determining an objective anti-tumor response according to RECIST 1.1 include complete response (CR); partial response (PR); progressive disease (PD); and stable disease (SD).
[0216] A. Cell isolation and processing Methods are provided for the preparation and processing of immune cells (e.g., modified immune cells) generated and used in the methods herein. As used herein, the term "modified immune cells" refers to immune cells or cell populations comprising immune cells that have been cultured, incubated, and / or contacted with an effective amount of a Cbl-b inhibitor to modulate the activity of said immune cells. In certain embodiments, modified immune cells may be used in immunotherapy, e.g., in connection with adoptive immunotherapy.
[0217] 1. Sample In certain embodiments, the modified immune cells or cell populations comprising modified immune cells are isolated from a sample, e.g., a biological sample, e.g., obtained from or derived from an individual (e.g., a human). In certain embodiments, the individual from whom the immune cells are isolated is an individual with a particular disease or condition (e.g., cancer) or an individual in need of or to be administered cell therapy. In certain embodiments, the individual is a human in need of a particular therapeutic intervention, such as adoptive immune cell therapy, from which immune cells are isolated, treated, and / or modified. Thus, in certain embodiments, the cells isolated from the individual are primary cells (e.g., primary human cells). As used herein, the term "primary cells" refers to cells isolated directly from a mammalian biological fluid or tissue (e.g., a human biological fluid or tissue).
[0218] In some embodiments, the modified immune cells are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. As used herein, the term "hematopoietic cells" includes hematopoietic stem cells and hematopoietic progenitor cells. In some embodiments, the modified immune cells are present in a heterogeneous cell population or a composition comprising a heterogeneous cell population. For example, the modified immune cells can be hematopoietic cells present in a heterogeneous cell population including cells such as differentiated cells derived from a tissue or organ. In some embodiments, the modified immune cells are present in a homogeneous cell population or a composition comprising a homogeneous cell population. For example, the modified immune cells can be hematopoietic cells present in a homogeneous cell population including only hematopoietic cells. In some embodiments, the modified immune cells or cell populations comprising the modified immune cells include one or more subsets of immune cells. For example, one or more subsets of immune cells can be CD4+ cells, CD8+ cells, and subpopulations thereof, defined by, for example, function, activation state, maturity, differentiation, proliferation, localization potential, persistence capacity, surface marker profile, cytokine secretion profile, and / or degree of differentiation.
[0219] In certain embodiments, biological samples as described herein include tissues, body fluids, and other samples taken directly from an individual, as well as samples obtained from one or more processing steps, e.g., separation, centrifugation, genetic modification (e.g., transduction with a viral vector encoding a recombinant chimeric receptor), washing, and / or incubation. Biological samples can be samples obtained directly from processed biological sources or samples. Biological samples include, but are not limited to, body fluids, e.g., blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue and organ samples (e.g., samples from tissues or organs, including tumors), including processed samples derived therefrom. In certain embodiments, the biological sample is a biological fluid sample or a biological tissue sample. In certain embodiments, the biological sample is a biological tissue sample. In certain aspects, the biological sample from which immune cells are derived or isolated is derived from blood or a blood-derived sample, or an apheresis or leukapheresis product.
[0220] Exemplary biological samples include whole blood, peripheral blood mononuclear cells (PBMCs), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testes, ovaries, tonsils, or other organs, and / or cells derived therefrom. In the context of cellular therapy (e.g., adoptive cellular therapy), biological samples include samples from autologous sources (i.e., obtained from or derived from an individual in need of cellular therapy) and allogeneic sources (i.e., obtained from or derived from an individual in need of cellular therapy or a source other than such individual).
[0221] In some embodiments, the modified immune cells or cell populations comprising modified immune cells are derived from a cell line (e.g., a T cell line, a B cell line, an NK cell line, etc.). In some embodiments, the modified immune cells or cell populations comprising modified immune cells are obtained from a heterologous source, e.g., from a mouse, a rat, a non-human primate, or a pig.
[0222] 2. Cell Processing and Isolation In certain embodiments, isolation of the modified immune cells comprises one or more preparation and / or cell separation steps. The one or more cell separation steps can be non-affinity-based or affinity-based separation. By way of example, non-affinity-based separation can be centrifugation of a composition comprising the modified immune cells. In certain embodiments, non-affinity-based separation methods include density-based cell separation methods, such as preparation of white blood cells from peripheral blood by lysing red blood cells and centrifugation through a Percoll or Ficoll gradient. Affinity-based separation methods can include contacting a composition comprising the modified immune cells with antibody-coated beads. Antibody-coated beads contemplated herein include, but are not limited to, magnetic beads coated with antibodies that bind to markers expressed on the surface of engineered immune cells (e.g., Dynabeads® sold by Life Technologies (Carlsbad, CA), MACS® microbeads sold by Miltenyi Biotec Inc. (Auburn, CA); or EasySep™ Direct RapidSpheres™ sold by Stemcell Technologies (Vancouver, BC, Canada). In certain embodiments, specific subpopulations of T cells, such as cells positive for one or more surface markers or expressing high levels of one or more surface markers, e.g., CD4+, CD8+, etc., are isolated by positive or negative selection techniques. Positive selection can be based on techniques in which target cells (e.g., engineered immune cells) are bound to a reagent and retained for further use. For example, T cells that are CD3+ can be positively selected using magnetic beads (e.g., MACS® CD3 human microbeads) bound to an anti-CD3 antibody. Negative selection can be based on techniques in which target cells (e.g., modified immune cells) that are not bound to the reagent are retained.For example, total human primary T cells can be isolated from peripheral blood mononuclear cells (PBMCs) using negative selection, in which a cocktail of antibodies against the surface markers CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and CD235a is incubated in a sample containing PBMCs, and then the sample is passed through magnetic beads to remove cells expressing those surface markers and retain the remaining cells in the sample for further processing. In certain embodiments, a cell population containing immune cells or modified immune cells is washed, centrifuged, and / or incubated in the presence of one or more reagents to, for example, remove unwanted components, enrich for desired components, or lyse or remove cells sensitive to a particular reagent. In certain instances, immune cells are separated based on one or more properties, such as density, adhesive properties, size, sensitivity to, and / or resistance to a particular component. The cell separation process does not require 100% enrichment or removal of a particular cell. In certain embodiments, positive selection or enrichment of a particular type of immune cell (e.g., CD4+ T cells) refers to increasing the number or percentage of such cells. In certain embodiments, removal or depletion of a particular type of non-targeted cell, such as by negative selection, refers to decreasing the number or percentage of such cells.
[0223] In some embodiments, immune cells or cell populations comprising immune cells are obtained from the circulating blood of an individual, e.g., by apheresis or leukapheresis. In some embodiments, the sample comprising the modified immune cells contains T cells, B cells, and NK cells, as well as lymphocytes, including monocytes, granulocytes, red blood cells, and / or platelets, and in some embodiments, cells other than red blood cells and platelets.
[0224] In some embodiments, blood cells collected from an individual are washed, e.g., to remove the plasma fraction and to place the cell population containing the modified immune cells in an appropriate buffer or medium for subsequent processing steps. In some embodiments, the cell population containing the modified immune cells is washed with phosphate-buffered saline. In some embodiments, the washing solution lacks calcium and / or magnesium. In some aspects, the washing step is accomplished by a semi-automated "flow-through" centrifuge. In some aspects, the washing step is accomplished by tangential flow filtration. In some embodiments, the modified immune cells or cell population containing the modified immune cells are resuspended after washing in a variety of suitable buffers, such as, for example, phosphate-buffered saline without calcium and / or magnesium. In some embodiments, components of the blood cell sample are removed and the modified immune cells or cell population containing the modified immune cells are directly resuspended in a suitable cell culture medium.
[0225] Representative methods for processing and / or isolating immune cells, such as hematopoietic cells, from a sample containing a cell population containing said hematopoietic cells (e.g., a sample containing PBMCs) are described in Biological Example 2 and Biological Example 3 herein. Methods and techniques for processing and / or isolating immune cells, such as hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells, are well known in the art. See, e.g., U.S. Patent Application Publication No. 2017 / 0037369; U.S. Patent Application Publication No. 2012 / 0148553; U.S. Patent No. 6,461,645; U.S. Patent No. 6,352,694; and U.S. Patent No. 7,776,562.
[0226] 3. Incubation and Treatment Provided herein are methods for modulating the activity of immune cells, such as the treated and / or isolated immune cells described above, by contacting the immune cells with an effective amount of a Cbl-b inhibitor described herein. Also provided herein are modified immune cells produced by any of the methods described herein, e.g., by culturing a cell population containing immune cells (e.g., the treated and / or isolated immune cells described above) in the presence of an effective amount of a Cbl-b inhibitor to modulate the activity of the immune cells, thereby producing the modified immune cells.
[0227] In some embodiments, the modified immune cells (e.g., the treated and / or isolated immune cells described above) are incubated and / or cultured in a suitable culture medium prior to contacting the immune cells with a Cbl-b inhibitor provided herein. In some embodiments, the modified immune cells are incubated and / or cultured in a suitable culture medium simultaneously with contacting the immune cells with a Cbl-b inhibitor provided herein.
[0228] The treated and / or separated modified immune cells or cell populations comprising modified immune cells can be differentiated and / or expanded in vitro. In certain embodiments, the modified immune cells are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. In certain embodiments, the modified immune cells are incubated in a suitable cell culture medium containing a Cbl-b inhibitor described herein prior to immune cell differentiation and / or expansion. In certain embodiments, the modified immune cells are incubated in a suitable cell culture medium containing a Cbl-b inhibitor described herein after immune cell differentiation and / or expansion. Immune cells are modified (i.e., modified immune cells) upon contact with an amount of a Cbl-b inhibitor provided herein effective to modulate the activity of the immune cells. In certain embodiments, the modified immune cells are not differentiated and / or expanded in vitro and are therefore the same cell type as the modified immune cells contacted with the Cbl-b inhibitor. For example, T cells can be incubated in a suitable medium containing a Cbl-b inhibitor without T cell differentiation. In other embodiments, the modified immune cells are differentiated and / or expanded in vitro and are therefore of a different cell type than the modified immune cells contacted with the Cbl-b inhibitor. For example, hematopoietic cells can be incubated in a suitable medium containing a Cbl-b inhibitor and other agents that promote the differentiation of hematopoietic cells into mature hematopoietic cells. Thus, in certain aspects of the embodiments herein, the modified immune cells are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and / or NK cells. Methods for the expansion and / or differentiation of immune cells are well known in the art. See, for example, International Patent Application No. WO 2017 / 037083.
[0229] An effective amount of a Cbl-b inhibitor is an amount or concentration of the Cbl-b inhibitor that is sufficient to modulate immune cell activity relative to a control sample. The control sample can be immune cells that have not been contacted with the Cbl-b inhibitor. In certain embodiments, the concentration of the Cbl-b inhibitor added to a composition (e.g., cell culture medium) comprising modified immune cells is about 1 pM to about 100 μM, about 5 pM to about 100 μM, about 10 pM to about 100 μM, about 20 pM to about 100 μM, about 40 pM to about 100 μM, about 60 pM to about 100 μM, about 80 pM to about 100 μM, about 1 nM to about 100 μM, about 3 nM to about 100 μM, about 10 nM to about 100 μM, about 15 nM to about 100 μM, or about 20 nM to about 100 μM. 00 μM, about 40 nM to about 100 μM, about 60 nM to about 100 μM, about 80 nM to about 100 μM, about 0.1 μM to about 100 μM, about 0.1 μM to about 90 μM, about 0.1 μM to about 80 μM, about 0.1 μM to about 70 μM, about 0.1 μM to about 60 μM, about 0.1 μM to about 50 μM, about 0.1 μM to about 40 μM, about 0.1 μM to about 30 μM, about 0.1 μM to about 20 μM, about 0.1 μM to about 10 μM, about 0.2 μM to about 10 μM, or about 0.3 μM to about 8 μM. In certain embodiments, the concentration of the Cbl-b inhibitor added to the composition (e.g., cell culture medium) comprising the modified immune cells is about 1 pM, about 2 pM, about 3 pM, about 4 pM, about 5 pM, about 10 pM, about 20 pM, about 30 pM, about 40 pM, about 50 pM, about 60 pM, about 70 pM, about 80 pM, about 90 pM, about 1 nM, about 3 nM, about 5 nM, about The Cbl-b inhibitor may be added to a composition comprising modified immune cells (e.g., cell culture medium) at a concentration of about 10 nM, about 20 nM, about 40 nM, about 50 nM, about 80 nM, about 0.1 μM, about 0.2 μM, about 0.3 μM, about 0.4 μM, about 0.5 μM, about 1 μM, about 5 μM, about 10 μM, about 15 μM, about 20 μM, about 25 μM, about 30 μM, about 40 μM, about 50 μM, about 60 μM, about 70 μM, about 80 μM, about 90 μM, or about 100 μM. In certain embodiments, the Cbl-b inhibitor is added to a composition comprising modified immune cells (e.g., cell culture medium) at a concentration of about 0.3 μM, about 1 μM, or about 4 μM. In certain embodiments, the Cbl-b inhibitor is added to a composition comprising modified immune cells (e.g., cell culture medium) at a concentration of about 1 μM or about 8 μM.
[0230] An effective amount of a Cbl-b inhibitor is contacted with immune cells for a time sufficient to modulate the activity of the immune cells relative to a control sample, which can be immune cells not contacted with the Cbl-b inhibitor but incubated for the same length of time with the immune cells and a composition (e.g., cell culture medium) comprising the Cbl-b inhibitor. In certain embodiments, the Cbl-b inhibitor is contacted with and / or incubated with immune cells for about 1 minute to about 1 hour, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 15 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 45 minutes to about 1 hour, about 1 hour to about 2 hours, about 1 hour to about 4 hours, about 1 hour to about 6 hours, about 1 hour to about 8 hours, about 1 hour to about 12 hours, about 1 hour to about 24 hours, about 2 hours to about 24 hours, about 6 hours to about 7 hours, about 6 hours to about 24 hours, about 8 hours to about 24 hours, about 10 hours to about 24 hours, about 15 hours to about 24 hours, about 20 hours to about 24 hours, about 12 hours to about 48 hours, about 24 hours to about 48 hours, or about 36 hours to about 48 hours. In certain embodiments, the Cbl-b inhibitor is contacted with and / or incubated with immune cells for about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 12 hours, about 14 hours, about 16 hours, about 18 hours, about 20 hours, about 22 hours, or about 24 hours. In certain embodiments, the Cbl-b inhibitor is contacted with and / or incubated with immune cells for about 1 day to about 7 days, about 2 days to about 7 days, about 3 days to about 7 days, about 4 days to about 7 days, about 5 days to about 7 days, or about 6 days to about 7 days. In certain embodiments, the Cbl-b inhibitor is contacted with and / or incubated with the immune cells for about 7 days to about 14 days, about 14 days to about 21 days, or about 21 days to about 28 days.In certain embodiments, the Cbl-b inhibitor is contacted with and / or incubated with the immune cells for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, or about 14 days.
[0231] In certain embodiments, immune cells or cell populations comprising immune cells are incubated under conditions suitable for inducing proliferation, expansion, activation, and / or survival of the immune cells. Suitable conditions during incubation include, but are not limited to, the use of one or more of cell culture medium, temperature, incubation time, the presence of stimulatory agents (e.g., anti-CD3 and / or anti-CD28 antibodies), and the presence of any other beneficial agents, such as growth factors, cytokines, chemokines, and / or recombinant soluble receptors.
[0232] In certain embodiments, conditions suitable for inducing immune cell proliferation, expansion, activation, and / or survival include providing stimulatory conditions including an agent capable of activating immune cells (e.g., NK cells). For example, conditions suitable for inducing T cell proliferation, expansion, activation, and / or survival include providing stimulatory conditions including an agent capable of activating intracellular signaling within the T cell. Full activation of a T cell generally requires recognition of an antigen by the T cell receptor, referred to herein as "TCR," (signal 1) and recognition of a costimulatory factor, such as CD28 (signal 2). In certain embodiments, one or more agents turn on or initiate an intracellular signaling cascade mediated by the TCR complex within the T cell. For example, a first agent can bind to a component of the TCR complex to activate the T cell, and a second agent can bind to a costimulatory molecule on the surface of the T cell, thereby stimulating the activated T cell. In one embodiment, the first agent stimulated a signal associated with the TCR / CD3 complex in the T cell by specifically binding to CD3 (e.g., an anti-CD3 antibody). In a further embodiment, the costimulatory molecule on the surface of the T cell can be CD28, and the second agent specifically binds to CD28 (e.g., an anti-CD28 antibody). Such agents include, but are not limited to, antibodies, bivalent antibody fragments, and binding molecules, such as those specific for a TCR complex component (e.g., an anti-CD3 antibody) and / or those specific for a costimulatory receptor (e.g., an anti-CD28 antibody). In one embodiment, the agent that specifically binds to CD3 is an anti-CD3 antibody, a bivalent antibody fragment of an anti-CD3 antibody (e.g., a (Fab)2' fragment or a bivalent scFv fragment), a monovalent antibody fragment of an anti-CD3 antibody (e.g., a Fab fragment, an Fv fragment, or an scFv fragment), or a CD3-binding molecule (e.g., an aptamer).In some embodiments, the agent that specifically binds to CD28 is an anti-CD28 antibody, a bivalent antibody fragment of an anti-CD28 antibody (e.g., a (Fab)2' fragment or a bivalent scFv fragment), a monovalent antibody fragment of an anti-CD28 antibody (e.g., a Fab fragment, an Fv fragment, or an scFv fragment), or a CD28-binding molecule (e.g., an aptamer). One or more agents provided herein (e.g., an anti-CD3 antibody and an anti-CD28 antibody) can be bound to a solid support such as beads or crosslinked with an anti-Fc antibody. In some embodiments, the expansion method step can further include adding an anti-CD3 antibody and / or an anti-CD28 antibody to the culture medium. In some embodiments, the stimulatory agent added to the cell culture medium includes one or more cytokines, such as, but not limited to, one or more of IL-2, IL-7, IL-15, and IL-21. For example, IL-2 can be added at a concentration of at least about 10 units / mL to cell culture medium containing immune cells and agents such as anti-CD3 and / or anti-CD28 antibodies.
[0233] In one embodiment, the conditions suitable for inducing T cell proliferation, expansion, activation, and / or survival include providing a stimulatory condition or an agent capable of activating intracellular signaling via the T cell receptor (TCR) complex and a Cbl-b inhibitor as described herein. In one embodiment, an immune cell or a cell population comprising an immune cell is incubated with a first agent that stimulates a signal associated with the TCR / CD3 complex in T cells by specifically binding to CD3 (e.g., an anti-CD3 antibody). In a further embodiment, an immune cell or a cell population comprising an immune cell is incubated with a first agent that stimulates a signal associated with the TCR / CD3 complex in T cells by specifically binding to CD3 (e.g., an anti-CD3 antibody), a second agent that binds to the costimulatory molecule CD28 (e.g., an anti-CD28 antibody), and a Cbl-b inhibitor at a concentration of about 1 pM to about 100 μM (e.g., about 0.3 μM, about 1 μM, or about 4 μM). In certain embodiments, conditions suitable for inducing T cell proliferation, expansion, activation, and / or survival do not require stimulation by a costimulatory molecule (e.g., CD28) when in the presence of a Cbl-b inhibitor. Contacting T cells with a Cbl-b inhibitor or a composition thereof can obviate the need for costimulation required for T cells to enter an activated state. In certain embodiments, immune cells or a cell population comprising immune cells are incubated with a first agent that stimulates a signal associated with the TCR / CD3 complex in T cells by specifically binding to CD3 (e.g., an anti-CD3 antibody) and a Cbl-b inhibitor at a concentration of about 0.001 μM to about 1,000 μM, about 0.01 μM to about 100 μM, about 0.1 μM to about 10 μM, or about 0.1 μM to about 50 μM (e.g., about 1 μM or about 8 μM).
[0234] In some embodiments of the method for modulating immune cell activity, the immune cell is a T cell, and modulating T cell activity comprises increased T cell activation and / or increased T cell proliferation. T cells contemplated in embodiments herein can be in a tolerant state even in the presence of an activator that binds to a component of the TCR complex, such as an anti-CD3 antibody, and in the presence of a stimulator that binds to a costimulatory molecule, such as an anti-CD28 antibody. In some embodiments, the method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, the method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In some embodiments, stimulation with a costimulatory CD28 molecule is not required to modulate T cell activity (e.g., increase T cell activation and / or increase T cell proliferation). In one embodiment, a method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody alone. In one embodiment, a method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with one or more agents that activate T cells (e.g., an anti-CD3 antibody), and wherein the agents do not include an agent that stimulates a CD28 costimulatory molecule (e.g., an anti-CD28 antibody).
[0235] In certain embodiments, the immune cells are T cells, and modulating the activity of T cells comprises enhanced T cell activation and / or enhanced T cell proliferation. For example, T cells contemplated in embodiments herein may be in an activated state when in the presence of an agent that activates T cells (e.g., an anti-CD3 antibody), and in certain further embodiments, in the presence of an agent that stimulates T cells (e.g., an anti-CD28 antibody). Contacting T cells with a Cbl-b inhibitor or a composition thereof may lower the threshold required for activation in the presence of an activator (e.g., an anti-CD3 antibody) and, in certain further embodiments, a stimulator (e.g., an anti-CD28 antibody), thereby promoting T cell activation and / or proliferation. In certain embodiments, a method of modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In one embodiment, a method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In one embodiment, stimulation with a costimulatory CD28 molecule is not required to modulate T cell activity (e.g., promote T cell activation and / or promote T cell proliferation). In one embodiment, a method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody alone. In one embodiment, a method for modulating T cell activity comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with one or more agents that activate T cells (e.g., an anti-CD3 antibody).
[0236] In one embodiment, the immune cell is a T cell, and modulating the activity of the T cell includes decreased T cell dysfunction, including decreased T cell exhaustion, decreased T cell tolerance, and / or decreased T cell anergy. The general principles of T cell dysfunction are well known in the art (see, e.g., Schietinger et al., Trends Immunol., 35:51-60, 2014). Immune tolerance is a process that is part of the normal function of the immune system. Antigen-specific tolerance is characterized by decreased responsiveness to an antigen, which is induced by previous exposure to the antigen. When a particular lymphocyte (e.g., T cell) encounters an antigen, the lymphocyte can be activated, resulting in an antigen-specific immune response, or the lymphocyte (e.g., T cell) can be inactivated or deleted, instead resulting in antigen-specific tolerance. In certain embodiments, immune tolerance can be caused by clonal anergy, peripheral clonal deletion, T cell suppression, and / or other forms of antigen-specific immune tolerance. In certain embodiments, immune tolerance can result from or be characterized by the induction of anergy. In certain embodiments, anergy can result from exposure of T cells to antigen in the absence of costimulation. Persistent antigen recognition by a single TCR in the absence of costimulatory signals can result in anergy (i.e., functional unresponsiveness). Anergic T cells can be refractory to subsequent antigen challenge and can suppress other immune responses. Generally, in natural settings, immune tolerance involves non-responsiveness or non-productive reactivity to self-antigens. However, in some cases, immune tolerance to "non-self" antigens can be induced. Thus, in certain embodiments, the same mechanism that renders mature T cells that recognize self-antigens in peripheral tissues subsequently unable to respond to these antigens can also regulate unresponsiveness to foreign or "non-self" antigens, such as those expressed by cancer cells. Thus, T cells contemplated in embodiments herein can be in a tolerized state even in the presence of a stimulatory agent, such as an agent that binds to a costimulatory molecule such as CD28.Contacting T cells with a Cbl-b inhibitor or a composition thereof provided herein can prevent conditions of T cell dysfunction, such as T cell tolerance, T cell anergy, and / or T cell exhaustion. In certain embodiments, a method for modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof. In certain embodiments of the methods herein, modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In certain embodiments of the methods herein, a method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In certain embodiments, stimulation with a costimulatory CD28 molecule is not required to modulate T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion). In certain embodiments of the methods herein, a method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody alone. In one embodiment, a method of modulating T cell activity (e.g., reducing T cell tolerance, reducing T cell anergy, and / or reducing T cell exhaustion) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has already been contacted with one or more agents that activate the T cell, such as an anti-CD3 antibody alone.
[0237] T cell activation and T cell tolerance are tightly regulated processes that regulate immune responses. Accordingly, provided herein are methods of modulating T cell activity, wherein modulating T cell activity comprises increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance. In certain embodiments, the method of modulating T cell activity (e.g., increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof. In certain embodiments of the methods herein, modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof in the presence of an anti-CD3 antibody in combination with an anti-CD28 antibody. In certain embodiments of the methods herein, a method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting T cells with an effective amount of a Cbl-b inhibitor or a composition thereof, wherein the T cells have already been contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. In certain embodiments, stimulation with a costimulatory CD28 molecule is not required to modulate T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance). In certain embodiments of the methods herein, a method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting T cells with an effective amount of a Cbl-b inhibitor provided herein or a composition thereof in the presence of an anti-CD3 antibody alone.In one embodiment, a method of modulating T cell activity (e.g., increasing T cell activation, increasing T cell proliferation, decreasing T cell exhaustion, and / or decreasing T cell tolerance) comprises contacting a T cell with an effective amount of a Cbl-b inhibitor or a composition thereof, where the T cell has already been contacted with one or more agents that activate the T cell (e.g., an anti-CD3 antibody).
[0238] In certain embodiments of the methods herein, increased T cell activation comprises increased production of one or more cytokines from T cells or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In certain embodiments, the one or more cytokines include, but are not limited to: IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In certain embodiments, the cytokine is one or more of IL-2, IFN-γ, TNFα, and GM-CSF. In certain embodiments, the cytokine is a chemokine. In certain embodiments, the one or more chemokines include, but are not limited to: IP-10, eotaxin, GRO α, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. Increased expression of cytokines can be measured by ELISA.
[0239] In certain embodiments of the methods herein, the increased T cell activation comprises increased cell surface expression of one or more T cell activation markers. In certain embodiments, the one or more T cell activation markers include, but are not limited to: CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In certain embodiments, the T cell activation marker is one or more of CD25, CD69, and CTLA4. The increased expression of cell surface markers can be measured by FACS.
[0240] Methods for experimentally determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are well known in the art. In certain embodiments, representative methods for determining T cell activation are found in Biological Example 2 provided herein. In certain embodiments, representative in vitro and in vivo methods for determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are found in Biological Example 3 provided herein.
[0241] In some embodiments of the methods for modulating immune cell activity, the immune cells are B cells, and modulating B cell activity comprises increased B cell activation. In some embodiments, the increased B cell activation comprises increased cell surface expression of one or more B cell activation markers. In some embodiments, the one or more B cell activation markers include, but are not limited to, CD69, CD86, and MHC class II (e.g., HLA-DR). In some embodiments, the B cell activation marker is CD69. The increased expression of cell surface markers can be measured by FACS. In some embodiments, the increased B cell activation comprises increased activation of proteins in signaling pathways such as those mediated by ERK, JNK, and Syk. The increased activation of the proteins can be detected by measuring the level of phosphorylation on the proteins using reagents available in the art, such as anti-phosphorylation antibodies.
[0242] In some embodiments of the methods for modulating immune cell activity, the immune cells are NK cells, and modulating NK cell activity comprises increased NK cell activity. In some embodiments, increased NK cell activation comprises secretion of one or more cytokines. In some embodiments, the one or more cytokines include, but are not limited to, IFN-γ, TNFα, and MIP-1β. Increased expression of cytokines can be measured by ELISA. In some embodiments, increased NK cell activation comprises increased cell surface expression of one or more NK cell activation markers. In some embodiments, the one or more NK cell activation markers include, but are not limited to, CD69 and CD107a. Increased expression of cell surface markers can be measured by FACS. In some embodiments, increased NK cell activation comprises increased killing of target cells, such as tumor cells, including primary tumor cells and tumor cells derived from cell lines, such as the K562 cell line.
[0243] Methods for experimentally determining increased B cell activation and NK cell activation are well known in the art (see, e.g., Fauriat et al., Blood. 115:2167-76, 2010; Beano et al., J. Transl. Med., 6:25 2008; Claus et al., J. Immunol. Methods, 341:154-64, 2009; and Fujisaki et al., Cancer Res. 69:4010-4017, 2009). In certain embodiments, a representative method for determining B cell activation is found in Biological Example 3 provided herein. In certain embodiments, a representative method for determining NK cell activation is found in Biological Example 3 provided herein.
[0244] Modulation of immune cell activity, such as T cells, B cells, or NK cells, can be measured by determining a baseline value for a parameter of interest (e.g., cytokine secretion). For example, T cell activation in a sample, such as one obtained from an in vitro experiment of cells contacted with a Cbl-b inhibitor, can be measured before contacting or administering the Cbl-b inhibitor to determine a baseline value. A reference value is then obtained for T cell activation after contacting or administering the Cbl-b inhibitor. The reference value is compared to the baseline value to determine the amount of T cell activation due to contacting or administering a Cbl-b inhibitor or composition thereof. For example, in one embodiment, immune cell (e.g., T cell) activation is increased by at least 0.1-fold in the sample compared to the baseline value, where the baseline value is obtained before contacting the immune cells (e.g., T cells) with the Cbl-b inhibitor or composition thereof. In certain embodiments, immune cell (e.g., T cell) activation is increased by at least about 0.1-fold, about 0.2-fold, about 0.3-fold, about 0.4-fold, about 0.5-fold, about 0.6-fold, about 0.7-fold, about 0.8-fold, about 0.9-fold, about 1-fold, about 2-fold, about 4-fold, about 6-fold, about 8-fold, about 10-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 75-fold, or about 100-fold (e.g., about 0.1-fold to about 100-fold, or about 1-fold to about 100-fold) over baseline values. Immune cell activation can be assessed by measuring biological markers of activation, such as increased cytokine secretion, increased cell surface expression of activation markers (e.g., cell surface markers), or increased phosphorylation of proteins in downstream signaling pathways. The fold increase over baseline values indicative of immune cell activation can be determined for the parameter being tested and the conditions under which the immune cells are treated. For example, to measure T cell activation, a baseline value is obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody, where the cells are not incubated with a Cbl-b inhibitor, and then a reference value is obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody, where the T cells have been or are being contacted with a Cbl-b inhibitor.A positive response to immune cell activation can then be determined by the obtained baseline values. Similar baseline measurements are obtained and compared to baseline values to assess T cell activation, T cell proliferation, T cell exhaustion, T cell tolerance, B cell activation, and / or NK cell activation. Measurements of these parameters are obtained using techniques well known in the art and those described in Biological Examples 2 and 3.
[0245] The term "baseline" or "baseline value," as used herein, can refer to a measurement or characterization prior to administration of a therapeutic agent disclosed herein (e.g., a composition comprising a Cbl-b inhibitor described herein) or at the start of administration of the therapeutic agent. The baseline value can be compared to the reference value to determine an increase or decrease in immune cell function (e.g., increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance). The term "baseline" or "reference value," as used herein, can refer to a measurement or characterization following administration of a therapeutic agent disclosed herein (e.g., a composition comprising a Cbl-b inhibitor described herein). The reference value can be measured one or more times during an experimental time course, dosing regimen, or treatment cycle, or at the completion of an experimental time course, dosing regimen, or treatment cycle. A "reference value" can be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an average value, a median, a mean value, or a value compared to the baseline value. Similarly, a "baseline value" can be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an average value, a median value, a mean value, or a value to be compared to a reference value. Reference and / or baseline values can be obtained from one sample (e.g., one sample obtained from an individual), two different samples (e.g., samples obtained from two different individuals), or a group of samples (e.g., samples obtained from a group of 2, 3, 4, 5, or more individuals).
[0246] In certain embodiments, a positive response to T cell activation, as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the presence of a Cbl-b inhibitor, is at least 2.5-fold relative to the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the absence of a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the presence of a Cbl-b inhibitor, is at least 1.3-fold relative to the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the absence of a Cbl-b inhibitor. In certain embodiments, the baseline value is obtained from T cells stimulated with an anti-CD3 antibody alone, where the cells are not incubated with a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with an anti-CD3 antibody alone in the presence of a Cbl-b inhibitor, is at least 0.1-fold relative to the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with an anti-CD3 antibody alone in the absence of a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with an anti-CD3 antibody alone in the presence of a Cbl-b inhibitor, is at least 0.6-fold relative to the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with an anti-CD3 antibody alone in the absence of a Cbl-b inhibitor.
[0247]
[0243] In one aspect, provided herein is a method of generating modified immune cells, the method comprising culturing a cell population containing immune cells in the presence of an effective amount of a Cbl-b inhibitor provided herein or a composition thereof to modulate the activity of the immune cells, thereby generating the modified immune cells. In one embodiment, the immune cells are T cells, B cells, or natural killer (NK) cells.
[0248] In some embodiments of the method for generating modified immune cells, the modified immune cells are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In some embodiments, the method further comprises culturing the immune cells with a stimulatory agent, such as a cytokine or an antibody that binds to an activating protein expressed by the immune cells (e.g., an anti-CD3 antibody and / or an anti-CD28 antibody). In some embodiments, the modified immune cells are in a cell population containing immune cells, wherein the cell population is obtained as a sample from an individual. In some embodiments, the modified immune cells are in a cell population containing immune cells, wherein the cell population is obtained from culturing a biological sample from an individual (e.g., a blood sample, a bone marrow sample, etc.). In some embodiments, the immune cells are modified by contacting the cell population containing immune cells with a Cbl-b inhibitor or a composition thereof, thereby generating the modified immune cells. In some embodiments, the engineered immune cells are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In some embodiments, the immune cells are of the same cell type as the engineered immune cells. For example, the immune cells can be inactive T cells, and the engineered immune cells can be activated T cells. In some embodiments, the immune cells are of a different cell type than the engineered immune cells. For example, the immune cells can be hematopoietic stem cells, and the engineered immune cells can be NK cells differentiated from hematopoietic stem cells. In some embodiments of the method of generating engineered immune cells, the method further comprises recovering the engineered immune cells. In some embodiments, the cell population containing immune cells, the immune cells, or the engineered immune cells are from an individual (e.g., a human). In some embodiments, the immune cells or engineered immune cells are human immune cells or human engineered immune cells, respectively.
[0249]
[0245] Further provided herein are modified immune cells produced by any of the methods described herein, such as culturing a cell population containing immune cells in the presence of an effective amount of a Cbl-b inhibitor to modulate the activity of the immune cells, thereby producing the modified immune cells.
[0250] In some embodiments, the Cbl-b inhibitors provided herein are cell membrane permeable. Thus, in some embodiments, the modified immune cells provided herein can contain the Cbl-b inhibitors described herein, such as in the cytoplasm of the modified immune cells.
[0251] In certain aspects, provided herein are isolated modified immune cells, wherein the modified immune cells have been contacted or are in contact with a Cbl-b inhibitor or composition thereof described herein. In certain embodiments, the modified immune cells are T cells, B cells, or natural killer (NK) cells. In certain embodiments, the modified immune cells are hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, or NK cells.
[0252] In some embodiments of the isolated modified immune cells, the modified immune cells are T cells, and the T cells exhibit increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance. In some embodiments, the increased T cell activation comprises increased production of one or more cytokines from the T cells or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In some embodiments, the one or more cytokines include, but are not limited to: IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In some embodiments, the one or more cytokines are one or more selected from the group consisting of IL-2, IFN-γ, TNFα, and GM-CSF. In some embodiments, the cytokine is a chemokine. In some embodiments, the one or more chemokines include, but are not limited to, IP-10, eotaxin, GRO α, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. In some embodiments, increased T cell activation comprises increased cell surface expression of one or more T cell activation markers. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In some embodiments, the one or more T cell activation markers include, but are not limited to, CD25, CD69, and CTLA4. In some embodiments, the T cell activation marker is CD25 and / or CD69. In some embodiments, the T cells have been contacted or have been contacted with an anti-CD3 antibody. In some embodiments, the T cells have been contacted or have been contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody.
[0253] In some embodiments of the isolated modified immune cells, the modified immune cells are NK cells, and the NK cells exhibit increased NK cell activation. In some embodiments, the increased NK cell activation comprises increased secretion of one or more cytokines (e.g., IFN-γ, TNFα, and / or MIP-1β). In some embodiments, the increased NK cell activation comprises increased cell surface expression of one or more NK cell activation markers (e.g., CD69 and / or CD107a).
[0254] In some embodiments of the isolated modified immune cells, the modified immune cells are B cells, and the B cells exhibit increased B cell activation. In some embodiments, the increased B cell activation comprises increased cell surface expression of one or more B cell activation markers (e.g., CD69, CD86, and / or HLA-DR).
[0255] In some embodiments of any of the methods or modified immune cells provided herein, the immune cell or modified immune cell is a mammalian cell (e.g., a human cell). In certain embodiments, the immune cell or modified immune cell is a human cell.
[0256]
[0252] In one aspect, incubation is carried out according to techniques such as those described in U.S. Patent No. 6,040,177; Klebanoff et al., J Immunother., 35:651-660, 2012; Terakura et al., Blood, 119:72-82, 2012; and Wang et al., J Immunother., 35:689-701, 2012.
[0257] The modified immune cells or engineered immune cells provided herein can be engineered to express a recombinant chimeric receptor, such as a chimeric antigen receptor (CAR). In some embodiments, a CAR comprises, from its N-terminus to its C-terminus: an extracellular ligand-binding domain, a transmembrane domain, an intracellular costimulatory domain, and an activating cytoplasmic signaling domain. In some embodiments, a CAR comprises, from its N-terminus to its C-terminus: an extracellular ligand-binding domain, a transmembrane domain, and an activating cytoplasmic signaling domain. The immune cells can be engineered to express a recombinant chimeric receptor (e.g., a CAR) before, during, or after administration of a Cbl-b inhibitor provided herein. In some embodiments, the modified immune cells are T cells (e.g., CD4 + T cells or CD8 + In a further embodiment, the T cell comprises a recombinant chimeric receptor, such as a CAR. In one embodiment, the engineered immune cell is an engineered T cell (e.g., a CD4 + T cells or CD8 + In a further embodiment, the engineered T cell comprises a recombinant chimeric receptor such as a CAR. Methods for generating immune cells expressing recombinant chimeric receptors, such as by introducing a nucleic acid encoding the recombinant chimeric receptor (e.g., a CAR) into an immune cell (e.g., a T cell) via a vector (e.g., a viral vector), are well known in the art. See, e.g., International Patent Application Publication No. WO 2017 / 096329 and U.S. Patent Application Publication No. 2017 / 0204372.
[0258] In particular, the present disclosure provides a method for generating an expanded population of lymphocytes, the method comprising: (a) obtaining a biological sample containing lymphocytes from an individual having cancer, where the individual has been or has been administered an effective amount of a Cbl-b inhibitor as a monotherapy or as part of a combination therapy; and (b) culturing the lymphocytes in a cell culture medium comprising at least one T cell growth factor to generate an expanded population of lymphocytes. In certain embodiments, the lymphocytes are tumor-infiltrating lymphocytes (TILs). In certain embodiments, the lymphocytes are TILs isolated or to be isolated from a tumor in a mammalian subject having cancer. In other embodiments, the lymphocytes are peripheral blood mononuclear cells (PBMCs). In certain embodiments, the at least one T cell growth factor comprises one or more of the group consisting of IL-2, IL-7, IL-15, and IL-21, and optionally, the at least one T cell growth factor comprises IL-2. In certain embodiments, the cell culture medium further comprises an anti-CD3 antibody, or both an anti-CD3 antibody and an anti-CD28 antibody. In some embodiments, the cell culture medium further comprises a Cbl-b inhibitor. In some embodiments, the cell culture medium further comprises irradiated feeder cells. In some embodiments, the individual is a human patient. Also provided herein is a composition comprising an expanded population of TILs produced by the above method and a physiologically acceptable buffer.
[0259] In certain embodiments, methods for isolating and processing modified or altered immune cells (i.e., modified immune cells) include freezing (e.g., cryopreserving) the cells before or after isolation, incubation (e.g., incubation with a Cbl-b inhibitor), and / or manipulating (e.g., introducing into the immune cells a nucleic acid encoding a recombinant chimeric receptor). A variety of freezing solutions and parameters known in the art can be used.
[0260] B. Adoptive immune cell therapy The modified immune cells, such as expanded populations of lymphocytes, or compositions thereof, produced by the methods described herein can be used as therapeutic agents in methods of treating individuals in need thereof, such as individuals with cancer. Such methods of treatment include adoptive cell therapy. In certain embodiments, the methods of treatment involve isolating cells from an individual, preparing, treating, culturing, and / or manipulating them as described herein, and reintroducing them into the same individual, before or after cryopreservation. In certain embodiments, the methods of treatment involve isolating cells from an individual, preparing, treating, culturing, and / or manipulating them as described herein, and reintroducing them into a different individual, before or after cryopreservation.
[0261]
[0257] Thus, in certain aspects, provided herein are methods for modulating an immune response in an individual, the method comprising administering an effective amount of the modified immune cells described herein or compositions thereof to an individual in need thereof (e.g., an individual having a T cell dysfunction disease). In certain embodiments, the individual has cancer. In certain embodiments, provided herein are methods for treating a cancer that responds to inhibition of Cbl-b activity, the method comprising administering an effective amount of the modified immune cells described herein or compositions thereof to an individual having a cancer that responds to inhibition of Cbl-b activity. In certain embodiments, provided herein are methods for inhibiting abnormal cell proliferation, the method comprising administering an effective amount of the modified immune cells described herein or compositions thereof to an individual in need thereof. As used herein, the term "abnormal cell proliferation" includes hyperplasia or cancer cell proliferation. Cancer cells can originate from a blood cancer or a non-blood cancer. In certain embodiments, the cancer is a blood cancer such as lymphoma, leukemia, or myeloma. In other embodiments, the cancer cells can originate from a non-blood cancer such as a sarcoma, carcinoma, or melanoma.
[0262] In certain embodiments, an individual in need of treatment, such as an individual with cancer or a T-cell dysfunction disorder, is administered a total cell count in the range of about 1 million to about 100 billion cells, e.g., 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the above values), e.g., about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the above values), and in some cases, about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells), or any value between these ranges.
[0263] The modified immune cells and compositions thereof are administered using standard administration techniques, formulations, and / or devices. Formulations and devices, such as syringes and vials, are provided for storing and administering the compositions. Formulations or pharmaceutical compositions containing the modified immune cells include those for intravenous, intraperitoneal, subcutaneous, or intramuscular administration. In certain embodiments, the modified immune cells are administered parenterally. As used herein, the term "parenteral" includes, but is not limited to, intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In certain embodiments, the cell population is administered to a subject using peripheral systemic delivery via intravenous, intraperitoneal, or subcutaneous injection. The modified immune cell composition can be provided as a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion, or viscous composition, which in certain aspects is buffered to a selected pH. Viscous compositions can be formulated within an appropriate viscosity range to provide a longer contact period with specific tissues. Liquid or viscous compositions may contain a carrier, which may be a solvent or dispersion medium containing, for example, water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Sterile injectable solutions may be prepared by incorporating the modified immune cells into a solvent, for example, as a mixture with a suitable carrier, diluent, or excipient such as sterile water, saline, glucose, dextrose, or the like.
[0264] In certain embodiments, the engineered immune cells are co-administered with one or more additional therapeutic agents or with another therapeutic intervention, simultaneously or sequentially in any order. For example, in certain therapeutic regimens disclosed herein, both engineered immune cells and a Cbl-b inhibitor are administered to a mammalian subject in need thereof, where the Cbl-b inhibitor is a compound of Formula (I), (IA)-(IN), (II-A)-(II-L), (III-A)-(III-D), (IV-A)-(IV-C), (VA)-(VG), or (VI-A)-(VI-D), or any variation thereof. Thus, in certain embodiments, the therapeutic regimen includes both adoptive immune cell therapy and chemotherapy.
[0265] After the engineered immune cells are administered to an individual (e.g., a human), the biological activity of the engineered immune cell population can be measured by methods known in the art. Parameters evaluated include specific binding of the engineered immune cells or other immune cells to an antigen in vivo (e.g., by imaging) or ex vivo (e.g., by ELISA or flow cytometry). In certain embodiments, the ability of the engineered immune cells to destroy target cells can be measured using a cytotoxicity assay (see, e.g., Kochenderfer et al., J. Immunotherapy, 32:689-702, 2009; and Herman et al., J. Immunological Methods, 285:25-40, 2004). In certain embodiments, the biological activity of the engineered immune cells can also be measured by assaying the expression and / or secretion of specific cytokines, such as IL-2 and IFNγ.
[0266] C. Administration of Cbl-b inhibitors In certain embodiments, a Cbl-b inhibitor or composition thereof can be administered directly to an individual to modulate an immune response, treat a disease or condition (e.g., cancer and / or abnormal cell proliferation), and / or inhibit Cbl-b activity in the individual. The Cbl-b inhibitor can be a compound of Table 1 and / or Table 1A, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
[0267]
[0263] In certain embodiments, provided herein are methods for modulating an immune response, the methods comprising administering to an individual an effective amount of a Cbl-b inhibitor provided herein or a composition thereof to modulate the immune response in the individual. In certain embodiments, the individual has cancer.
[0268]
[0264] In one embodiment, provided herein is a method for treating a cancer that responds to inhibition of Cbl-b activity, the method comprising administering to an individual an effective amount of a Cbl-b inhibitor or composition thereof provided herein to treat the cancer that responds to inhibition of Cbl-b activity.
[0269]
[0265] In one embodiment, provided herein is a method for inhibiting abnormal cell proliferation (e.g., hyperplasia), the method comprising administering to an individual an effective amount of a Cbl-b inhibitor or composition thereof provided herein to inhibit abnormal cell proliferation in the individual.
[0270]
[0266] In one embodiment, provided herein is a method for inhibiting Cbl-b activity, the method comprising administering to an individual an effective amount of a Cbl-b inhibitor or composition thereof provided herein to inhibit Cbl-b activity in the individual.
[0271] In certain embodiments, for treating a disease or condition in an individual (e.g., cancer and / or abnormal cell proliferation in an individual), and / or inhibiting Cbl-b activity in an individual, such as modulating the immune response in an individual in need thereof (e.g., an individual with a T-cell dysfunction disorder), the appropriate dosage of the active agent will depend on the type of condition, disease, or disorder being treated, the severity and course of the condition, disease, or disorder, whether the agent is being administered for prophylactic or therapeutic purposes, previous treatments, the subject's medical history and response to the Cbl-b inhibitor, and the judgment of the attending physician. The Cbl-b inhibitor or composition thereof is suitably administered to the individual at one time or over a series of treatments. In certain embodiments, treatment includes multiple administrations of the Cbl-b inhibitor or composition thereof, where the interval between administrations can vary. For example, the interval between the first and second administrations is about one month, and the interval between subsequent administrations is about three months. In certain embodiments, the Cbl-b inhibitor is administered in a flat dose. In certain embodiments, the Cbl-b inhibitor is administered to an individual at a fixed dose based on the individual's body weight (eg, mg / kg).
[0272] In some embodiments of the present disclosure, the cancer is a blood cancer. For example, the blood cancer can be lymphoma, leukemia, or myeloma. In other embodiments of the present disclosure, the cancer is a non-blood cancer. In particular, the non-blood cancer can be carcinoma, sarcoma, or melanoma.
[0273] In certain embodiments, a Cbl-b inhibitor is co-administered with one or more additional therapeutic agents or with another therapeutic intervention, simultaneously or sequentially in any order. For example, in some treatment regimens disclosed herein, both a Cbl-b inhibitor and engineered immune cells are administered to a mammalian subject in need thereof, where the Cbl-b inhibitor is a compound of Formula (I), (IA)-(IN), (II-A)-(II-L), (III-A)-(III-D), (IV-A)-(IV-C), (VA)-(VG), or (VI-A)-(VI-D), or any variation thereof. The Cbl-b inhibitor can be a compound of Table 1 and / or Table 1A, a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Thus, in certain embodiments, a treatment regimen includes both adoptive immune cell therapy and chemotherapy.
[0274] In certain embodiments, the effectiveness of administering a Cbl-b inhibitor in a method herein (e.g., a method of modulating an immune response in an individual) can be assessed by measuring the biological activity of immune cells present in a sample (e.g., a blood sample) isolated from the treated individual. For example, the ability of immune cells isolated from an individual after treatment with a Cbl-b inhibitor to destroy target cells in a cytotoxicity assay can be measured to assess therapeutic efficacy. In certain embodiments, the biological activity of immune cells present in a sample (e.g., a blood sample) can be measured by assaying the expression and / or secretion of certain cytokines, such as IL-2 and IFNγ.
[0275]
[0271] The present disclosure provides a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of an additional therapeutic agent. Also provided is a method of treating an individual having cancer, comprising administering to the individual an effective amount of a Cbl-b inhibitor; and administering to the individual an effective amount of an additional therapeutic agent. Further provided is a method of increasing an anti-cancer immune response, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of an additional therapeutic agent. Further provided is a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, wherein the individual has been or is being administered an effective amount of an additional therapeutic agent.
[0276] In certain embodiments of the method of the previous paragraph, the Cbl-b inhibitor and the additional therapeutic agent are administered consecutively in either order. As used herein, the terms "consecutively," "sequentially," and "sequentially" refer to administration of the Cbl-b inhibitor after the additional therapeutic agent, or administration of the Cbl-b inhibitor after the additional therapeutic agent. For example, sequential administration may include administration of the Cbl-b inhibitor in the absence of the additional therapeutic agent during an induction phase (primary therapy), followed by a post-induction treatment phase comprising administration of the additional therapeutic agent. The method may further include a maintenance phase comprising administration of the Cbl-b inhibitor or the additional therapeutic agent. Alternatively, sequential administration may include administration of the additional therapeutic agent in the absence of the Cbl-b inhibitor during an induction phase (primary therapy), followed by a post-induction treatment phase comprising administration of the Cbl-b inhibitor. The method may further include a maintenance phase comprising administration of the Cbl-b inhibitor or the additional therapeutic agent.
[0277] In certain embodiments of combination therapy, the Cbl-b inhibitor and the additional therapeutic agent are administered simultaneously. As used herein, the terms "concurrently," "simultaneously," and "concurrently" refer to the administration of the Cbl-b inhibitor and the additional therapeutic agent during the same visit or treatment phase. For example, both the Cbl-b inhibitor and the additional therapeutic agent may be administered during one or more of the induction phase, treatment phase, and maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the additional therapeutic agent be present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the additional therapeutic agent be administered at exactly the same time.
[0278] 1. Combination therapy including a Cbl-b inhibitor and an immune checkpoint inhibitor In certain embodiments of the combination therapy disclosed herein for treating cancer, the additional therapeutic agent comprises an immune checkpoint inhibitor. While the term "immune checkpoint" refers to a signaling pathway that prevents immune cell activation, the term "immune checkpoint inhibitor" refers to a compound that prevents an immune checkpoint from releasing the brakes on immune cell activation. In certain embodiments, the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule. In certain embodiments, the inhibitory checkpoint molecule is selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), CTLA-4 (CD125), LAG3 (CD223), PVR (CD155), PVRL2 (CD112), PVRL3 (CD113), TIGIT, TIM3 (CD366), and VISTA. In one embodiment, the immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA-4 (CD152).
[0279] PD-1 refers to programmed cell death protein 1 (PD-1). PD-1 antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biological molecule that blocks the binding of PD-L1 expressed on cancer cells or antigen-presenting cells to PD-1 expressed on lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PD-1 and its ligands include CD279, PDCD1, PD1, and SLEB2 for PD-1; and CD274, PDCD1L1, PDL1, B7H1, B7-4, and B7-H for programmed cell death 1 ligand 1 (PD-L1). In certain embodiments in which a human subject is treated, the PD-1 antagonist blocks the binding of human PD-L1 to human PD-1. The amino acid sequence of the mature form of human PD-1 is listed as residues 21-288 in NCBI Locus No. NP_005009. The amino acid sequence of the mature form of human PD-L1 is listed as residues 19-290 in NCBI Locus No. NP_054862.
[0280] CTLA-4 refers to cytotoxic T-lymphocyte-associated protein 4. CTLA-4 antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biological molecule that blocks the binding of CTLA-4 expressed on lymphocytes (T cells, B cells, and / or NK cells) to its ligands (CD80 and / or CD86) expressed on antigen-presenting cells. Alternative names or synonyms for CTLA-4 include CD152, CTLA4, ALPS5, CELIAC3, GRD4, GSE, and IDDM12. In certain embodiments in which a human subject is treated, the CTLA-4 antagonist blocks the binding of human CTLA-4 to its human ligands. The amino acid sequence of the mature form of human CTLA-4 is listed as residues 36-223 in NCBI Locus No. NP_005205.
[0281] LAG3 refers to lymphocyte activation gene 3 protein. LAG3 antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biological molecule that blocks the binding of LAG3 expressed in lymphocytes (T cells, B cells, and / or NK cells) to a ligand (MHC class II) expressed on antigen-presenting cells. LAG3 is also known as CD223. In certain embodiments in which a human subject is treated, the LAG3 antagonist blocks the binding of human LAG3 to its human ligand. The amino acid sequence of the mature form of human LAG3 is listed as residues 23-525 in NCBI Locus No. NP_002277.
[0282] PVR refers to the poliovirus receptor. PVR antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biomolecule that blocks the binding of PVR expressed in cancer cells or antigen-presenting cells to TIGIT expressed in lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVR include CD155, PVS, HVED, NECL5, nectin-like protein 5, and TAGE4. In certain embodiments in which a human subject is treated, the PVR antagonist blocks the binding of human PVR to human TIGIT. There are multiple isoforms of human PVR. The amino acid sequence of the α isoform of human PVR is listed in NCBI Locus No. NP_006496. The amino acid sequence of the β isoform of human PVR is listed in NCBI Locus No. NP_001129240. The amino acid sequence of the gamma isoform of human PVR is listed in NCBI Locus No. NP_001129241. The amino acid sequence of the delta isoform of human PVR is listed in NCBI Locus No. NP_001129242.
[0283] PVRL2 refers to poliovirus receptor-related 2. PVRL2 antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biological molecule that blocks the binding of PVRL2 expressed in cancer cells or antigen-presenting cells to TIGIT expressed in lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVRL2 include CD112, NECTIN2, HVEB, herpesvirus entry mediator B, PRR2, and PVRR2. In certain embodiments in which a human subject is treated, the PVRL2 antagonist blocks the binding of human PVRL2 to human TIGIT. The amino acid sequence of the α isoform of human PVRL2 is described in NCBI Locus No. NP_002847. The amino acid sequence of the δ isoform of human PVRL2 is described in NCBI Locus No. NP_001036189.
[0284] PVRL3 refers to poliovirus receptor-related 3. PVRL3 antagonists suitable for the therapeutic methods, medicaments, and uses of the present disclosure include any chemical compound or biological molecule that blocks the binding of PVRL3 expressed in cancer cells or antigen-presenting cells to TIGIT expressed in lymphocytes (T cells, B cells, and / or NK cells). Alternative names or synonyms for PVRL3 include CD113, NECTIN3, PRR3, and PVRR3. In certain embodiments in which a human subject is treated, the PVRL3 antagonist blocks the binding of human PVRL3 to human TIGIT. The amino acid sequence of human PVRL3 isoform 1 is described in NCBI Locus No. NP_056295. The amino acid sequence of human PVRL3 isoform 2 is described in NCBI Locus No. NP_001230215. The amino acid sequence of human PVRL3 isoform 3 is listed in NCBI Locus No. NP_001230217.
[0285] TIGIT refers to a T cell immunoreceptor having Ig and ITIM domain proteins. Suitable TIGIT antagonists for use in the therapeutic methods, medicaments, and methods disclosed herein include any chemical compound or biomolecule that blocks the binding of TIGIT expressed in lymphocytes (T cells, B cells, or NK cells) to ligands (CD112, CD113, and / or CD155) expressed on cancer cells or antigen-presenting cells. Alternative names or synonyms for TIGIT include VSIG9, V-set and immunoglobulin domain-containing 9, VSTM3, V-set and transmembrane domain-containing 3, and Washington University cell adhesion molecule (WUCAM). In certain embodiments in which a human subject is treated, the TIGIT antagonist blocks the binding of human TIGIT to its human ligand. The amino acid sequence of the mature form of human TIGIT is listed as residues 22-244 in NCBI Locus No. NP_776160.
[0286] TIM3 refers to T cell immunoglobulin and mucin domain-containing 3 protein. TIM3 antagonists suitable for the therapeutic methods, medicaments, and uses of the present disclosure include any chemical compound or biomolecule that blocks the binding of TIM3 expressed in lymphocytes (T cells, B cells, or NK cells) to its ligand (galectin-9 phosphatidylserine) expressed in antigen-presenting cells. Alternative names or synonyms for TIM3 include CD366, HAVCR2, hepatitis A virus cellular receptor 2, KIM3, and SPTCL. In certain embodiments in which a human subject is treated, the TIM3 antagonist blocks the binding of human TIM3 to its human ligand. The amino acid sequence of the mature form of human TIM3 is listed as residues 22-301 in NCBI Locus No. NP_116171.
[0287] VISTA refers to V-domain Ig suppressor of T cell activation. VISTA antagonists suitable for use in the therapeutic methods, medicaments, and methods of the present disclosure include any chemical compound or biomolecule that blocks the binding of VISTA, expressed in lymphocytes (T cells, B cells, and / or NK cells), to ligands expressed in cancer cells or antigen-presenting cells. Alternative names or synonyms for VISTA include VSIR, V-set immunoregulatory receptor, PD-1H, B7H5, GI24, PP2135, SISP1, and Dies1. In certain embodiments in which a human subject is treated, the VISTA antagonist blocks the binding of human VISTA to its human ligand. The amino acid sequence of the mature form of human VISTA is listed as residues 33-311 in NCBI Locus No. NP_071436.
[0288] The immune checkpoint inhibitor may be a biomolecule. For example, the immune checkpoint inhibitor may comprise an antibody or an antigen-binding fragment thereof. The antibody or fragment may be a monoclonal antibody (mAb), such as a human antibody, a humanized antibody, or a chimeric antibody, and may comprise a human constant region. In certain embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in certain embodiments, the human constant region is an IgG1 or IgG4 constant region. In certain embodiments, the antibody or fragment is a bispecific antibody. In certain embodiments, the antigen-binding fragment comprises one of the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.
[0289] In some embodiments, the at least one inhibitory checkpoint molecule comprises PD-1. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, and biosimilars thereof. In one embodiment, the anti-PD-1 antibody is pembrolizumab (MK-3475, sold as KEYTRUDA® by Merck & Co.). In one embodiment, the anti-PD-1 antibody is nivolumab (BMS-936558 or MDX-1106, sold as OPDIVO® by Bristol-Myers Squibb). In one embodiment, the anti-PD-1 antibody is cemiplimab (REGN2810, Regeneron). In some embodiments, the immune checkpoint inhibitor is a variant of pembrolizumab, nivolumab, or cemiplimab.
[0290] In some embodiments, the at least one inhibitory checkpoint molecule comprises PD-L1. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of atezolizumab, avelumab, durvalumab, and biosimilars thereof. In one embodiment, the anti-PD-L1 antibody is atezolizumab (sold as TECENTRIQ® by Genentech, Inc.). In one embodiment, the anti-PD-L1 antibody is avelumab (sold as BAVENCIO® by EMD Serono, Inc. and Pfizer, Inc.). In one embodiment, the anti-PD-L1 antibody is durvalumab (MEDI4736, sold as IMFINZI® by AstraZeneca). In some embodiments, the immune checkpoint inhibitor is a variant of atezolizumab, avelumab, or durvalumab.
[0291] In some embodiments, the at least one inhibitory checkpoint molecule comprises CTLA-4. In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, and biosimilars thereof. In one embodiment, the anti-CTLA4 antibody is ipilimumab (MDX-010 or BMS-734016, sold as YERVOY® by Bristol-Myers Squibb). In one embodiment, the anti-CTLA4 antibody is tremelimumab (ticilimumab, CP-675,206, developed by AstraZeneca). In some embodiments, the immune checkpoint inhibitor is ipilimumab or a variant of tremelimumab.
[0292] In certain embodiments, the monoclonal antibody is a "variant" antibody that comprises heavy and light chain sequences that are identical to those in a "reference" antibody, except for three, two, or one conservative amino acid substitution at a position located outside the light chain CDR, and / or six, five, four, three, two, or one conservative amino acid substitution located outside the heavy chain CDR (e.g., the variant position is located in a framework region or constant region). In other words, the reference antibody and the variant antibody differ from each other by comprising identical CDR sequences but having conservative amino acid substitutions at no more than three or six other positions in their full-length light and heavy chain sequences, respectively. The variant antibody is substantially similar to the reference antibody with respect to the following properties: binding affinity for an inhibitory checkpoint molecule and ability to block binding of the inhibitory checkpoint molecule to its ligand.
[0293]
[0289] In other embodiments, immune checkpoint inhibitors may comprise immunoadhesins comprising the inhibitory checkpoint molecule binding domain of one of its ligands fused to a constant region, such as the Fc region, of an immunoglobulin molecule.
[0294] As used herein, the term "biosimilar" refers to a biological product that is similar to a reference product approved by the U.S. Food and Drug Administration (FDA) and does not have clinically important differences in safety and efficacy. For example, differences in clinically inactive ingredients may exist between the biosimilar product and the reference product (e.g., differences in formulation excipients, slight differences in glycosylation, etc.). Clinically important properties may be evaluated by pharmacokinetic and pharmacodynamic studies. In some embodiments, the biosimilar product is an interchangeable product as determined by the FDA.
[0295] 2. Combination therapy comprising a Cbl-b inhibitor and an antitumor agent In certain embodiments of the combination therapy methods herein for treating cancer, the additional therapeutic agent comprises an anti-tumor agent. As used herein, the terms "anti-neoplastic agent" and "antineoplastic agent" refer to therapeutic agents classified according to the Anatomical Therapeutic Chemical Classification System (ATC) code L01, developed by the World Health Organization. In certain embodiments, the anti-tumor agent is classified as one of the groups consisting of cytotoxic antibiotics (ATC code L01D), plant alkaloids (ATC code L01C), antimetabolites (ATC code L01B), alkylating agents (ATC code L01A), and other anti-tumor agents (ATC code L01X). In certain embodiments, the anti-tumor agent is a small molecule drug (e.g., a cancer chemotherapeutic agent), as opposed to a biomolecule.
[0296] Cytotoxic antibiotics are suitable antitumor agents for the therapeutic methods, medicaments, and uses of the present disclosure. In certain embodiments, the cytotoxic antibiotic is selected from the group consisting of ixabepilone, mitomycin, plicamycin, bleomycin, pixantrone, amrubicin, valrubicin, pirarubicin, mitoxantrone, idarubicin, zorubicin, aclarubicin, epirubicin, daunorubicin, doxorubicin, and dactinomycin.
[0297] Plant alkaloids are suitable antitumor agents for the therapeutic methods, medicaments, and uses of the present disclosure. In some embodiments, the plant alkaloid is selected from the group consisting of trabectedin, cabazitaxel, polyglutamic acid-added paclitaxel, docetaxel, paclitaxel, demecolcine, teniposide, etoposide, vintafolide, vinflunine, vinorelbine, vindesine, vincristine, and vinblastine.
[0298]
[0294] Antimetabolites are antitumor agents suitable for the therapeutic methods, medicaments, and uses of the present disclosure. In some embodiments, the antimetabolite is a pyrimidine analog, a purine analog, or a folic acid analog. In some embodiments, the antimetabolite is selected from the group consisting of floxuridine, trifluridine, tegafur, fluorouracil, decitabine, azacitidine, capecitabine, gemcitabine, carmofur, tegafur, fluorouracil, cytarabine, nelarabine, clofarabine, fludarabine, cladribine, thioguanine, mercaptopurine, pralatrexate, pemetrexed, raltitrexed, and methotrexate.
[0299] Alkylating agents are suitable anti-tumor agents for the therapeutic methods, medicaments, and uses of the present disclosure. In certain embodiments, the alkylating agent is selected from the group consisting of dacarbazine, temozolomide, pipobroman, mitobronitol, etoglucide, uracil mustard, ranimustine, nimustine, fotemustine, streptozocin, semustine, lomustine, carmustine, carboquone, triaziquone, thiotepa, mannosulfan, treosulfan, busulfan, bendamustine, prednimustine, trofosfamide, ifosfamide, mechlorethamine, melphalan, chlorambucil, and cyclophosphamide.
[0300]
[0296] In other embodiments, the antitumor agent comprises another antitumor agent selected from the group consisting of platinum compounds (ATC code L01XA), methylhydrazine (ATC code L01XB), sensitizers (ATC code L01XD), protein kinase inhibitors (ATC code L01XE), and other drugs (ATC code L01XA).
[0301]
[0297] Platinum compounds are suitable anti-tumor agents for the therapeutic methods, medicaments, and uses of the present disclosure. In certain embodiments, the platinum compound is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, and polyplatylene.
[0302] 3. Combination therapy including Cbl-b inhibitors and radiation therapy
[0298] The present disclosure provides a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of radiation therapy. Also provided is a method of treating an individual having cancer, comprising administering to the individual an effective amount of Cbl-b, and administering to the individual an effective amount of radiation therapy. Further provided is a method of increasing an anti-cancer immune response, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of radiation therapy. Further provided is a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, wherein the individual has received or is receiving an effective amount of radiation therapy.
[0303] In some embodiments, the radiation therapy is external beam radiation therapy. In other embodiments, the radiation therapy is internal radiation therapy. In some embodiments, the radiation therapy is ablative radiation therapy.
[0304]
[0300] In one embodiment, the combination treatment regimen disclosed herein includes administration of a Cbl-b inhibitor, radiation therapy, and one or both of an immune checkpoint inhibitor and an anti-tumor agent.
[0305] Provided herein is a method for treating cancer, comprising administering to an individual having cancer a combination therapy comprising an effective amount of a Cbl-b inhibitor and an effective amount of a cancer vaccine. Also provided is a medicament comprising a Cbl-b inhibitor for use in combination with a cancer vaccine for treating cancer, and a medicament comprising both a Cbl-b inhibitor and a cancer vaccine for use in treating cancer. Further provided is the use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer in an individual when administered in combination with a cancer vaccine. Further provided is the use of a Cbl-b inhibitor and a cancer vaccine in the manufacture of a medicament for treating cancer. In certain embodiments, the Cbl-b inhibitor is a "small molecule."
[0306] Also provided herein is a method for treating cancer, comprising administering to an individual with cancer a combination therapy comprising an effective amount of a Cbl-b inhibitor and an effective amount of an oncolytic virus. Also provided are agents comprising a Cbl-b inhibitor for use in combination with an oncolytic virus to treat cancer, and agents comprising both a Cbl-b inhibitor and an oncolytic virus for use in treating cancer. Further provided is the use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer in an individual when administered in combination with an oncolytic virus. Further provided is the use of a Cbl-b inhibitor and an oncolytic virus in the manufacture of a medicament for treating cancer. In certain embodiments, the Cbl-b inhibitor is a "small molecule."
[0307] In some embodiments of the disclosed methods, medicaments, and uses, the cancer is a blood cancer such as lymphoma, leukemia, or myeloma. In other embodiments of the disclosed methods, medicaments, and uses, the cancer is a non-blood cancer such as sarcoma, carcinoma, or melanoma.
[0308] Hematological cancers include, but are not limited to, one or more leukemias such as B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), and acute lymphoblastic leukemia (ALL); one or more chronic leukemias including, but not limited to, chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL); and one or more chronic leukemias including, but not limited to, B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and hairy cell leukemia. Additional blood cancers or hematological conditions include small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and "preleukemia," which are a diverse group of hematological conditions united by ineffective production (or dysplasia) of bone marrow blood cells.
[0309]
[0305] Non-hematological cancers include, but are not limited to, neuroblastoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, squamous cell carcinoma, melanoma, gastric cancer, brain cancer, lung cancer (e.g., NSCLC), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, uterine cancer, adrenal cancer, and head and neck cancer.
[0310] In some embodiments, the efficacy of an administered activation threshold lowering agent (activation threshold lowering agent) or costimulation requirement reducer, e.g., a Cbl-b inhibitor, in treating cancer is measured by assessing clinical outcomes such as reduction in tumor size or number of tumors and / or survival. In some embodiments, "treating cancer" includes assessing a patient's response to a treatment regimen according to the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), as described (see, e.g., Eisenhauer et al., Eur J Cancer, 45:228-247, 2009; and Nishino et al., Am J Roentgenol, 195:281-289, 2010). Response criteria for determining an objective anti-tumor response according to RECIST 1.1 include complete response (CR); partial response (PR); progressive disease (PD); and stable disease (SD).
[0311] Also provided herein is a method for treating cancer, the method comprising administering to an individual having cancer a combination therapy comprising an effective amount of an agent that lowers the activation threshold of immune cells (e.g., T cells, B cells, and / or NK cells) (an activation threshold lowering agent), and an effective amount of a cancer vaccine. Also provided is a medicament for treating cancer comprising an activation threshold lowering agent for use in combination with a cancer vaccine, and a medicament for use in treating cancer comprising both an activation threshold lowering agent and a cancer vaccine. Further provided is the use of an activation threshold lowering agent in the manufacture of a medicament for treating cancer in an individual when administered in combination with a cancer vaccine. Further provided is the use of an activation threshold lowering agent and a cancer vaccine in the manufacture of a medicament for treating cancer.
[0312] Also provided herein is a method for treating cancer, comprising administering to an individual with cancer a combination therapy comprising an effective amount of an agent that lowers the activation threshold of immune cells (e.g., T cells, B cells, and / or NK cells) (an activation threshold lowering agent) and an effective amount of an oncolytic virus. Also provided are agents for treating cancer comprising an activation threshold lowering agent for use in combination with an oncolytic virus, and agents for use in treating cancer comprising both an activation threshold lowering agent and an oncolytic virus. Further provided is the use of an activation threshold lowering agent in the manufacture of a medicament for treating cancer in an individual when administered in combination with an oncolytic virus. Further provided is the use of an activation threshold lowering agent and an oncolytic virus in the manufacture of a medicament for treating cancer.
[0313] In one embodiment, the agent that lowers the activation threshold (activation threshold lowering agent) is an agent that reduces the need for costimulation of immune cells (e.g., T cells, B cells, and / or NK cells) (co-stimulation requirement reducer). In one embodiment, the agent that lowers the activation threshold (activation threshold lowering agent) is an agent that promotes tumor immunosurveillance. In one embodiment, the agent that lowers the activation threshold (activation threshold lowering agent) is a Cbl-b inhibitor. In one embodiment, the agent that reduces the need for costimulation is a Cbl-b inhibitor. In one embodiment, the agent that promotes tumor immunosurveillance is a Cbl-b inhibitor.
[0314] In certain embodiments, activation threshold lowering agents, such as Cbl-b inhibitors, can increase T cell activation and / or T cell proliferation. In certain embodiments, activation threshold lowering agents, such as Cbl-b inhibitors, can decrease T cell exhaustion, T cell tolerance, and / or T cell anergy.
[0315] In certain embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, can increase production of one or more cytokines by T cells or surrounding immune cells (e.g., myeloid cells) in the activated T cell microenvironment. In certain embodiments, the one or more cytokines include, but are not limited to: IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, IL-18, TNFα, and GM-CSF. In certain embodiments, the cytokine is one or more of IL-2, IFN-γ, TNFα, and GM-CSF. In certain embodiments, the cytokine is a chemokine. In certain embodiments, the one or more chemokines include, but are not limited to: IP-10, eotaxin, GRO α, RANTES, MIP-1α, MIP-1β, MIP-2, MCP-1, and MCP-3. Increased cytokine expression can be measured by ELISA.
[0316] In certain embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, is capable of increasing cell surface expression of one or more T cell activation markers. In certain embodiments, the one or more T cell activation markers include, but are not limited to: CD25, CD44, CD62L, CD69, CD152 (CTLA4), CD154, CD137, and CD279. In certain embodiments, the T cell activation marker is one or more of CD25, CD69, and CTLA4. The increased expression of cell surface markers can be measured by FACS.
[0317] Methods for experimentally determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are well known in the art. In certain embodiments, representative methods for determining T cell activation are found in Biological Example 9 and / or Biological Example 13 provided herein. In certain embodiments, representative in vitro and in vivo methods for determining increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance are found in Biological Example 10 and / or Biological Example 14.
[0318] In certain embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, is capable of increasing B cell activation. In certain embodiments, increased B cell activation comprises increased cell surface expression of one or more B cell activation markers. In certain embodiments, the one or more B cell activation markers include, but are not limited to, CD69, CD86, and MHC class II (e.g., HLA-DR). In certain embodiments, the B cell activation marker is CD69. Increased expression of cell surface markers can be measured by FACS. In certain embodiments, increased B cell activation comprises increased activation of proteins in signal transduction pathways, such as those mediated by ERK, JNK, and Syk. Increased activation of proteins can be detected by measuring the level of phosphorylation in the proteins using reagents available in the art, such as anti-phosphorylation antibodies.
[0319] In certain embodiments, an activation threshold lowering agent, such as a Cbl-b inhibitor, is capable of increasing NK cell activation. In certain embodiments, increased NK cell activation includes secretion of one or more cytokines. In certain embodiments, the one or more cytokines include, but are not limited to, IFN-γ, TNFα, and MIP-1β. Increased expression of cytokines can be measured by ELISA. In certain embodiments, increased NK cell activation includes increased cell surface expression of one or more NK cell activation markers. In certain embodiments, the one or more NK cell activation markers include, but are not limited to, CD69 and CD107a. Increased expression of cell surface markers can be measured by FACS. In certain embodiments, increased NK cell activation includes increased killing of target cells, such as tumor cells, including primary tumor cells and tumor cells derived from cell lines, such as the K562 cell line.
[0320] Methods for experimentally determining increased B cell activation and NK cell activation are well known in the art. In certain embodiments, representative methods for determining B cell activation are found in Biological Example 10 and / or Biological Example 14. In certain embodiments, representative methods for determining NK cell activation are found in Biological Example 10 and / or Biological Example 14.
[0321] Modulation of immune cell activity, such as T cells, B cells, or NK cells, can be measured by determining a baseline value for a parameter of interest (e.g., cytokine secretion). For example, T cell activation in a sample, such as one obtained from an in vitro experiment of cells contacted with a Cbl-b inhibitor, can be measured before contacting or administering the Cbl-b inhibitor to determine a baseline value. A reference value is then obtained for T cell activation after contacting or administering the Cbl-b inhibitor. The reference value is compared to the baseline value to determine the amount of T cell activation due to contacting or administering a Cbl-b inhibitor or composition thereof. For example, in certain embodiments, immune cell (e.g., T cell) activation is increased by at least 0.1-fold in the sample compared to the baseline value, where the baseline value is obtained before contacting the immune cells (e.g., T cells) with the Cbl-b inhibitor or composition thereof. In certain embodiments, immune cell (e.g., T cell) activation is increased by at least about 0.1-fold, about 0.2-fold, about 0.3-fold, about 0.4-fold, about 0.5-fold, about 0.6-fold, about 0.7-fold, about 0.8-fold, about 0.9-fold, about 1-fold, about 2-fold, about 4-fold, about 6-fold, about 8-fold, about 10-fold, about 20-fold, or about 30-fold, but not more than about 50-fold, above baseline values. Immune cell activation can be assessed by measuring biological markers of activation, such as increased cytokine secretion, increased cell surface expression of activation markers (e.g., cell surface markers), or increased phosphorylation of proteins in downstream signaling pathways. The fold increase over baseline, indicative of immune cell activation, can be determined for the parameter being tested and the conditions under which the immune cells are treated. For example, to measure T cell activation, a baseline value can be obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody, where the cells are not incubated with a Cbl-b inhibitor. A baseline value is then obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody, where the T cells have been or are being contacted with a Cbl-b inhibitor, and a positive response to immune cell activation can then be determined from the obtained baseline value.Similar baseline measurements are obtained and compared to baseline values to assess T cell activation, T cell proliferation, T cell exhaustion, T cell tolerance, B cell activation, and / or NK cell activation. Measurements of these parameters are obtained using techniques well known in the art and those described in Biological Examples 9, 10, 12, and 13.
[0322] The term "baseline" or "baseline value," as used herein, can refer to a measurement or characterization prior to administration of a therapeutic agent disclosed herein (e.g., a composition comprising a Cbl-b inhibitor described herein) or at the start of administration of the therapeutic agent. The baseline value can be compared to the reference value to determine an increase or decrease in immune cell function (e.g., increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and / or decreased T cell tolerance). The term "baseline" or "reference value," as used herein, can refer to a measurement or characterization following administration of a therapeutic agent disclosed herein (e.g., a composition comprising a Cbl-b inhibitor described herein). The reference value can be measured one or more times during an experimental time course, dosing regimen, or treatment cycle, or at the completion of an experimental time course, dosing regimen, or treatment cycle. A "reference value" can be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an average value, a median, a mean value, or a value compared to the baseline value. Similarly, a "baseline value" can be an absolute value, a relative value, a value with upper and / or lower limits, a range of values, an average value, a median value, a mean value, or a value to be compared to a reference value. Reference and / or baseline values can be obtained from one sample (e.g., one sample obtained from an individual), two different samples (e.g., samples obtained from two different individuals), or a group of samples (e.g., samples obtained from a group of 2, 3, 4, 5, or more individuals).
[0323] In certain embodiments, a positive response to T cell activation, as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the presence of a Cbl-b inhibitor, is at least 2.5-fold relative to the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the absence of a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the presence of a Cbl-b inhibitor, is at least 1.3-fold relative to the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with an anti-CD3 antibody in combination with an anti-CD28 antibody in the absence of a Cbl-b inhibitor. In certain embodiments, the baseline value is obtained from T cells stimulated with an anti-CD3 antibody alone, where the cells are not incubated with a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by cytokine secretion (e.g., IL-2 secretion) by T cells stimulated with an anti-CD3 antibody alone in the presence of a Cbl-b inhibitor, is at least 0.1-fold relative to the baseline value for cytokine secretion (e.g., IL-2 secretion) obtained from T cells stimulated with an anti-CD3 antibody alone in the absence of a Cbl-b inhibitor. In certain embodiments, a positive response to T cell activation, as measured by surface marker expression (e.g., CD25 surface marker staining) by T cells stimulated with an anti-CD3 antibody alone in the presence of a Cbl-b inhibitor, is at least 0.6-fold relative to the baseline value for surface marker expression (e.g., CD25 surface marker staining) obtained from T cells stimulated with an anti-CD3 antibody alone in the absence of a Cbl-b inhibitor.
[0324]
[0320] The present disclosure provides a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of a cancer vaccine. Also provided is a method of treating an individual having cancer, comprising administering to the individual an effective amount of a Cbl-b inhibitor; and administering to the individual an effective amount of a cancer vaccine. Further provided is a method of increasing an anti-cancer immune response, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of a cancer vaccine. Further provided is a method of treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, wherein the individual has been or is being administered an effective amount of a cancer vaccine.
[0325]
[0321] Furthermore, the present disclosure provides a method for treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of an oncolytic virus. Also provided is a method for treating an individual having cancer, comprising administering to the individual an effective amount of a Cbl-b inhibitor; and administering to the individual an effective amount of an oncolytic virus. Furthermore, the present disclosure provides a method for increasing an anti-cancer immune response, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, and administering to the individual an effective amount of an oncolytic virus. Further provided is a method for treating cancer, comprising administering to an individual having cancer an effective amount of a Cbl-b inhibitor, wherein the individual has been or is being administered an effective amount of an oncolytic virus.
[0326] In certain embodiments of the method of the previous paragraph, the Cbl-b inhibitor and the cancer vaccine are administered consecutively in either order. In certain embodiments, as used herein, the terms "consecutively," "sequentially," and "sequentially" refer to the administration of a cancer vaccine followed by a Cbl-b inhibitor, or the administration of a Cbl-b inhibitor followed by a cancer vaccine. For example, the sequential administration may include the administration of a Cbl-b inhibitor in the absence of a cancer vaccine during an induction phase (primary therapy), followed by a post-induction treatment phase comprising the administration of both the cancer vaccine and the Cbl-b inhibitor. The method may further include a maintenance phase comprising the administration of the Cbl-b inhibitor or an additional dose of the cancer vaccine. Alternatively, the sequential administration may include the administration of a cancer vaccine in the absence of a Cbl-b inhibitor during an induction phase (primary therapy), followed by a post-induction treatment phase comprising the administration of a Cbl-b inhibitor. The method may include a maintenance phase comprising the administration of an additional dose of the Cbl-b inhibitor or the cancer vaccine.
[0327] In certain embodiments of the method of the previous paragraph, the Cbl-b inhibitor and the oncolytic virus are administered consecutively in either order. In certain embodiments, as used herein, the terms "consecutively," "sequentially," and "sequentially" refer to administration of the oncolytic virus followed by the Cbl-b inhibitor, or administration of the Cbl-b inhibitor followed by the oncolytic virus. For example, sequential administration can include administration of the Cbl-b inhibitor in the absence of the oncolytic virus during an induction phase (primary therapy), followed by a post-induction treatment phase involving administration of both the oncolytic virus and the Cbl-b inhibitor. The method can include a maintenance phase involving administration of the Cbl-b inhibitor or administration of additional doses of the oncolytic virus. Alternatively, sequential administration can include administration of the oncolytic virus in the absence of the Cbl-b inhibitor during an induction phase (primary therapy), followed by a post-induction treatment phase involving administration of the Cbl-b inhibitor. The method may further include a maintenance phase comprising administering additional doses of the Cbl-b inhibitor or oncolytic virus.
[0328] In some embodiments of combination therapy, the Cbl-b inhibitor and the cancer vaccine are administered simultaneously. In certain embodiments, as used herein, the terms "concurrently," "simultaneously," and "concurrently" refer to the administration of the Cbl-b inhibitor and the cancer vaccine during the same visit or the same treatment phase. For example, both the Cbl-b inhibitor and the cancer vaccine may be administered during one or more of the induction phase, treatment phase, and maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the cancer vaccine be present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the cancer vaccine be administered at exactly the same time.
[0329] In some embodiments of combination therapy, the Cbl-b inhibitor and the oncolytic virus are administered simultaneously. In certain embodiments, as used herein, the terms "concurrently," "simultaneously," and "concurrently" refer to the administration of the Cbl-b inhibitor and the oncolytic virus during the same visit or treatment phase. For example, both the Cbl-b inhibitor and the oncolytic virus may be administered during one or more of the induction phase, treatment phase, and maintenance phase. However, simultaneous administration does not require that the Cbl-b inhibitor and the oncolytic virus be present together in a single formulation or pharmaceutical composition, or that the Cbl-b inhibitor and the oncolytic virus be administered at exactly the same time.
[0330] In some aspects, treatment involves multiple administrations of a Cbl-b inhibitor or composition thereof, where the interval between administrations can vary. In some embodiments, the Cbl-b inhibitor is administered to an individual at a flat dose (e.g., mg / adult or mg / child). In some embodiments, the Cbl-b inhibitor is administered to an individual at a fixed dose based on the individual's body weight (e.g., mg / kg).
[0331] In certain embodiments, the efficacy of the combination therapies disclosed herein can be assessed by measuring the biological activity of immune cells present in a sample isolated from the treated individual. For example, the ability of immune cells isolated from the individual after treatment to destroy target cells using a cytotoxicity assay can be used to assess therapeutic efficacy. In certain embodiments, the biological activity of immune cells present in a sample can be measured by assaying the expression and / or secretion of certain cytokines, such as IL-2 and IFNγ.
[0332]
[0328] As used herein, unless otherwise specified, the term "cancer vaccine" refers to a "therapeutic cancer vaccine" administered to an individual with cancer for the purpose of treating the cancer (and optionally preventing the recurrence of the cancer). In contrast, a "preventative cancer vaccine" (prophylactic cancer vaccine) is one administered to an individual without cancer for the purpose of preventing cancer or reducing the individual's risk of developing cancer. Examples of prophylactic cancer vaccines are human papillomavirus vaccines for the prevention of squamous cell carcinoma and hepatitis B virus vaccines for the prevention of hepatocellular carcinoma. A cancer vaccine is an immunogenic composition comprising a pharmaceutically acceptable excipient and at least one tumor antigen, such as a tumor-specific antigen or a tumor-associated antigen.
[0333] As used herein, the terms "oncolytic virus" and "OV" refer to viruses that infect and kill cancer cells. Cancer cell death is the result of both direct cell lysis and the induction of anti-tumor immunity. In one embodiment, an "oncolytic virus" is a replication-competent virus that selectively replicates in cancer cells. In another embodiment, an "oncolytic virus" is a replication-deficient virus that does not replicate in cancer cells, either as a result of genetic recombination or inactivation (e.g., UV irradiation or heat) of the oncolytic virus.
[0334] In some embodiments, tumor antigens include "common tumor antigens" that are common to many cancers of the same type. Non-limiting examples of common tumor antigens are the breast cancer antigen HER2, the prostate cancer antigens PAP and PSA, and the melanoma antigens MART-1 and MAGE. In other embodiments, tumor antigens include "neoantigens" that arise as a result of tumor-specific DNA alterations (e.g., somatic mutations). Thus, neoantigens typically have amino acid sequences that are not present in the normal mammalian genome (Schumacher and Schreiber, Science, 348:69-74, 2015). Non-limiting examples of neoantigens are BRAF V600E, KRAS G12D, KRAS G12V, PIK3CA H1047R, and PIC3CA E545K. The Tumor-Specific Neoantigen Database (TSNAdb) is now freely available (Wu et al., Genomics Proteomics Bioinformatics 16:276-282, 2018).
[0335] Various techniques are suitable for identifying neoantigens for inclusion in cancer vaccines as part of a combination therapy that includes an activation threshold-lowering agent, such as a Cbl-b inhibitor. For example, neoantigens can be identified by methods that involve isolating DNA from a tumor biopsy obtained from an individual, sequencing the DNA, and computer analysis of the sequence to identify one or more neoantigens (Aldous and Dong, Bioorg Med Chem, 26:2842-2849, 2018). In one embodiment, the computer analysis involves identifying peptides 8 to 11 amino acids in length that are predicted to bind to at least one HLA allele expressed by tumor cells and contain at least one missense mutation (Wu et al., Genomics Proteomics Bioinformatics 16:276-282, 2018). Including neoantigens in cancer vaccines may be advantageous for overcoming immune tolerance and reducing the risk of autoimmunity.
[0336]
[0332] Suitable cancer vaccine platforms for use in the methods, agents, and uses of the present disclosure include, but are not limited to, synthetic peptides, recombinant proteins, nucleic acids (DNA or mRNA), microbial vectors, tumor cells, and antigen-presenting cells (see, e.g., DeMaria and Bilusic, Hematol Oncol Cin North Am, 33:199-214, 2019; and Maeng and Berzofsky, F1000Research 2019, 8(F1000 Faculty Rev):654, 2019).
[0337] In some embodiments, the tumor antigen of the cancer vaccine comprises at least one synthetic peptide or recombinant protein. In some embodiments, the synthetic peptide is at least 8 amino acids in length, and in certain embodiments, less than 80 amino acids in length. In some embodiments, the tumor antigen comprises multiple synthetic peptides, or the tumor antigen comprises a synthetic peptide or recombinant protein comprising the amino acid sequences of two, three, or more epitopes. An "epitope" is a portion of an antigen that is bound by an antibody or B-cell receptor, or presented for binding by a T-cell receptor by a major histocompatibility complex molecule (MHC class I or class II) on the surface of a cell, such as a tumor cell or dendritic cell. In some embodiments, the epitope is a "linear epitope" composed of consecutive amino acids (primary structure) of the tumor antigen sequence. In some embodiments, the epitope is a "conformational epitope" composed of non-consecutive amino acids (tertiary structure) of the tumor antigen. In some embodiments, the tumor antigen comprises a recombinant protein comprising both linear and conformational epitopes.
[0338] In some embodiments, the tumor antigen is encoded by a DNA or mRNA molecule. In some embodiments, the tumor antigen is encoded by the nucleic acid of a microbial vector, or by other such methods, and the cancer vaccine comprises the microbial vector. In some embodiments, the microbial vector is a live attenuated microbial vector. In one embodiment, the live attenuated microbial vector is TICE® BCG, a live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis, sold by Organon USA, Inc. (Roseland, NJ). TICE® BCG is approved by the U.S. Food and Drug Administration (FDA) for intravesical use after reconstitution with sterile saline (e.g., a pharmaceutically acceptable excipient), and is indicated for the treatment and prevention of intravesical carcinoma in situ of the bladder and the prevention of early or recurrent Ta and / or T1 papillary tumors after transurethral resection.
[0339] In some embodiments, the microbial vector is a recombinant microbial vector, such as a recombinant viral vector or a recombinant bacterial vector. Recombinant viral vectors suitable for use in the combination therapy of the present disclosure include, but are not limited to, retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, poxviruses, and herpesviruses (Chulpanova et al., Biomedicines, 6:94, 2018). In some embodiments, the microbial vector is a recombinant bacterial vector. Recombinant bacterial vectors suitable for use in the combination therapies of the present disclosure include, but are not limited to, Clostridium (C. novyi), Listeria (e.g., L. monocytogenes), Pseudomonas (e.g., P. aeruginosa), and Salmonella (S. typhimurium) (Toussant et al., Expert Rev Vaccines, 12:1139-1154, 2013).
[0340] In some embodiments, the cancer vaccine comprises antigen-presenting cells (APCs) contacted with a tumor antigen, such as a synthetic peptide or recombinant protein. In some embodiments, the APCs are transfected with a nucleic acid encoding the tumor antigen. In some embodiments, the APCs are transfected with a nucleic acid encoding a cytokine. In some embodiments, the APCs comprise dendritic cells or mesenchymal stem cells. In one embodiment, the cancer vaccine is PROVENGE® (Sipuleucel-T), sold by Dendreon Corp. (Seattle, WA). PROVENGE® comprises lactated Ringer's solution (e.g., a pharmaceutically acceptable excipient) and peripheral blood mononuclear cells (PBMCs) activated with a PAP-GM-CSF fusion protein consisting of prostatic acid phosphatase linked to granulocyte-macrophage colony-stimulating factor. PROVENGE® is approved by the U.S. Food and Drug Administration (FDA) for intravenous injection for the treatment of asymptomatic or minimally symptomatic metastatic prostate cancer.
[0341] In some embodiments, the cancer vaccine comprises killed tumor cells. In some embodiments, the cancer vaccine comprises a tumor cell lysate. In some embodiments, the cancer vaccine comprises APCs contacted with a tumor cell lysate.
[0342] Cancer vaccine adjuvants suitable for use in the methods, medicaments, and uses of the present disclosure include, but are not limited to, adjuvants that are FDA-approved. In particular, current FDA-approved adjuvants include aluminum salts, monophosphoryl lipid A, oil-in-water emulsions (e.g., squalene-in-water emulsions MF59 or AS03), saponin, and CpG oligodeoxynucleotides.
[0343] Oncolytic viruses suitable for use in the methods, medicaments, and uses of the present disclosure include, but are not limited to, adenovirus, coxsackievirus, echovirus, fowlpox virus, herpes simplex virus, Maraba virus, measles virus, myxoma virus, Newcastle disease virus, parvovirus, poliovirus, retrovirus, reovirus, Seneca Valley virus, Semiliki Forest virus, vaccinia virus, and vesicular stomatitis virus (see, e.g., Russell and Peng, Chin Clin Oncol, 7:16, 2018; and Sivanandam et al., Molecular Therapy Oncolytics, 13:93-106).
[0344] In some embodiments, the oncolytic virus is not genetically modified (non-recombinant virus). In some embodiments, the non-recombinant virus is an echovirus (e.g., Rigvir), Newcastle disease virus, parvovirus, reovirus, or Seneca Valley virus.
[0345] In some embodiments, the oncolytic virus is a recombinant virus that has been genetically engineered to contain one or more gene deletions, one or more gene insertions, or one or more gene deletions and one or more gene insertions. In some embodiments, the recombinant virus has been genetically engineered to alter host cell specificity and / or tumor cell cytotoxicity. In some embodiments, the recombinant oncolytic virus has been genetically engineered by functional deletion of one or more viral genes encoding proteins that suppress a host cell response (e.g., an antiviral response) and / or by insertion of one or more transgenes encoding proteins that promote a host cell response (e.g., an antitumor response) (see, e.g., Guo et al., Frontiers in Immunology, 8:Article 555, 2017; and Lin et al., Oncology Letters, 15:4053-4060, 2018). In some embodiments, the recombinant virus is further engineered by insertion of a transgene encoding a detectable marker, such as a fluorescent protein. The desired antitumor response includes one or both of an innate immune response and an adaptive immune response.
[0346] In certain embodiments, the recombinant oncolytic virus is a recombinant herpes simplex virus (HSV), such as HSV type 1. In one embodiment, the recombinant oncolytic virus is IMLYGIC®, also known as talimogene laherparepvec or T-VEC, sold by Amgen Inc. (Thousand Oaks, CA). IMLYGIC® is a recombinant HSV-1 containing a functional deletion of the ICP34.5 and ICP47 genes and an insertion of a nucleic acid encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). IMLYGIC® is approved by the U.S. Federal Drug Administration (FDA) for the local treatment by intralesional injection (intratumoral administration) of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. Additionally, IMLYGIC® is approved by the European Medicines Agency (EMA) for the treatment of adults with locally or distantly metastatic unresectable melanoma (stage IIIB, IIIC, or IVM1a). Specifically, the EMA-approved product is administered by intralesional injection (intratumoral administration) into cutaneous, subcutaneous, and / or nodal lesions that are visible, palpable, or detectable by ultrasound guidance.
[0347] In certain embodiments, the recombinant oncolytic virus is a recombinant adenovirus, such as a serotype 5 adenovirus. In one embodiment, the recombinant adenovirus is Oncorine (H101), formerly known as Onyx-015. Oncorine is a serotype 5 adenovirus engineered by inactivation (functional deletion) of the viral E1B-55k and viral E3 genes. Oncorine has been approved by the Chinese State Food and Drug Administration for the treatment of head and neck cancer in combination with chemotherapy (anti-neoplastic drug therapy).
[0348] In some embodiments, the recombinant oncolytic virus is a recombinant poxvirus. In some embodiments, the poxvirus is a vaccinia virus or a fowlpox virus. In some embodiments, the vaccinia virus is Modified Vaccinia Ankara. In some embodiments, the recombinant vaccinia virus has been genetically modified by functional deletion of one or more viral genes encoding proteins that suppress a host cell response (e.g., an antiviral response) and / or by insertion of one or more transgenes encoding proteins that promote a host cell response (e.g., an anti-tumor response) (see, e.g., Guo et al., Journal of ImmunoTherapy of Cancer, 7:6, 2019). In one embodiment, the recombinant vaccinia virus is Pexa-Vec, also known as pexathymodindebasilepvec and JX-594, a vaccinia virus engineered by inactivation (functional deletion) of the viral thymidine kinase gene and by insertion of transgenes encoding human GM-CSF and β-galactosidase (Heo et al., Nat Med, 19:329-336, 2013). In another embodiment, the recombinant vaccinia virus comprises functional deletions of the viral thymidine kinase and vaccinia growth factor genes and insertion of a transgene encoding the chemokine CXCL11 (see, e.g., Liu et al., OncoImmunology, 5:3, e1091554, 2016; and Liu et al., Nature Communications, 8:14754, 2017).
[0349] Further embodiments of the combination therapy of the present disclosure include at least one additional therapeutic agent, hi certain embodiments, the at least one additional therapeutic agent is selected from the group consisting of an immune checkpoint inhibitor, chemotherapy (anti-tumor agent), radiation therapy, and combinations thereof.
[0350] In certain embodiments, the immune checkpoint inhibitor is an antagonist of at least one inhibitory immune checkpoint molecule. In certain embodiments, the at least one inhibitory immune checkpoint molecule is selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA4 (CD152). The immune checkpoint inhibitor may be a therapeutic biologic. For example, the immune checkpoint inhibitor may comprise an antibody or an antigen-binding fragment thereof. The antibody or fragment may be a monoclonal antibody (mAb), a human antibody, a humanized antibody, or a chimeric antibody and may comprise a human constant region. In certain embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in certain embodiments, the human constant region is an IgG1 or IgG4 constant region. In certain embodiments, the antibody or fragment is a bispecific antibody. In certain embodiments, the antigen-binding fragment comprises one of the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.
[0351] In certain embodiments, the chemotherapy includes at least one anti-tumor agent (i.e., WHO ATC code L01). In certain embodiments, the at least one anti-tumor agent is selected from the group consisting of cytotoxic antibiotics, plant alkaloids, antimetabolites, and alkylating agents, other anti-tumor agents, and combinations thereof. When used in reference to chemotherapy, an anti-tumor agent is a "drug," in contrast to a "therapeutic biologic."
[0352] In some embodiments, the radiation therapy is external beam radiation therapy. In other embodiments, the radiation therapy is internal radiation therapy. In some embodiments, the radiation therapy is ablative radiation therapy.
[0353] As used herein, the term "biosimilar" refers to a biological product that is similar to a reference product approved by the U.S. Food and Drug Administration (FDA) and does not have clinically important differences in safety and efficacy. For example, differences in clinically inactive ingredients may exist between the biosimilar product and the reference product (e.g., differences in formulation excipients, slight differences in glycosylation, etc.). Clinically important properties may be evaluated by pharmacokinetic and pharmacodynamic studies. In some embodiments, a biosimilar product is an interchangeable product as determined by the FDA. In some embodiments, a cancer vaccine is a biosimilar of an FDA-approved product.
[0354] IV. Compositions, Formulations and Routes of Administration Pharmaceutical compositions of any of the compounds disclosed herein, or salts thereof, or solvates thereof are encompassed by the present disclosure. Accordingly, the present disclosure includes pharmaceutical compositions comprising a Cbl-b inhibitor (wherein the Cbl-b inhibitor is a compound of Formula (I), (IA) to (IN), (II-A) to (II-L), (III-A) to (III-D), (IV-A) to (IV-C), (VA) to (VG), or (VI-A) to (VI-D) disclosed herein, or any variation thereof, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof), and a pharmaceutically acceptable excipient, such as a pharmaceutically acceptable vehicle or a pharmaceutically acceptable carrier. In certain embodiments, the compound is a compound selected from compound numbers 1 to 45 in Table 1, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. In certain embodiments, the compound is a compound selected from compound numbers 47 to 52 in Table 1, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. In one aspect, the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid.
[0355] The compounds and compositions disclosed herein can be administered in any suitable form and by any suitable route that provides sufficient levels of the compound for treatment of a disease or disorder. In some embodiments, the Cbl-b inhibitor and / or additional therapeutic agent are administered by enteral administration. In some embodiments, the enteral administration is oral administration. In other embodiments, the Cbl-b inhibitor and / or additional therapeutic agent are administered by parenteral administration. In some embodiments, the parenteral administration is intratumoral injection. In some embodiments, the parenteral administration is by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous.
[0356] Suitable routes of administration include parenteral administration, including oral, enteral, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intraperitoneal, intralesional, intraarticular, and intratumoral injections, or infusion techniques. The compounds and compositions may also be administered sublingually, mucosally, bucally, subcutaneously, spinally, epidurally, intraventricularly, by inhalation (e.g., as a mist or spray), intranasally, intravaginally, rectally, topically, or transdermally, or by sustained-release or sustained-release mechanisms. The compounds and compositions may be administered in unit-dosage formulations containing conventional pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles, as appropriate. The compounds and compositions may be administered directly to specific or affected organs or tissues. The compounds may be mixed with pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles to form compositions suitable for the desired route of administration. In certain embodiments, the compound may be mixed with one or both of an antigen and an adjuvant, hi certain embodiments, the antigen is a cancer antigen.
[0357] In certain embodiments disclosed herein, particularly those in which the formulations are used for injection or other parenteral administration, including those routes enumerated herein, but also any other routes of administration described herein (oral, enteral, intragastric, etc.), the formulations and preparations used in the methods are sterile. Sterile pharmaceutical formulations are compounded or manufactured in accordance with pharmaceutical-grade sterilization standards known to those skilled in the art (United States Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code 4127.7; 16 California Code of Regulations 1751, 21 Code of Federal Regulations 211). A "sterile" formulation is aseptic or free or substantially free of all live microorganisms and their spores. Examples of methods for sterilizing pharmaceutical formulations include, but are not limited to, sterile filtration through sterile filtration membranes, exposure to radiation such as gamma radiation, and heat sterilization.
[0358] Oral administration is advantageous due to its ease of implementation and patient compliance. If the patient has swallowing difficulties, the introduction of the drug via a feeding tube, feeding syringe, or gastrostomy tube can be used to achieve enteral administration. The active compound and, if present, other co-administered drugs can be enterally administered in any other pharmaceutically acceptable excipient suitable for formulation via a feeding tube, feeding syringe, or gastrostomy tube.
[0359]
[0355] Intravenous administration can also be advantageously used to deliver the compound or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract.
[0360] The compounds and compositions described for use herein can be administered in solid, liquid, or aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), powder mixtures, granules, injectables, solutions, suppositories, enemas, colonic washes, emulsions, dispersions, food premixes, cachets, lozenges, lozenges, gums, ointments, poultices, pastes, powders, bandages, creams, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds and compositions can also be administered in liposomal formulations. The compounds can also be administered as prodrugs, where the prodrug is converted to a therapeutically active form in the treated subject.
[0361]
[0357] In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, adjusters, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Formulations containing compounds may also contain other substances with beneficial therapeutic properties. Pharmaceutical formulations can be prepared by known pharmaceutical methods. Further formulation and administration methods are known in the art. Suitable formulations can be found, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), which is incorporated herein by reference.
[0362]
[0358] Injectable preparations, for example, sterile injectable aqueous or oily suspensions, can be formulated using suitable dispersants or wetting agents and suspending agents according to methods known in the art. Sterile injectable preparations can also be sterile injectable solutions or suspensions in parenterally acceptable diluents or solvents, for example, as solutions in propylene glycol. Among the acceptable vehicles and solvents that can be used, water, physiological saline, Ringer's solution, and isotonic sodium chloride solution are particularly suitable. In addition, sterile fixed oils are commonly used as solvents or suspending media. For this purpose, any sterile fixed oil, including synthetic mono- or diglycerides, can be used. In addition, fatty acids such as oleic acid can be used in the preparation of injectable preparations.
[0363]
[0359] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be mixed with at least one inert diluent such as sucrose, lactose, talc, or starch. Such dosage forms may also contain additional excipient substances other than inert diluents, for example, lubricants such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. Tablets and pills may further be prepared with enteric coatings. Acceptable excipients for soft-shelled gel capsules include, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, etc.
[0364]
[0360] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also contain additional agents such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweeteners, flavorings, and aromatics. Alternatively, compounds may also be administered in their original form, if appropriate.
[0365] The compounds and compositions can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed of mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The compositions of the present invention in liposome form can contain stabilizers, preservatives, excipients, etc., in addition to the compounds disclosed herein. Useful lipids include natural and synthetic phospholipids and phosphatidylcholines (lecithins). Methods for forming liposomes are known in the art. See, for example, Gregoriadis, G. Ed., Liposome Technology, Third Edition: Liposome Technology: Liposome Preparation and Related Techniques, CRC Press, Boca Raton, Florida (2006); and Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, NW, p. 33 et seq (1976).
[0366] The amount of active ingredient that can be combined with a carrier material to produce a single dosage form can vary depending on the patient to whom the active ingredient is administered and the particular method of administration. However, it will be understood that the specific dosage level for any particular patient will depend on a variety of factors, including the specific compound used; the patient's age, weight, body surface area, body mass index (BMI), overall health, sex, and dietary habits; the timing and route of administration used; excretion rate; and combination medications, if any, used. The compound can be administered in a unit dosage formulation. The selected drug unit dosage is manufactured and administered to provide a sufficient concentration of the drug in the patient, subject, or individual.
[0367]
[0363] The compounds for use described herein can be administered as a single active pharmaceutical agent, but they can also be used in combination with one or more other agents. When an additional active agent is used in combination with a compound for use described herein, the additional active agent can generally be used in a therapeutic amount as set forth in the Physicians' Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or in such therapeutically useful amounts as would be known to one of ordinary skill in the art, or as determined empirically for each patient.
[0368] Combinations of two or more of the compounds and compositions disclosed herein may also be used. Two or more compounds or compositions may be mixed together immediately prior to administration and administered together. Two or more compounds or compositions may be administered simultaneously, either by the same route of administration or different routes of administration. Two or more compounds or compositions may be administered sequentially, either by the same route of administration or different routes of administration. In one embodiment, a kit form may contain two or more compounds or compositions as individual compounds or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds or compositions, as separate compounds or compositions administered simultaneously, or as separate compounds or compositions administered sequentially. When three or more compounds or compositions are administered, they may be administered as a mixture of compounds or compositions, as separate compounds or compositions administered simultaneously, as separate compounds or compositions administered sequentially, as separate compounds or compositions where two or more are administered simultaneously and the rest may be administered sequentially before or after the simultaneous administration, or any other possible combination of mixed, simultaneous, and sequential administration.
[0369] The compounds disclosed herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are disclosed herein. Compositions comprising the compounds disclosed herein or salts thereof, such as compositions of substantially pure compounds, are provided. In certain embodiments, compositions comprising the compounds disclosed herein or salts thereof are in substantially pure form. In one aspect, "substantially pure" contemplates a composition containing 35% or less impurities, where impurities refer to compounds other than the compound (or compounds, if a combination of compounds is used) or salts or solvates of the compound (or compounds, if a combination of compounds is used) administered in the composition. The weight of any added vehicle, carrier, or excipient is excluded from such calculations; added vehicle, carrier, or excipient is not considered an impurity. For example, a composition of a substantially pure compound selected from the compounds of Table 1 refers to a composition containing 35% or less impurities, where impurities refer to compounds other than the compound or salts or solvates thereof. In one aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 25% or less impurities. In another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 20% or less impurities. In yet another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 10% or less impurities. In a further aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 5% or less impurities. In another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 3% or less impurities. In yet another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 1% or less impurities. In a further aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 0.5% or less impurities.In yet another embodiment, a composition of a substantially pure compound means that the composition contains 15% or less, 10% or less, 5% or less, 3% or less, or 1% or less of impurities. An impurity can be a compound of a stereochemical form different from the desired stereochemical form. For example, a composition of a substantially pure (S)-compound means that the composition contains 15% or less, 10% or less, 5% or less, 3% or less, or 1% or less of the (R)-form of the compound. Alternatively, as used herein, "enantiomeric excess (ee)" refers to a dimensionless molar ratio that represents the purity of, for example, a chiral substance containing a single stereocenter. For example, an enantiomeric excess of 0 can indicate a racemate (e.g., a 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). As a further example, an enantiomeric excess of 99 can indicate a nearly stereochemically pure enantiomeric compound (i.e., a significant excess of one enantiomer over the other). Percentage enantiomeric excess, % ee = ([(R)-compound] - [(S)-compound]) / ([(R)-compound] + [(S)-compound]) × 100 (where (R)-compound > (S)-compound); or % ee = ([(S)-compound] - [(R)-compound]) / ([(S)-compound] + [(R)-compound]) × 100 (where (S)-compound > (R)-compound). Furthermore, as used herein, "diastereomeric excess (de)" refers to a dimensionless molar ratio that represents the purity of a chiral substance containing two or more stereocenters. For example, a diastereomeric excess of 0 may indicate an equimolar mixture of diastereoisomers. As a further example, a diastereomeric excess of 99 may indicate a nearly stereochemically pure diastereomeric compound (i.e., one diastereomer is in significant excess over the other). Diastereomeric excess can be calculated by a method similar to ee. As will be understood by those skilled in the art, de is usually reported as a percentage (% de), which can be calculated in a similar manner to % ee.
[0370] In certain aspects, provided herein are compositions comprising cell populations containing modified immune cells, such as those described herein or produced by the methods disclosed herein. In certain embodiments, the compositions comprise cell populations containing modified immune cells that have been contacted or contacted with a Cbl-b inhibitor or composition thereof described herein. In certain embodiments, the modified immune cells have been contacted or contacted with an anti-CD3 antibody alone. In certain embodiments, the modified immune cells have been contacted or contacted with an anti-CD3 antibody in combination with an anti-CD28 antibody. The provided compositions comprising cell populations containing modified immune cells described herein may further comprise a pharmaceutically acceptable excipient.
[0371] Also provided herein, in one aspect, is a cell culture composition comprising a cell population containing immune cells and a Cbl-b inhibitor described herein. In one embodiment, the immune cells are human immune cells. In one embodiment, the immune cells are cells selected from the group consisting of hematopoietic cells, pluripotent stem cells, myeloid progenitor cells, lymphoid progenitor cells, T cells, B cells, and NK cells. In one embodiment, the cell culture composition further comprises an anti-CD3 antibody. In one embodiment, the cell culture composition further comprises an anti-CD3 antibody in combination with an anti-CD28 antibody. Methods for culturing cell compositions containing immune cells are well known in the art and are contemplated herein.
[0372] The modified immune cells or compositions described herein, e.g., compositions or pharmaceutical compositions comprising cell populations containing modified immune cells, can be provided in a suitable container. Suitable containers include, for example, bottles, vials (e.g., dual-chamber vials), syringes (e.g., single- or dual-chamber syringes), bags (e.g., intravenous bags), and tubing (e.g., test tubes). Containers can be formed from a variety of materials, such as glass or plastic.
[0373] In certain embodiments, a composition (e.g., a cell culture composition) comprising a cell population containing the modified immune cells described herein is provided in a culture vessel. Culture vessels provided herein include, but are not limited to, tubes (e.g., test tubes), dishes (e.g., tissue culture dishes), bags, multiwell plates (e.g., 6-well tissue culture plates), and flasks (e.g., cell culture flasks).
[0374] Also provided are compositions described for any of the uses described herein. In some embodiments, the compositions described herein are for the preparation of a medicament for treating or preventing a disease or condition associated with Cbl-b activity. In some embodiments, the compositions described herein are for the preparation of a medicament for treating cancer.
[0375]
[0371] Pharmaceutical compositions of any of the compounds disclosed herein, or salts or solvates thereof, for use in combination with a cancer vaccine are encompassed by the present disclosure. Thus, the present disclosure includes pharmaceutical compositions comprising a Cbl-b inhibitor for use in combination with a cancer vaccine, wherein the Cbl-b inhibitor is a compound of 1-719 of International Patent Application WO 2019 / 148005 (including the "a" and "b" variants thereof) or a compound of any of Formula (IA), Formula (I), Formula (II-A), Formula (II), Formula (III-A), Formula (III), or Formula (IV), or any variant thereof disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof.
[0376]
[0372] Additionally, pharmaceutical compositions of any of the compounds disclosed herein, or salts or solvates thereof, for use in combination with an oncolytic virus are encompassed by the present disclosure. Accordingly, the present disclosure includes pharmaceutical compositions comprising a Cbl-b inhibitor for use in combination with an oncolytic virus, wherein the Cbl-b inhibitor is any of compounds 1-719 of International Patent Application WO 2019 / 148005 (including "a" and "b" variants thereof) or a compound of any of Formula (IA), Formula (I), Formula (II-A), Formula (II), Formula (III-A), Formula (III), or Formula (IV), or any variant thereof disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. The composition may further comprise a pharmaceutically acceptable excipient, such as a pharmaceutically acceptable vehicle or a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises both a small molecule Cbl-b inhibitor and a cancer vaccine. In some embodiments, the compound is a compound selected from Compound Nos. 53-61 in Table 1A, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof. Furthermore, in some embodiments, the pharmaceutical composition comprises both a small molecule Cbl-b inhibitor and an oncolytic virus. In some embodiments, the compound is a compound selected from Compound Nos. 53-61 in Table 1A, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof.In certain embodiments, the compound is selected from the Cbl-b inhibitors disclosed in the following patent applications: compounds 1-719 (including the "a" and "b" variants thereof) of International Patent Application WO 2019 / 148005 or any compound of formula (IA), formula (I), formula (II-A), formula (II), formula (III-A), formula (III), or formula (IV) therein; compound 1 of U.S. Provisional Patent Application No. 62 / 831,392; Compounds 1 to 45 and 47 to 52 of U.S. Provisional Patent Application No. 62 / 866,909 or compounds of formula (I) therein; Compounds 1 to 45 and 47 to 52 of U.S. Provisional Patent Application No. 62 / 880,267 or compounds of formula (I) therein; or any variation thereof, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer thereof, or a stereoisomer or mixture of stereoisomers thereof.
[0377]
[0373] In one aspect, the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic acid or an organic acid.
[0378] The compounds, vaccines, and compositions disclosed herein can be administered in any suitable form and by any suitable route that provides sufficient levels of the compound, vaccine, or composition for treatment of a disease or disorder. In certain embodiments, the Cbl-b inhibitor and / or cancer vaccine is administered by enteral administration. The compounds, oncolytic viruses, and compositions disclosed herein can be administered in any suitable form and by any suitable route that provides sufficient levels of the compound, oncolytic virus, or composition for treatment of a disease or disorder. In certain embodiments, the Cbl-b inhibitor and / or oncolytic virus is administered by enteral administration. In certain embodiments, the enteral administration is oral administration. In other embodiments, the Cbl-b inhibitor and / or cancer vaccine is administered by parenteral administration. In other embodiments, the Cbl-b inhibitor and / or oncolytic virus is administered by parenteral administration. In certain embodiments, the parenteral administration is intratumoral injection. In certain embodiments, the parenteral administration is by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous.
[0379] Suitable routes of administration include parenteral administration, including oral, enteral, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intraperitoneal, intralesional, intraarticular, and intratumoral injections, or injection techniques. The compounds, vaccines, and compositions may also be administered sublingually, mucosally, bucally, subcutaneously, spinally, epidurally, intraventricularly, by inhalation (e.g., as a mist or spray), intranasally, intravaginally, rectally, topically, or transdermally, or by sustained-release or sustained-release mechanisms. The compounds, vaccines, and compositions may be administered in unit-dosage formulations containing conventional pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles, as appropriate. The compounds, vaccines, and compositions may be administered directly to specific or affected organs or tissues. The compounds and / or vaccines may be mixed with pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles to form a composition suitable for the desired route of administration. The compounds, oncolytic viruses, and compositions may also be administered sublingually, mucosally, orally, subcutaneously, spinally, epidurally, intraventricularly, by inhalation (e.g., as a mist or spray), nasally, vaginally, rectally, topically, or transdermally, or by sustained-release or sustained-release mechanisms. The compounds, oncolytic viruses, and compositions may be administered in unit-dosage formulations containing conventional pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles, as appropriate. The compounds, oncolytic viruses, and compositions may be administered directly to specific or affected organs or tissues. The compounds and / or oncolytic viruses may be mixed with pharmaceutically acceptable carriers, excipients, adjuvants, and vehicles to form a composition suitable for the desired route of administration.
[0380] In certain embodiments disclosed herein, particularly those in which the formulations are used for injection or other parenteral administration, including the routes enumerated herein, but also any other route of administration described herein (oral, enteral, intragastric, etc.), the formulations and preparations used in the methods are sterile, except for the presence of the microbial vector in the particular cancer vaccine. To prepare such preparations, all components of the formulation or preparation are prepared in a sterile manner before combining with the microbial vector. In certain embodiments disclosed herein, particularly those in which the formulations are used for injection or other parenteral administration, including the routes enumerated herein, but also any other route of administration described herein (oral, enteral, intragastric, etc.), the formulations and preparations used in the methods are sterile, except for the presence of the oncolytic virus. To prepare such preparations, all components of the formulation or preparation are prepared in a sterile manner before combining with the oncolytic virus. Sterile pharmaceutical formulations are compounded or manufactured in accordance with pharmaceutical-grade sterilization standards known to those skilled in the art (United States Pharmacopeia Chapters 797, 1072, and 1211; California Business & Professions Code 4127.7; 16 California Code of Regulations 1751, 21 Code of Federal Regulations 211). A "sterile" formulation is aseptic or free or substantially free of all live microorganisms and their spores. Examples of methods for sterilization of pharmaceutical formulations include, but are not limited to, sterile filtration through sterile filtration membranes, exposure to radiation such as gamma radiation, and heat sterilization.
[0381] Oral administration is advantageous due to its ease of implementation and patient compliance. If the patient has swallowing difficulties, introduction of the drug via a feeding tube, feeding syringe, or gastrostomy tube can be used to achieve enteral administration. The active compound, vaccine, or composition, and, if present, other co-administered drugs, can be enterally administered in any other pharmaceutically acceptable excipient suitable for formulation via a feeding tube, feeding syringe, or gastrostomy tube. The active compound, oncolytic virus, or composition, and, if present, other co-administered drugs, can be enterally administered in any other pharmaceutically acceptable excipient suitable for formulation via a feeding tube, feeding syringe, or gastrostomy tube.
[0382] Intravenous administration may also be advantageously used to deliver a compound, vaccine, or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract. Intravenous administration may also be advantageously used to deliver a compound, oncolytic virus, or composition to the bloodstream as quickly as possible and to avoid the need for absorption from the gastrointestinal tract.
[0383] The compounds, vaccines, and compositions described for use herein may be administered in solid, liquid, or aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard or soft elastic gelatin capsules), powder mixtures, granules, injectables, solutions, suppositories, enemas, colonic washes, emulsions, dispersions, food premixes, cachets, lozenges, lozenges, gums, ointments, poultices, pastes, powders, bandages, creams, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds, vaccines, and compositions may also be administered in liposomal formulations. The compounds, oncolytic viruses, and compositions described for use herein can be administered in solid, liquid, or aerosol form, or in the form of tablets, pills, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), powder mixtures, granules, injections, solutions, suppositories, enemas, colonic washes, emulsions, dispersions, food premixes, cachets, lozenges, lozenges, gums, ointments, compresses, pastes, powders, bandages, creams, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), elixirs, or other forms suitable for the route of administration. The compounds, oncolytic viruses, and compositions can also be administered in liposomal formulations. The compounds can also be administered as prodrugs, where the prodrug is converted to a therapeutically effective form in the treated subject.
[0384]
[0380] In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, adjusters, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Formulations containing compounds, vaccines, or compositions may also contain other substances with beneficial therapeutic properties. Formulations containing compounds, oncolytic viruses, or compositions may also contain other substances with beneficial therapeutic properties. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Further formulation and administration methods are known in the art. Suitable formulations may be found, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), incorporated herein by reference.
[0385] Injectable preparations of small molecule Cbl-b inhibitors, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to methods known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions or suspensions in parenterally acceptable diluents or solvents, for example, as solutions in propylene glycol. Among the acceptable vehicles and solvents that can be used are water, saline, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are commonly used as solvents or suspending media. For this purpose, any sterile, fixed oil, including synthetic mono- or diglycerides, can be used. In addition, fatty acids such as oleic acid can be used in the preparation of injectable preparations.
[0386]
[0382] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound, vaccine, or composition may be mixed with at least one inert diluent such as sucrose, lactose, talc, or starch. In such solid dosage forms, the active compound, oncolytic virus, or composition may be mixed with at least one inert diluent such as sucrose, lactose, talc, or starch. Such dosage forms may also contain additional excipients other than inert diluents, for example, lubricants such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. Tablets and pills may further be prepared with enteric coatings. Acceptable excipients for soft-shell gel capsules include, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, etc.
[0387]
[0383] Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also contain additional agents such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweeteners, flavorings, and aromatics. Alternatively, compounds may also be administered in their original form if appropriate.
[0388] The compounds, vaccines, and compositions can also be administered in the form of liposomes. The compounds, oncolytic viruses, and compositions can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed of mono- or multi-lamellar hydrated liquid crystals dispersed in an aqueous medium. Any physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The compositions of the present invention in liposome form can contain stabilizers, preservatives, excipients, etc. in addition to the compounds or vaccines disclosed herein. The compositions of the present invention in liposome form can contain stabilizers, preservatives, excipients, etc. in addition to the compounds or oncolytic viruses disclosed herein. Useful lipids include natural and synthetic phospholipids and phosphatidylcholines (lecithins). Methods for forming liposomes are known in the art. See, for example, Gregoriadis, G. Ed., Liposome Technology, Third Edition: Liposome Technology: Liposome Preparation and Related Techniques, CRC Press, Boca Raton, Florida (2006); and Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, NW, p. 33 et seq (1976).
[0389] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form may vary depending on the patient to whom the active ingredient is administered and the particular method of administration. However, it will be understood that the specific dosage level for any particular patient will depend on a variety of factors, including the specific compound or vaccine used; the patient's age, weight, body surface area, body mass index (BMI), general health, sex, and dietary habits; the timing and route of administration used; excretion rate; and the combination drug, if any, used. Compounds, vaccines, and compositions may be administered in unit dosage formulations. However, it will be understood that the specific dosage level for any particular patient will depend on a variety of factors, including the specific compound or oncolytic virus used; the patient's age, weight, body surface area, body mass index (BMI), general health, sex, and dietary habits; the timing and route of administration used; excretion rate; and the combination drug, if any, used. Compounds, oncolytic viruses, and compositions may be administered in unit dosage formulations. The selected drug unit dosage is manufactured and administered to provide a sufficient concentration of drug in the patient, subject, or individual.
[0390]
[0386] The compounds, vaccines, and compositions for use described herein can be administered as a single active pharmaceutical agent, although they can also be used in combination with one or more other agents. When an additional active agent is used in combination with a compound, vaccine, or composition for use described herein, the additional active agent can generally be used in a therapeutic amount as set forth in the Physicians' Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or such therapeutically useful amount as would be known to one of skill in the art, or as empirically determined for each patient. The compounds, oncolytic viruses, and compositions for use described herein can be administered as a single active pharmaceutical agent, although they can also be used in combination with one or more other agents. When an additional active agent is used in combination with a compound, oncolytic virus, or composition for use described herein, the additional active agent may generally be used in a therapeutic amount as set forth in the Physicians' Desk Reference (PDR) 71st Edition (2017), which is incorporated herein by reference, or such therapeutically useful amount as would be known to one of skill in the art, or as determined empirically for each patient.
[0391] Combinations of two or more of the compounds, vaccines, and compositions disclosed herein may also be used. Two or more compounds, vaccines, or compositions may be mixed together immediately prior to administration and administered together. Two or more compounds, vaccines, or compositions may be administered simultaneously, either by the same route of administration or different routes of administration. Two or more compounds, vaccines, or compositions may be administered sequentially, either by the same route of administration or different routes of administration. In one embodiment, a kit form may contain two or more compounds, vaccines, or compositions as individual compounds, vaccines, or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds, vaccines, or compositions, as separate compounds, vaccines, or compositions administered simultaneously, or as separate compounds, vaccines, or compositions administered sequentially. When more than two compounds, vaccines, or compositions are administered, they may be administered as a mixture of compounds, vaccines, or compositions, as separate compounds, vaccines, or compositions that are administered simultaneously, as separate compounds, vaccines, or compositions that are administered sequentially, as separate compounds, vaccines, or compositions where two or more are administered simultaneously and the rest may be administered sequentially before or after simultaneous administration, or any other possible combination of mixed, simultaneous, and sequential administration.
[0392] Combinations of two or more of the compounds, oncolytic viruses, and compositions disclosed herein may also be used. Two or more compounds, oncolytic viruses, or compositions may be mixed together immediately prior to administration and administered together. Two or more compounds, oncolytic viruses, or compositions may be administered simultaneously, either by the same or different routes of administration. Two or more compounds, oncolytic viruses, or compositions may be administered sequentially, either by the same or different routes of administration. In one embodiment, a kit form may contain two or more compounds, oncolytic viruses, or compositions as individual compounds, oncolytic viruses, or compositions, along with printed or electronic instructions for administration, either as a mixture of compounds, oncolytic viruses, or compositions, as separate compounds, oncolytic viruses, or compositions administered simultaneously, or as separate compounds, oncolytic viruses, or compositions administered sequentially. When more than two compounds, oncolytic viruses, or compositions are administered, they may be administered as a mixture of compounds, oncolytic viruses, or compositions, as separate compounds, oncolytic viruses, or compositions that are administered simultaneously, as separate compounds, oncolytic viruses, or compositions that are administered sequentially, as separate compounds, oncolytic viruses, or compositions where two or more are administered simultaneously and the rest may be administered sequentially before or after simultaneous administration, or any other possible combination of mixed, simultaneous, and sequential administration.
[0393] The compounds disclosed herein for use in the pharmaceutical compositions and methods described herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are disclosed herein. Compositions comprising the compounds disclosed herein or salts thereof, such as compositions of substantially pure compounds, are provided. In certain embodiments, compositions comprising the compounds disclosed herein or salts thereof are in substantially pure form. In one aspect, "substantially pure" contemplates a composition containing 35% or less impurities, where impurities refer to compounds other than the compound (or compounds, if a combination of compounds is used) or salts or solvates of the compound (or compounds, if a combination of compounds is used) administered in the composition. The weight of any added vehicle, carrier, or excipient is excluded from such calculations; added vehicle, carrier, or excipient is not considered an impurity. For example, a composition of a substantially pure compound selected from the compounds of Table 1A refers to a composition containing 35% or less impurities, where impurities refer to compounds other than the compound or salts or solvates thereof. In one aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 25% or less impurities. In another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 20% or less impurities. In yet another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 10% or less impurities. In a further aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 5% or less impurities. In another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 3% or less impurities. In yet another aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 1% or less impurities. In a further aspect, a composition of a substantially pure compound or a salt or solvate thereof is provided, wherein the composition contains 0.5% or less impurities.In yet another embodiment, a composition of a substantially pure compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of an impurity. An impurity can be a compound of a different stereochemical form than the desired stereochemical form. For example, a composition of a substantially pure (S)-compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of the (R)-form of the compound.
[0394] Alternatively, as used herein, "enantiomeric excess (ee)" refers to a dimensionless molar ratio that represents, for example, the purity of a chiral substance containing a single stereocenter. For example, an enantiomeric excess of 0 can indicate a racemate (e.g., a 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). As a further example, an enantiomeric excess of 99 can indicate a nearly stereochemically pure enantiomeric compound (i.e., a significant excess of one enantiomer over the other). Percentage enantiomeric excess, % ee = ([(R)-compound] - [(S)-compound]) / ([(R)-compound] + [(S)-compound]) × 100 (where (R)-compound > (S)-compound); or % ee = ([(S)-compound] - [(R)-compound]) / ([(S)-compound] + [(R)-compound]) × 100 (where (S)-compound > (R)-compound). Furthermore, as used herein, "diastereomeric excess (de)" refers to a dimensionless molar ratio that represents the purity of a chiral substance containing two or more stereocenters. For example, a diastereomeric excess of 0 may indicate an equimolar mixture of diastereoisomers. As a further example, a diastereomeric excess of 99 may indicate a nearly stereochemically pure diastereomeric compound (i.e., one diastereomer is in significant excess over the other). Diastereomeric excess can be calculated by a method similar to ee. As will be understood by those skilled in the art, de is usually reported as a percentage (% de), which can be calculated in a similar manner to % ee.
[0395] The compounds, vaccines, or compositions disclosed herein may be provided in a suitable container. The compounds, oncolytic viruses, or compositions disclosed herein may be provided in a suitable container. Suitable containers include, for example, bottles, vials (e.g., dual-chamber vials), syringes (e.g., single- or dual-chamber syringes), bags (e.g., intravenous bags), and tubes (e.g., test tubes). The containers may be formed from a variety of materials, such as glass or plastic.
[0396] V. Products or Kits Also provided are articles of manufacture containing any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions described herein. The articles of manufacture include suitable containers or packaging materials for the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions. Examples of suitable containers include, but are not limited to, bottles, vials, syringes, intravenous bags, or tubing. For cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions, suitable containers may be culture vessels, including, but not limited to, tubes, dishes, bags, multi-well plates, or flasks.
[0397] Kits containing any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions described herein are also provided. The kits may contain the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions in suitable containers or packaging, including, but not limited to, bottles, vials, syringes, intravenous bags, or tubing. The kits may contain the cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions in culture vessels, including, but not limited to, tubes, dishes, bags, multi-well plates, or flasks. The kits may contain the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions for administration to an individual in a single-dosage form or in a multiple-dosage form. The kit may further include instructions or a label for administering the compound, pharmaceutical composition, cell, modified immune cell, cell population, cell composition, cell culture, or cell culture composition to an individual according to any of the methods disclosed herein. The kit may further include an implement for administering the compound, pharmaceutical composition, cell, modified immune cell, cell population, cell composition, cell culture, or cell culture composition to an individual, including, but not limited to, a needle, syringe, tubing, or intravenous bag. The kit may further include instructions for producing any of the compounds, pharmaceutical compositions, cells, modified immune cells, cell populations, cell compositions, cell cultures, or cell culture compositions disclosed herein.
[0398] Also provided are articles of manufacture comprising any of the compounds, vaccines, or pharmaceutical compositions described herein. The articles of manufacture include suitable containers or packaging materials for the compounds, vaccines, or pharmaceutical compositions. Also provided are articles of manufacture comprising any of the compounds, oncolytic viruses, or pharmaceutical compositions described herein. The articles of manufacture include suitable containers or packaging materials for the compounds, oncolytic viruses, or pharmaceutical compositions. Examples of suitable containers include, but are not limited to, bottles, vials, syringes, intravenous bags, or tubing.
[0399] Kits including any of the compounds, vaccines, or pharmaceutical compositions described herein are also provided. The kits may contain the compounds, vaccines, or pharmaceutical compositions in suitable containers or packaging, including, but not limited to, bottles, vials, syringes, intravenous bags, or tubing. The kits may include the compounds, vaccines, or pharmaceutical compositions for administration to an individual in single-dose or multiple-dose form. The kits may further include instructions or labels for administering the compounds, vaccines, or pharmaceutical compositions to an individual according to any of the methods disclosed herein. The kits may further include equipment for administering the compounds, vaccines, or pharmaceutical compositions to an individual, including, but not limited to, needles, syringes, tubing, or intravenous bags. The kits may further include instructions for producing any of the compounds, vaccines, or pharmaceutical compositions disclosed herein.
[0400] Kits containing any of the compounds, oncolytic viruses, or pharmaceutical compositions described herein are also provided. The kits may contain the compounds, oncolytic viruses, or pharmaceutical compositions in suitable containers or packaging, including, but not limited to, bottles, vials, syringes, intravenous bags, or tubing. The kits may include the compounds, oncolytic viruses, or pharmaceutical compositions for administration to an individual in single-dose or multiple-dose form. The kits may further include instructions or labels for administering the compounds, oncolytic viruses, or pharmaceutical compositions to an individual according to any of the methods disclosed herein. The kits may further include equipment for administering the compounds, oncolytic viruses, or pharmaceutical compositions to an individual, including, but not limited to, needles, syringes, tubing, or intravenous bags. The kits may further include instructions for producing any of the compounds, oncolytic viruses, or pharmaceutical compositions disclosed herein.
[0401] VI. Illustrative Embodiments
[0397] The present disclosure is further illustrated by the following embodiments, and the features of each of the embodiments may be combined with any of the other embodiments where appropriate and practical.
[0402] Embodiment 1. A compound of formula (Ia): [ka] (In the formula: [ka] but, [ka] and; X is CH or N; Z 1 is CH or N; Z 2 is CH or N; R 1a and R 1b are independently H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 2a is -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyl-OH, C1-C6 alkyl-CN, or -(C1-C6 alkylene)-O-(C1-C6 alkyl); R 2b is H, halo, or C1-C6 alkyl; or R 2a and R 2b together with the carbon atom to which they are attached form a spiro 3- to 6-membered heterocyclyl or a spiro C3-C6 cycloalkyl; wherein at least one atom of the spiroheterocyclyl adjacent to the connecting piperidinyl ring is carbon; R 3a and R 3b is independently H, halo, or C1-C6 alkyl; or R 3a and R 3b together with the carbon atom to which they are attached form a C3-C4 cycloalkyl; R 4 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; [ka] but, [ka] and Y is CR 5a R 5b or S; or [ka] but, [ka] and Y is a bond; W is O or a bond; R 5a and R 5b is independently H, halo, or C1-C6 alkyl; or R 5a and R 5b together with the carbon atom to which they are attached form a C3-C6 cycloalkyl; R 6 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 7 is H, C3-C6 cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C1-C6 alkyl), -NH-(C3-C6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C1-C6 alkyl), or -O-(C3-C6 cycloalkyl); R 8 is C1-C6 alkyl, C1-C6 haloalkyl, or C3-C6 cycloalkyl; R 9is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl-OH; R 10 is -CF3 or cyclopropyl) or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0403]
[0399] Embodiment 2. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0404]
[0400] Embodiment 3. Z 1 is CH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0405]
[0401] Embodiment 4. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0406]
[0402] Embodiment 5. Z 1 is N, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0407]
[0403] Embodiment 6. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0408]
[0404] Embodiment 7. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0409]
[0405] Embodiment 8. Z 2 is CH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0410]
[0406] Embodiment 9. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0411]
[0407] Embodiment 10. Z 2 is N, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0412]
[0408] Embodiment 11. [ka] but, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0413]
[0409] Embodiment 12. [ka] but, [ka] and Y is CR 5a R 5b or S, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0414]
[0410] Embodiment 13. The compound of embodiment 12, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein W is a bond.
[0415]
[0411] Embodiment 14. The compound of embodiment 12, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein W is O.
[0416]
[0412] Embodiment 15. [ka] but, [ka] and Y is a bond, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0417]
[0413] Embodiment 16. R 8 is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0418]
[0414] Embodiment 17. R 8 is —CH 3 , —CF 3 , or cyclopropyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0419]
[0415] Embodiment 18. 18. The compound of any one of embodiments 1-17, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein X is CH.
[0420]
[0416] Embodiment 19. 18. The compound of any one of embodiments 1-17, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein X is N.
[0421]
[0417] Embodiment 20. 20. The compound of any one of embodiments 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein Y is a bond.
[0422]
[0418] Embodiment 21. Y is CR 5a R 5b 20. The compound of any one of embodiments 1-19, wherein:
[0423]
[0419] Embodiment 22. R 5a and R 5b is independently H, halo, or C1-C3 alkyl; or R 5a and R 5btaken together with the carbon atom to which they are attached form a C3-C4 cycloalkyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0424]
[0420] Embodiment 23. R 5a and R 5b is independently H, F, or -CH3; or R 5a and R 5b taken together with the carbon atom to which they are attached form cyclopropyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0425]
[0421] Embodiment 24. R 5a and R 5b is independently H or F, or a tautomer or a pharmaceutically acceptable salt thereof.
[0426]
[0422] Embodiment 25. 20. The compound of any one of embodiments 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein Y is S.
[0427]
[0423] Embodiment 26. R 1a and R 1b is independently H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0428]
[0424] Embodiment 27. R 1a and R 1b is independently H, —CH 3 , —CF 3 , or —CH 2 OH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0429]
[0425] Embodiment 28. R 1b The compound of any one of embodiments 1-27, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein is H.
[0430]
[0426] Embodiment 29. R 2a is -CN, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkyl-OH, C1-C3 alkyl-CN, or -(C1-C3 alkylene)-O-(C1-C3 alkyl), or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0431]
[0427] Embodiment 30. R 2a is —CN, —CH 3 , —CF 3 , —CH 2 OH, —CH 2 CN, or —CH 2 —O—CH 3 , or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0432]
[0428] Embodiment 31. R 2b The compound of any one of embodiments 1-30, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein is H, halo, or C1-C3 alkyl.
[0433]
[0429] Embodiment 32. R 2b is H, F, or —CH 3 , or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0434]
[0430] Embodiment 33. R 2a and R 2b taken together with the carbon atom to which they are attached form a spiro 4- to 5-membered heterocyclyl or spiro C3-C4 cycloalkyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0435]
[0431] Embodiment 34. R 2a and R 2b together with the carbon atom to which they are attached form spirocyclopropyl, [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0436]
[0432] Embodiment 35. R 3a and R 3b is independently H, halo, or C1-C3 alkyl; or R 3a and R 3b are taken together with the carbon atom to which they are attached to form a C3-C4 cycloalkyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0437]
[0433] Embodiment 36. R 3a and R 3b is independently H, F, or -CH3; or R 3a and R 3b taken together with the carbon atom to which they are attached form cyclopropyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0438]
[0434] Embodiment 37. R 4 The compound of any one of embodiments 1-36, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH.
[0439]
[0435] Embodiment 38. R 4is H, —CH 3 , —CF 3 , or —CH 2 OH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0440]
[0436] Embodiment 39. R 6 The compound of any one of embodiments 1-38, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein is C1-C3 alkyl, C1-C3 haloalkyl, or C3-C4 cycloalkyl.
[0441]
[0437] Embodiment 40. R 6 is —CH 3 , —CHF 2 , or cyclopropyl, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0442]
[0438] Embodiment 41. R 7 is H, C3-C4 cycloalkyl, -NH(4- to 5-membered heterocyclyl), -NH(C1-C3 alkyl), -NH(C3-C5 cycloalkyl), -O(C1-C3 alkyl), -O(4- to 5-membered heterocyclyl), or -O(C3-C5 cycloalkyl); or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0443]
[0439] Embodiment 42. R 7 is H, cyclopropyl, -NH(CH2CH3), -NH(cyclopropyl), -OCH2CH3, -O(cyclopropyl), [ka] or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0444]
[0440] Embodiment 43. R 9The compound of any one of embodiments 1-42, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkyl-OH.
[0445]
[0441] Embodiment 44. R 9 is H, —CH 3 , —CF 3 , or —CH 2 OH, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0446]
[0442] Embodiment 45. A compound selected from the compounds in Table 1, or a tautomer thereof, or a pharmaceutically acceptable salt thereof.
[0447]
[0443] Embodiment 46. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 45, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0448]
[0444] Embodiment 47. A method for modulating the activity of an immune cell, comprising contacting the immune cell with an effective amount of a Cbl-b inhibitor to modulate the activity of the immune cell, wherein the Cbl-b inhibitor is a compound described in any one of embodiments 1 to 45.
[0449] [0445 Embodiment 48. 48. The method of embodiment 47, wherein the immune cells comprise T cells, B cells, or natural killer (NK) cells.
[0450]
[0446] Embodiment 49. 49. The method of embodiment 47 or 48, wherein the immune cells are tumor-infiltrating lymphocytes (TILs) isolated from a tumor in a mammalian subject having cancer before the immune cells are contacted with the Cbl-b inhibitor.
[0451]
[0447] Embodiment 50. 50. The method of any one of embodiments 47-49, further comprising isolating immune cells from a tumor of a mammalian subject having cancer before the immune cells are contacted with the Cbl-b inhibitor.
[0452]
[0448] Embodiment 51. 51. The method of any one of embodiments 47-50, wherein the immune cells comprise T cells, and modulating the activity of T cells comprises one or more of increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and decreased T cell immune tolerance.
[0453]
[0449] Embodiment 52. 52. The method of embodiment 51, wherein the increased T cell activation comprises increased production of cytokines.
[0454]
[0450] Embodiment 53. 53. The method of embodiment 52, wherein the cytokine comprises one or more selected from the group consisting of IL-2, IFN-γ, TNFα, and GM-CSF.
[0455]
[0451] Embodiment 54. 53. The method of embodiment 51 or 52, wherein increased T cell activation comprises increased cell surface expression of one or more T cell activation markers.
[0456]
[0452] Embodiment 55. 55. The method of embodiment 54, wherein the T cell activation markers comprise one or more selected from the group consisting of CD25, CD69, and CTLA4.
[0457]
[0453] Embodiment 56. 56. The method of any one of embodiments 51 to 55, wherein the T cells have been or are being contacted with an anti-CD3 antibody, alone or in combination with an anti-CD28 antibody.
[0458]
[0454] Embodiment 57. 56. The method of any one of embodiments 51 to 55, further comprising culturing the immune cells with IL-2, alone or in combination with an anti-CD3 antibody and / or an anti-CD28 antibody.
[0459]
[0455] Embodiment 58. The method of any one of embodiments 47-50, wherein the immune cells comprise NK cells and modulating the activity of NK cells comprises increased NK cell activation.
[0460]
[0456] Embodiment 59. 59. The method of embodiment 58, wherein the increased NK cell activation comprises increased production of cytokines.
[0461]
[0457] Embodiment 60. 60. The method of embodiment 59, wherein the cytokine comprises one or more selected from the group consisting of IFN-γ, TNFα, and MIP1β.
[0462]
[0458] Embodiment 61. 61. The method of any one of embodiments 47-60, wherein the immune cells comprise B cells, and...
Claims
1. Compounds of formula (I): [Case 1] (In the formula, [Case 2] but, [C3] and X is CH or nitrogen; Z 1 is CH or nitrogen; Z 2 is CH or nitrogen; R 1a and R 1b are independently hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; R 2a But, -CN,C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, C 1 ~C 6 Alkyl-CN or -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl); R 2b is hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 2a and R 2b together with the carbon atom to which they are attached, form a spiro 3- to 6-membered heterocyclyl or a spiro C 3 ~C 6 Forming a cycloalkyl, wherein at least one of the atoms of the spiroheterocyclyl adjacent to the linked piperidinyl ring is carbon; R 3aand R 3b are independently hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 3a and R 3b together with the carbon atom to which they are attached, C 3 ~C 4 Forming a cycloalkyl; R 4 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; [C4] but, [C5] and Y is CR 5a R 5b or sulfur; or [C6] but, [C7] and Y is a bond; W is oxygen or a bond; R 5a and R 5b are independently hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 5a and R 5b together with the carbon atom to which they are attached, C 3 ~C 6 Forming a cycloalkyl; R 6 But, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 3 ~C 6 is cycloalkyl; R 7 But hydrogen, halo, C 3 ~C 6 Cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C 1 ~C 6 alkyl), -NH-(C 3 ~C 6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C 1 ~C 6 alkyl), or -O-(C 3 ~C 6 cycloalkyl); R 8 But, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 3 ~C 6 is cycloalkyl; R 9 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; R 10 But -CF 3 or cyclopropyl) or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof.
2.
8. but, [C9] or Z 1 is CH; or [C10] but, [C11] or Z 1 is nitrogen; or [C12] but, [C13] That is, The compound of claim 1.
3.
14. but, [C15] or Z 2 is CH; or [C16] but, [C17] or Z 2 is nitrogen; or [C18] but, [C19] That is, The compound of claim 1.
4.
20. but, [C21] and Y is CR 5a R 5b or sulfur; or W is a bond; or W is oxygen; or [C22] but, [C23] and Y is a bond; or R 8 But, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 3 ~C 4 is cycloalkyl; or R 8 But -CH 3 , -CF 3 or cyclopropyl; The compound according to any one of claims 1 to 3.
5. X is CH; or X is nitrogen; and / or Y is a bond; or Y is CR 5a R 5b or Y is sulfur; The compound according to any one of claims 1 to 4.
6. Y is CR 5a R 5b and R 5a and R 5b are independently hydrogen, halo, or C 1 ~C 3 is alkyl, or R 5a and R 5b together with the carbon atom to which they are attached, C 3 ~C 4 forming a cycloalkyl; or R 5a and R 5b are independently hydrogen, fluorine, or -CH 3 or R 5a and R 5b together with the carbon atom to which they are attached form a cyclopropyl; or R 5a and R 5b is independently hydrogen or fluorine; The compound according to claim 5.
7. R 1a and R 1b are independently hydrogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 1 ~C 3 is alkyl-OH; or R 1a and R 1b are independently hydrogen, -CH 3, -CF 3 , or -CH 2 is OH; or R 1b is hydrogen, The compound according to any one of claims 1 to 6.
8. R 2a But, -CN,C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, C 1 ~C 3 Alkyl-OH, C 1 ~C 3 Alkyl-CN or -(C 1 ~C 3 alkylene)-O-(C 1 ~C 3 alkyl); or R 2a -CN, -CH 3 , -CF 3 , -CH 2 OH, -CH 2 CN, or -CH 2 -O-CH 3 or R 2b is hydrogen, halo, or C 1 ~C 3 is alkyl; or R 2b is hydrogen, fluorine, or -CH 3 That is, A compound according to any one of claims 1 to 7.
9. R 2a and R 2b together with the carbon atom to which they are attached, form spiro 4- to 5-membered heterocyclyl or spiro C 3 ~C 4 forming a cycloalkyl; or R 2a and R 2b together with the carbon atom to which they are attached, form spirocyclopropyl, [C24] Forming A compound according to any one of claims 1 to 7.
10. R 3a and R 3b are independently hydrogen, halo, or C 1 ~C 3 is alkyl; Or R 3a and R 3b together with the carbon atom to which they are attached, C 3 ~C 4 forming a cycloalkyl; or R 3a and R 3b are independently hydrogen, fluorine, or -CH 3 is; Or R 3a and R 3b together with the carbon atom to which they are attached form a cyclopropyl; A compound according to any one of claims 1 to 9.
11. R 4 is hydrogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 1 ~C 3 is alkyl-OH; or R 4 is hydrogen, -CH 3 , -CF 3 , or -CH 2 is OH; and / or R 6 But, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 3 ~C 4 is cycloalkyl; or R 6 But -CH 3 , -CHF 2 or cyclopropyl; A compound according to any one of claims 1 to 10.
12. R 7 But hydrogen, halo, C 3 ~C 4 Cycloalkyl, -NH(4- to 5-membered heterocyclyl), -NH(C 1 ~C 3 alkyl), -NH(C 3 ~C 5 cycloalkyl), -O(C 1 ~C 3 alkyl), -O(4- to 5-membered heterocyclyl), or -O(C 3 ~C 5 cycloalkyl); or R 7 is hydrogen, chlorine, cyclopropyl, -NH(CH 2 CH 3 ), —NH(cyclopropyl), —OCH 2 CH 3 , —O(cyclopropyl), [C25] and / or R 9 is hydrogen, C 1 ~C 3 Alkyl, C 1 ~C 3 Haloalkyl, or C 1 ~C 3 is alkyl-OH; or R 9 is hydrogen, -CH 3 , -CF 3 , or -CH 2 OH, A compound according to any one of claims 1 to 11.
13. The compound is a compound of formula (I-a): [C26] (In the formula: [C27] but, [C28] and X is CH or nitrogen; Z 1 is CH or nitrogen; Z 2 is CH or nitrogen; R 1a and R 1b are independently hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; R 2a But, -CN,C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, C 1 ~C 6 Alkyl-OH, C 1 ~C 6 Alkyl-CN or -(C 1 ~C 6 alkylene)-O-(C 1 ~C 6 alkyl); R 2b is hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 2a and R 2b together with the carbon atom to which they are attached, form a spiro 3- to 6-membered heterocyclyl or a spiro C 3 ~C 6 Forming a cycloalkyl, wherein at least one of the atoms of the spiroheterocyclyl adjacent to the linked piperidinyl ring is carbon; R 3a and R 3b are independently hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 3a and R 3b together with the carbon atom to which they are attached, C 3 ~C 4 Forming a cycloalkyl; R 4 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; [C29] but, [C30] and Y is CR 5a R 5b or sulfur; or [C31] but, [C32] and Y is a bond; W is oxygen or a bond; R 5a and R 5b are independently hydrogen, halo, or C 1 ~C 6 is alkyl; Or R 5a and R 5b together with the carbon atom to which they are attached, C 3 ~C 6 Forming a cycloalkyl; R 6 But, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 3 ~C 6 is cycloalkyl; R 7 is hydrogen, C 3 ~C 6 Cycloalkyl, -NH-(3- to 6-membered heterocyclyl), -NH-(C 1 ~C 6 alkyl), -NH-(C 3 ~C 6 cycloalkyl), -O-(3- to 6-membered heterocyclyl), -O-(C 1 ~C 6 alkyl), or -O-(C 3 ~C 6 cycloalkyl); R 8 But, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 3 ~C 6 is cycloalkyl; R 9 is hydrogen, C 1 ~C 6 Alkyl, C 1 ~C 6 Haloalkyl, or C 1 ~C 6 alkyl-OH; R 10 But -CF 3 or cyclopropyl) or a tautomer, a stereoisomer, or a pharma- ceutically acceptable salt thereof.
14. 2. The compound of claim 1 selected from the following: [C33-1] [C33-2] [C33-3] [C33-4]
15. 2. The compound of claim 1 selected from the following: [C34]
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 and a pharma- ceutically acceptable excipient.
17. A method of modulating the activity of an immune cell in vitro or ex vivo, comprising contacting said immune cell with an effective amount of a Cbl-b inhibitor to modulate the activity of said immune cell, said Cbl-b inhibitor being a compound according to any one of claims 1 to 15; the immune cells comprise T cells, B cells, or natural killer (NK) cells; or the immune cells were or are isolated from a blood sample from a mammalian subject; or The immune cell is a tumor infiltrating lymphocyte (TIL) that has been or is isolated from a tumor in a mammalian subject with cancer; or the immune cells include T cells, and modulating an activity of the T cells includes one or more of increased T cell activation, increased T cell proliferation, decreased T cell exhaustion, and decreased T cell tolerance; and / or wherein the increased T cell activation comprises increased production of cytokines, and / or said cytokines comprise one or more selected from the group consisting of IL-2, IFN-γ, TNFα, and GM-CSF; and / or and / or wherein the increased T cell activation comprises increased cell surface expression of one or more T cell activation markers, and / or said T cell activation markers comprise one or more selected from the group consisting of CD25, CD69, and CTLA4; and / or the T cells have been or are contacted with an anti-CD3 antibody, alone or in combination with an anti-CD28 antibody; and / or and / or further comprising culturing the immune cells with IL-2, alone or in combination with an anti-CD3 antibody and / or an anti-CD28 antibody; and / or the immune cells comprise NK cells, and modulating the activity of NK cells comprises increased NK cell activation; and / or increased NK cell activation includes increased production of cytokines; and / or the cytokines comprise one or more selected from the group consisting of IFN-γ, TNFα, and MIP1β; and / or the immune cells comprise B cells, and modulating the activity of B cells comprises increased B cell activation, optionally, increased B cell activation comprises increased expression of CD69; and / or the immune cells are human immune cells; and / or The method, wherein said immune cell comprises a recombinant chimeric receptor, and optionally, said recombinant chimeric receptor is a chimeric antigen receptor.
18. 16. A method of generating an engineered immune cell, comprising culturing a cell population containing an immune cell in the presence of an effective amount of a Cbl-b inhibitor to modulate an activity of the immune cell, thereby generating the engineered immune cell, wherein the Cbl-b inhibitor is a compound according to any one of claims 1 to 15.
19. further comprising culturing the immune cells with an anti-CD3 antibody, alone or in combination with an anti-CD28 antibody; or further comprising culturing the immune cells with IL-2, alone or in combination with an anti-CD3 antibody and / or an anti-CD28 antibody; or further comprising recovering the modified immune cells.
20. The method of claim 18.
20. The immune cells are isolated or are isolated from a blood sample from a mammalian subject, or the immune cells are tumor infiltrating lymphocytes (TILs) isolated or are isolated from a tumor in a mammalian subject having cancer; or the immune cell is a cell selected from the group consisting of a hematopoietic cell, a pluripotent stem cell, a myeloid progenitor cell, a lymphoid progenitor cell, a T cell, a B cell, and a NK cell; or the engineered immune cell is a cell selected from the group consisting of a hematopoietic cell, a pluripotent stem cell, a myeloid progenitor cell, a lymphoid progenitor cell, a T cell, a B cell, and a NK cell; or the immune cells are tumor infiltrating lymphocytes (TILs); or the immune cell is a human immune cell; or the immune cell or modified immune cell comprises a recombinant chimeric receptor; or The recombinant chimeric receptor is a chimeric antigen receptor.
20. The method of claim 18 or 19.
21. 20. Use of a Cbl-b inhibitor in the manufacture of a medicament for treating or preventing a disease or condition associated with Cbl-b activity, wherein said Cbl-b inhibitor is a compound according to any one of claims 1 to 15.
22. 20. Use of a Cbl-b inhibitor in the manufacture of a medicament for treating cancer, wherein said Cbl-b inhibitor is a compound according to any one of claims 1 to 15.
23. 16. A Cbl-b inhibitor for use in the treatment or prevention of a disease or condition associated with Cbl-b activity, the Cbl-b inhibitor being a compound according to any one of claims 1 to 15.
24. A Cbl-b inhibitor for use in the treatment of cancer, the Cbl-b inhibitor being a compound according to any one of claims 1 to 15.
25. A compound according to any one of claims 1 to 15 for use in the manufacture of a medicament for treating cancer together with an effective amount of a further therapeutic agent.
26. the compound and the additional therapeutic agent are to be administered sequentially in any order; or the compound and the additional therapeutic agent are for simultaneous administration; 26. The compound of claim 25.
27. the additional therapeutic agent comprises an immune checkpoint inhibitor; or the additional therapeutic agent comprises an anti-tumor agent; 26. The compound of claim 25.
28. The immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), CTLA-4 (CD125), LAG3 (CD223), PVR (CD155), PVRL2 (CD112), PVRL3 (CD113), TIGIT, TIM3 (CD366), and VISTA; or The immune checkpoint inhibitor is an antagonist of at least one inhibitory checkpoint molecule selected from the group consisting of PD-1 (CD279), PD-L1 (CD274), and CTLA-4 (CD152); or the at least one inhibitory checkpoint molecule comprises PD-1, and optionally the immune checkpoint inhibitor is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, and biosimilars thereof; or the at least one inhibitory checkpoint molecule comprises PD-L1, and optionally the immune checkpoint inhibitor is selected from the group consisting of atezolizumab, avelumab, durvalumab, and biosimilars thereof; or the at least one inhibitory checkpoint molecule comprises CTLA-4, and optionally the immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, and biosimilars thereof; or the immune checkpoint inhibitor comprises an antibody or antigen-binding fragment thereof, optionally wherein the antibody or fragment is a human or humanized antibody or fragment; or The antitumor agent is classified as one of the groups consisting of cytotoxic antibiotics, plant alkaloids, antimetabolites, alkylating agents, and other antitumor agents; or the anti-tumor agent comprises a cytotoxic antibiotic, optionally wherein the cytotoxic antibiotic is selected from the group consisting of ixabepilone, mitomycin, plicamycin, bleomycin, pixantrone, amrubicin, valrubicin, pirarubicin, mitoxantrone, idarubicin, zorubicin, aclarubicin, epirubicin, daunorubicin, doxorubicin, and dactinomycin; or the antitumor agent comprises a plant alkaloid, optionally wherein the plant alkaloid is selected from the group consisting of trabectedin, cabazitaxel, polyglutamylated paclitaxel, docetaxel, paclitaxel, demecolcine, teniposide, etoposide, vintafolide, vinflunine, vinorelbine, vindesine, vincristine, and vinblastine; or the antitumor agent comprises an antimetabolite, optionally the antimetabolite is a pyrimidine analog, a purine analog, or a folate analog, optionally the antimetabolite is selected from the group consisting of floxuridine, trifluridine, tegafur, fluorouracil, decitabine, azacitidine, capecitabine, gemcitabine, carmofur, tegafur, fluorouracil, cytarabine, nelarabine, clofarabine, fludarabine, cladribine, thioguanine, mercaptopurine, pralatrexate, pemetrexed, raltitrexed, and methotrexate; or the antineoplastic agent comprises an alkylating agent, optionally wherein the alkylating agent is selected from the group consisting of dacarbazine, temozolomide, pipobroman, mitobronitol, etoglucide, uracil mustard, ranimustine, nimustine, fotemustine, streptozocin, semustine, lomustine, carmustine, carboquone, triaziquone, thiotepa, mannosulfan, treosulfan, busulfan, bendamustine, prednimustine, trofosfamide, ifosfamide, mechlorethamine, melphalan, chlorambucil, and cyclophosphamide; or The anti-tumor agent comprises another anti-tumor agent selected from the group consisting of platinum compounds, protein kinase inhibitors, and other drugs; or the antitumor agent comprises a platinum compound, optionally wherein the platinum compound is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, satraplatin, and polyplatin; or the anti-tumor agent comprises a protein kinase inhibitor; or The antitumor agent includes other drugs.
28. The compound of claim 27.
29. A compound according to any one of claims 1 to 15 for use in the manufacture of a medicament for treating cancer in conjunction with an effective amount of radiation therapy.
30. the radiation therapy is external beam radiation therapy; or The radiation therapy is internal radiation therapy.
30. The compound of claim 29.
31. the compound is for administration by enteral administration, optionally wherein the enteral administration is oral administration; or the compound is for administration by parenteral administration, optionally wherein said parenteral administration is intratumoral injection, or said parenteral administration is by a route selected from the group consisting of intravenous, intraperitoneal, and subcutaneous; The compound according to any one of claims 25 to 30.
32. the cancer is a hematological cancer; or the hematological cancer is lymphoma, leukemia, or myeloma; or the cancer is a non-hematological cancer; or The non-hematological cancer is a carcinoma, a sarcoma, or a melanoma. The compound according to any one of claims 25 to 30.
33. 1. A method for generating an expanded population of tumor infiltrating lymphocytes (TILs), comprising: (a) obtaining a biological sample containing TILs from an individual treated with a compound according to any one of claims 25 to 32; and (b) culturing the TILs in a cell culture medium containing at least one T cell growth factor to generate an expanded population of TILs. The method includes:
34. 34. The method of claim 33, wherein the at least one T cell growth factor comprises IL-2.
35. the cell culture medium further comprises an anti-CD3 antibody, or both an anti-CD3 antibody and an anti-CD28 antibody; or the cell culture medium further comprises the compound; or the cell culture medium further comprises irradiated feeder cells; A method according to claim 33 or claim 34.
36. A composition comprising an expanded population of TILs produced by the method of any one of claims 33 to 35, and a physiologically acceptable buffer.
37. 13. A method of generating an expanded population of tumor infiltrating lymphocytes (TILs) comprising the compound of claim 1.
38. A compound according to any one of claims 1 to 15 for use in the manufacture of a medicament for immunization comprising the administration of an effective amount of said compound and the administration of an effective amount of a vaccine.
39. 40. The compound of claim 38, wherein the immunization is for use in treating cancer and comprises administering to the cancer an effective amount of the compound together with an effective amount of a therapeutic cancer vaccine.
40. the compound and the cancer vaccine are administered sequentially; or the compound and the cancer vaccine are administered simultaneously; 40. The compound of claim 39.
41. the cancer vaccine is an immunogenic composition comprising at least one tumor antigen and a pharma- ceutically acceptable excipient; Optionally, the at least one tumor antigen comprises at least one synthetic peptide or recombinant protein; or Optionally, the immunogenic composition further comprises an adjuvant; or Optionally, the adjuvant comprises one or more members of the group consisting of aluminum salts, squalene, and saponins; or Optionally, said immunogenic composition further comprises an antigen presenting cell (APC), optionally said APC is a dendritic cell, and optionally said cancer vaccine is PROVENGE; or Optionally, the cancer vaccine comprises a microbial vector, and optionally, the microbial vector is TICE-BCG; or Optionally, the microbial vector is a recombinant viral vector or a recombinant bacterial vector; or Optionally, the cancer vaccine comprises killed cancer cells or cancer cell lysates.
41. A compound according to claim 39 or 40.
42. 16. A compound according to any one of claims 1 to 15 for use in the manufacture of a medicament for treating cancer comprising administering to the cancer an effective amount of the compound and administering an effective amount of an oncolytic virus.
43. the compound and the oncolytic virus are to be administered sequentially; or the compound and the oncolytic virus are to be administered simultaneously; 43. The compound of claim 42.
44. the oncolytic virus is a virus selected from the group consisting of adenovirus, coxsackievirus, echovirus, fowlpox virus, herpes simplex virus, maraba virus, measles virus, myxoma virus, Newcastle disease virus, parvovirus, poliovirus, retrovirus, reovirus, Seneca Valley virus, Semliki Forest virus, vaccinia virus, and vesicular stomatitis virus; or the oncolytic virus is a recombinant virus that contains one or both of a functional deletion of at least one viral gene and an insertion of at least one transgene; or the recombinant virus comprises a functional deletion of at least one viral gene and an insertion of at least one transgene; or the transgene encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF); or the oncolytic virus is a transgenic serotype 5 adenovirus; or the oncolytic virus is a transgenic herpes simplex virus type 1 (HSV-1), optionally wherein the transgenic HSV-1 is talimogene laherparepvec; or the oncolytic virus is a transgenic vaccinia virus, optionally wherein the transgenic vaccinia virus is pexasthymodin debasilepvec; or the oncolytic virus is a non-recombinant oncolytic virus, optionally wherein the non-recombinant oncolytic virus is a virus selected from the group consisting of echovirus, Newcastle disease virus, parvovirus, reovirus, and Seneca Valley virus; 44. A compound according to claim 42 or 43.
45. the cancer is a hematological cancer; or the hematological cancer is lymphoma, leukemia, or myeloma; or the cancer is a non-hematological cancer; or The non-hematological cancer is a carcinoma, a sarcoma, or a melanoma. A compound according to any one of claims 39 to 44.
46. An effective amount of a compound according to any one of claims 1 to 15 for use in the manufacture of a medicament for treating cancer comprising administration of an effective amount of the compound, and administration of an effective amount of a therapeutic cancer vaccine, or administration of an effective amount of an oncolytic virus.
47. The compound is further capable of reducing the requirement for costimulation of immune cells; or The compound is further capable of promoting tumor immune surveillance.
47. The compound of claim 46.
48. A pharmaceutical composition comprising a cancer vaccine and a compound according to any one of claims 1 to 15, optionally further comprising a pharma- ceutically acceptable excipient.
49. 17. The pharmaceutical composition of claim 16 for use in generating a population of tumor infiltrating lymphocytes (TIL).
50. 20. Use of cells obtained by the method according to claim 17 in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Cbl-b activity.
51. 20. Use of cells obtained by the method of claim 17 in the manufacture of a medicament for the treatment of cancer.
52. The method of claim 17, wherein the cells are for use in the treatment or prevention of a disease or condition associated with Cbl-b activity.
53. The method of claim 17, wherein the cells are for use in the treatment of cancer.
54. The method of claim 18, wherein the cells are for use in the manufacture of a medicament for the treatment or prevention of a disease or condition associated with Cbl-b activity.
55. The method of claim 18, wherein the cells are for use in the manufacture of a medicament for the treatment of cancer.
56. The method of claim 18, wherein the cells are for use in the treatment or prevention of a disease or condition associated with Cbl-b activity.
57. The method of claim 18, wherein the cells are for use in the treatment of cancer.
Citation Information
Patent Citations
Ubiquitin ligase inhibitor
JP2007314469A
